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Charcot-Marie-Tooth Disease (CMT) is a clinically and genetically heterogeneous 
collection of inherited peripheral neuropathies generally characterized by 
progressive muscle atrophy, weakness, and loss of sensation in the distal 
extremities. This inherited disorder, for which there is currently no curative 
treatment, is the most common inherited disease of the peripheral nervous system, 
affecting 1:2,500 individuals worldwide.  
Clinically, CMT is broadly divided into demyelinating (type 1) and axonal (type 
2) forms. Although the clinical presentation can vary greatly in severity and 
progression within individual patients. Genetically, over 1,000 mutations in over 
80 loci in the human genome have been linked to specific subtypes of CMT, 
suggesting there are many cellular and molecular routes to neurodegeneration in 
CMT. Together, these factors conspire against a single effective therapy, for all 
subtypes of CMT, suggesting that personalized genetic approaches may represent 
a more efficacious therapeutic strategy.  
 
One presumed basis for the phenotypic variability of CMT is the presence of 
genetic modifiers. Here, we have used mouse models of CMT to investigate 
genetic modifiers of neuropathy. We show that the phenotype of these CMT 
mouse models becomes more severe in the presence of either of two other 
mutations that cause “subclinical” changes at peripheral nodes. These results have 
implications for CMT genetic diagnosis and prognosis and suggest possible 
personalized treatment strategies.  
 
Furthermore, the development of gene therapy has provided an effective strategy 
for treating Mendelian disorders, such as CMT, where disease is primarily caused 
by a single mutation. Personalized gene therapy approaches are being successfully 
deployed to treat recessive genetic disorders by restoring the expression of   
diseases, where treatment requires a reduction in expression of the mutated allele, 
has yet to be established.  Here we use virally-delivered allele-specific RNAi to 
demonstrate the effectiveness of allele-specific silencing as a long-term treatment 
for dominantly-inherited forms of CMT. Importantly, this strategy will also have 
broad implications for other dominantly-inherited neuromuscular disorders.  
 
Together, both studies clearly demonstrate how precision genetic approaches, 
either by targeting genetic modifiers or the disease allele itself may represent a 
more efficacious therapeutic strategy for individuals with CMT and others 
inherited neuromuscular disorders.  
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CHAPTER 1 
CHARCOT-MARIE-TOOTH DISEASE: AN OVERVIEW OF 
PATHOPHYSIOLOGY & POTENTIAL THERAPEUTIC STRATEGIES 
Introduction 
Named after the three physicians who initially described it in 1886—J.M 
Charcot, P. Marie, and H.H. Tooth—Charcot-Marie-Tooth disease (CMT) 
represents a large, heterogeneous group of inherited peripheral neuropathies (Skre 
et al.,1974, Charcot et al.,1886 and Tooth, 1886). This inherited disorder, for 
which there is currently no curative treatment, is the most common inherited 
disease of the peripheral nervous system, affecting 1:2,500 individuals worldwide 
or approximately 125,000 people in the United States (Barisic et al., 2008 and 
Zuchner et al., 2006). While CMT is used as a term for hereditary motor and 
sensory neuropathies, it may also be viewed as a spectrum, ranging from the pure 
motor neuropathies to the predominantly pure sensory neuropathies (Brennan et 
al., 2015). CMT is generally characterized by progressive and length-dependent 
degeneration of peripheral nerves, resulting in gradual distal and symmetrical 
muscle weakness and atrophy within the intrinsic foot and peroneal muscles. As 
the disease progresses, muscles of the hands and forearms also become affected, 
and a reduction in tendon reflexes, skeletal deformities, and sensory loss may 
develop.   
In many cases, the age of onset is within the first to second decade, 
although cases emerging during infancy and up to late-adulthood have been 
reported, with clinical severity ranging from mild to severe (Saporta and Shy, 
 2 
2013, Dyck and Thomas, 2005). Symptoms are highly debilitating and often limit 
mobility, requiring patients to use assistive walking devices such as leg braces or 
a wheelchair. Clinically, CMT is broadly divided into demyelinating (type 1) and 
axonal (type 2) forms, with intermediate forms that have both axonal and 
demyelinating features (Brennan et al., 2015). Genetically, over 1,000 mutations 
in over 80 loci in the human genome have been linked to specific subtypes of 
CMT (Timmerman et al., 2014).  
The identification of disease-associated genes has helped categorize the 
pathophysiological bases of CMT, such as structural proteins of myelin (type 1) 
and the axonal cytoskeleton, axonal transport, and mitochondrial dysfunction 
(type 2), but many forms do not clearly fit these categories, suggesting there are 
many cellular and molecular routes to neurodegeneration. Together, these factors 
conspire against a single effective therapy for all subtypes of CMT, suggesting 
that personalized genetic approaches may represent a more efficacious therapeutic 
strategy.  
                                   Classification of CMT 
CMT is further classified into different subtypes based on the prevalence 
of myelin or axonal involvement, electrophysiological examinations, the mode of 
inheritance, and the genetic cause. For example, CMT1 causes the demyelination 
of peripheral nerves and yields a reduced motor nerve conduction velocity 
(MNCV) as slow as 35 m/s with sural nerve biopsies revealing segmental 
demyelination and onion bulb formation. On the other hand, CMT2 is a peripheral 
neuropathy caused by axon degeneration, and is diagnosed when patients have 
 3 
normal MNCVs of about 45 m/s but reduced compound motor action potentials 
due to axon loss. Both types are inherited through an autosomal dominant 
inheritance pattern and make up 90% of CMT cases. Neurophysiology studies 
have also identified another group, CMT intermediate, with nerve conduction 
demonstrating intermediate velocities (less than 45 m/s and greater than 38 m/s) 
(Hoyle et al., 2016, Saporta et al., 2011 and Reilly and Shy., 2009). 
The mode of inheritance further subdivides CMT neuropathies into CMT4 
for recessive demyelinating CMT, CMT2R for recessive axonal CMT, CMTDI, 
and CMTRI for dominant and recessive intermediate CMT respectively, and 
CMT-X for the X-linked CMT. Furthermore, de novo mutations may occur, and 
there are many forms of CMT that show incomplete penetrance (Hoyle et al., 
2016 and Blair et al, 1996). Each subtype can be further distinguished by the 
specific gene that is altered by the addition of a unique letter of the alphabet. The 
letters are in order in which each subtype of CMT was formally defined as a 
distinct entity. For example, CMT1B is a demyelinating neuropathy specifically 
caused by mutations in the MPZ gene, the second demyelinating form mapped as 
denoted by “B”.  
Diagnosis & Clinical Management 
As alluded to above, electrodiagnostic studies have been valuable clinical 
diagnostic tools to differentiate demyelinating and axonal forms of CMT and can 
further distinguish a sensorimotor polyneuropathy from a pure motor neuropathy, 
or separate a neuropathy from a distal myopathy (Kaku et al., 1993). They can 
also distinguish CMT from an acquired neuropathy such as chronic immune 
 4 
demyelinating polyneuropathy, which typically causes conduction block or 
temporal dispersion, two electrophysiological characteristics that are not usually 
observed in CMT (Hoyle et al., 2016). This specific distinction is extremely 
important to avoid neurotoxic immunosuppressive treatments that may exacerbate 
CMT symptoms. However, electrodiagnostic studies have been confounded as 
signs of acquired neuropathy have been occasionally observed in patients with 
CMTX, CMT1B, CMT1C, and CMT4J (Cottenie et al., 2013, Murphy et al., 
2011, Michell et al., 2009, and Gerding et al., 2009). Neurologists may also look 
for specific phenotypic features to further classify a patient’s subtype of CMT. 
Examples of this include white matter lesions with transient focal symptoms or 
stroke-like presentations in X-linked CMT, or vocal cord or diaphragm 
involvement in CMT2C, an axonal neuropathy caused by mutations in TRPV4 
(Sagnelli et al., 2014, McKinney et al., 2014, Echaniz-Laguna et al., 2014, 
Landoure et al., 2012, Anand et al., 2010, and Santoro et al., 2002). However, the 
clinical presentation of CMT can be extremely similar among patients with 
different subtypes. Also, different CMT symptoms can be caused by mutations in 
the same gene, and mutations in different genes may result in the same phenotype. 
This makes a specific diagnosis based on clinical signs alone impossible, and 
prognosis often unreliable.  
Clearly genetic testing is the only way to get a clear diagnosis for patients 
and our only hope at defining pathological mechanisms underlying CMT required 
for proposing treatment strategies (Rossor et al., 2013). CMT-causing loci and 
genes were originally identified using tedious genetic linkage studies. Genetic 
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testing for CMT first became available in 1991 after the discovery of the PMP22 
duplication a molecular lesion underpinning CMT1A (Roa et al., 1991). This 
duplication remains the most common genetic cause of the majority of CMT1 
cases and about 50% off all CMT cases (Murphy et al., 2012). However, original 
DNA sequencing methods, predominantly Sangor sequencing, were expensive 
limiting their use in genetic diagnostics (Hoyle et al., 2016). The development of 
high-throughput DNA sequencing such as Next-generation sequencing has 
allowed whole genomes and exomes to be sequenced in a relatively quick and 
inexpensive manner greatly accelerating the identification of CMT loci and genes 
(Ankala et al., 2015 and Rossor et al., 2013). In fact, with the use of next-
generation sequencing, several genome wide association studies have been 
completed, showing that over 90% of patients with CMT originating from North 
America or Europe have mutations in one of only four genes (PMP22, MPZ, 
GJB1 and MFN2) (Ekins et al., 2015, DiVincenzo et al., 2014, Ostern et al., 2013, 
and Murphy et al., 2012). Based on these data, a genetic panel that screens 
patients for mutations in these four genes should be developed as a quick and 
cost-efficient diagnosis for individuals with typical cases of CMT. At the same 
time, some CMT-causing mutations are ultra-rare and may require whole-genome 
or whole-exome sequencing for identification, as well as further testing to confirm 
pathogenicity.  
Currently there is no curative, or even disease-modifying, treatment for 
any subtype of CMT—only supportive care. Ankle foot orthoses can improve 
walking in patients with significant ankle dorsiflexion weakness, and thumb 
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opposition splints have been shown to improve hand function in patients with 
severe hand muscle weakness (Menotti et al., 2014, Dufek et al., 2014, 
Ramdharry et al., 2014, Phillips et al., 2012, Videler et al., 2012, and Guillebastre 
et al., 2013). Assistive walking devices, such as full leg braces or wheel chairs, 
may also help with mobility. Although data is limited, exercise also appears to be 
a safe therapeutic intervention, and may modestly slow down the progression of 
several subtypes (Burns et al., 2009 and Chetlin et al., 2004). The genetic defects 
and associated pathophysiology of various forms of CMT may increase a patient’s 
susceptibility to toxicity from certain chemical exposures (Fonkem et al., 2014, 
Beutler et al., 2014, Ursino et al., 2013, Nakamura et al., 2012, and Weimer et al., 
2006). Thus, all neurotoxic medications such as chemotherapy should be avoided. 
In summary, although diagnosis remains a complex endeavor and treatment 
options are limited, continuing to identify CMT-causing genes will hopefully 
soon lead to the identification of cellular pathways underlying pathology, and 
provide needed information for targeted therapies.  
Emerging Molecular Pathologies & Tested Therapeutic Strategies  
CMT1: Altered Proteostasis in Myelinating Schwann Cells   
All motor, sensory, and cognitive functions rely on the rapid propagation 
of nerve impulses also known as action potentials along central and peripheral 
nerves to their effecting target (i.e., muscle, skin, brain, etc.). Much like the 
insulation around wires in electrical circuits, glial cells form a fatty, membranous 
sheath surrounding axons known as myelin. Myelin is critical for the rapid 
propagation of nerve impulses along axons as it reduces the transverse 
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capacitance and increases the transverse resistance of the axonal plasma 
membrane (axolemma). This provides the structural basis for saltatory conduction 
and thereby increases the conduction velocity of action potentials along nerves.  
While oligodendrocytes myelinate the axons of the central nervous 
system, myelin insulating peripheral axons is composed of glia known as 
Schwann cells. To properly insulate peripheral axons, myelinating Schwann cells 
contain high concentrations of cholesterol, sphingolipids, and many proteins 
including peripheral myelin protein 22 (PMP22), myelin protein zero (P0) and 
myelin basic protein (MBP) (Nave et al., 2014 and Scherer et al., 2002). The 
regulation of expression and proper folding of all myelin proteins are essential for 
the development and homeostasis of peripheral myelin.  In fact, mutations in 
genes that encode myelin proteins including PMP22, P0, early growth response 
gene 2 (EGR-2) and connexin-32 (Cx-32) account for the genetic etiology of most 
cases of demyelinating forms of CMT including CMT1A, CMT1B, CMT1D, 
CMT2E, and CMTX (Brennan et al., 2016).  
CMT1A is the most common form of CMT accounting for ~70% of 
CMT1 as well as 50% of all cases of CMT, and is one of the first examples of a 
“genomic” disorder (Timmerman et al., 2014). In 1989, the CMT1A locus was 
assigned to chromosome 17 through genetic linkage studies in large HMSN 
families (Raeymaekers et al., 1989 and Vance et al., 1989). Two years later it was 
found that this 1.4 Mb chromosomal region is flanked by two 24 kb homologous 
low copy repeats (LCRs) called the proximal and distal CMT1A-REPs 
(Raeymaekers et al., 1991 and Lupski et al., 1991). This unique genomic 
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architecture creates a non-allelic homologous recombination (NAHR) which can 
cause either a tandem-duplication or the deletion of these 1.4 megabases on 
chromosome 17 (Timmerman et al., 2014). In 1992, with use of chromosomal 
hybrid cell lines, pulsed field gel electrophoresis, and yeast artificial chromosome 
maps, it was discovered that the PMP22 gene was in the middle of this 1.4-Mb 
region (Matsunami et al., 1992, Patel et al., 1992, Timmerman et al., 1992, and 
Valentijn et al., 1992). Subsequently, it was determined by Lupski et al. that an 
extra copy (trisomy) of PMP22, resulting in the overproduction of the protein, 
was linked to CMT1A (Lupski et al., 1992). In contrast, the heterozygous deletion 
of PMP22 that results in the reduction of PMP22 causes a completely different 
neuropathy known as hereditary neuropathy with liability to pressure palsy 
(HNPP) (Lupski et al., 1992). It remained unclear why the difference in genetic 
dosage of this genomic region causes two independent inherited peripheral 
neuropathies. To further complicate things, 61 different point mutations in 
PMP22 have been linked to both CMT1A as well as HNPP, and missense 
mutations in PMP22 that alter the protein’s amino acid sequence cause another 
form of CMT1 known as CMT1E (Russo et al., 2011). Taken together, all of these 
studies confirmed that any dysregulation of PMP22 can have drastic effects on 
myelin homeostasis and, thus, peripheral nerve function.  
 PMP22 is a 22-kDa membrane glycoprotein which contributes 
approximately 2-5% of myelin proteins and is thought to play an integral role in 
myelin synthesis and assembly (Garbay et al., 2000). However, its exact function 
within the peripheral nervous system remains unclear. It was first identified as a 
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growth arrest gene in fibroblasts and may be involved in the cell cycle of 
Schwann cells (Jetten et al., 2000). Additional studies in injured nerves suggest a 
role critical in Schwann cell growth and differentiation (D’Urso et al., 1997, De 
Leon et al., 1994, Snipes et al., 1993, Kuhn et al., 1993, Spreyer et al., 1991 and 
Welcher et al., 1991). A novel role for PMP22 has been found in the linkage of 
the actin cytoskeleton with the plasma membrane, possibly through regulating the 
cholesterol content of lipid rafts (Lee et al., 2014). Yet, the mechanisms 
underlying these hypotheses have yet to be established and how its dysregulation 
causes neuropathy remains elusive. Several established rodent models of PMP22-
associated CMT1, including the Trembler (Tr) and Trembler J (Tr J) mice which 
are spontaneous Pmp22 mutants harboring two missense mutations, Gly150Asp 
and Leu16Pro, respectively, and the transgenic rats and mice carrying extra copies 
of the Pmp22 gene, are being used to gain significant insights into the 
pathophysiology underpinning these neuropathies (Jetten et al., 2000, Sereda et 
al., 1996, Maycox et al., and Suter et al., 1992). For example, several studies 
using both Trembler (Tr) and Trembler-J (Tr J) mice have reported that both 
missense mutations within PMP22 disrupt its trafficking to the plasma membrane 
of Schwann cells from endoplasmic reticulum or Golgi apparatus (Schlebach et 
al., 2015, Fontanini et al., 2005, Tobler et al., 2002, Ryan et al., 2002, Dickson et 
al., 2002, Colby et al., 2000, Naef et al., 1999, and Naef et al., 1997). This 
increases the propensity of PMP22 to misfold and become degraded by the 
endoplasmic reticulum associated degradation system. These data suggest that a 
loss-of-function mechanism may contribute to pathogenesis of CMT1E. However, 
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both Trembler models have significantly less peripheral myelin and a more severe 
neuropathy phenotype compared to mice that are hemizygous for PMP22, 
suggesting that dominant-negative or toxic gain-of-function mechanisms may also 
contribute to disease (Mittendorf et al., 2017).  
Considering much more needs to be understood about the mechanism 
through which different mutations in PMP22 cause demyelination, current 
treatment strategies aimed to regulate PMP22 gene dosage are being developed. 
Two compounds that have been shown to alter PMP22 mRNA levels in rodents 
are ascorbic acid and progesterone. Ascorbic acid (Vitamin C) is necessary for 
myelination and Schwann cell basal lamina formation (Passage et al., 2004). 
Interestingly, ascorbic acid supplementation was found to reduce PMP22 mRNA 
expression as well as improve myelination in a transgenic mouse model of 
CMT1A with several copies (7) of Pmp22 (Passage et al., 2004). However, it was 
not found to be effective in mitigating neuropathy in adults nor children with 
CMT1A in several international clinical trials (Lewis et al., 2013, Micallef et al., 
2009, Burns et al., 2009, Verhamme et al., 2009, Pareyson et al., 2008, Pareyson 
et al., 2006). Animal studies also have shown some promise with the progesterone 
antagonist, onapristone, to decrease PMP22 expression and improve myelination 
(Sereda et al., 2003). Unfortunately, onapristone was found to be toxic in humans, 
although further research is ongoing to develop less toxic progesterone 
antagonists suitable for future clinical trials (Brennan et al., 2015). Ongoing 
efforts to identify additional compounds that reduce Pmp22 expression that are 
safe and effective at treating individuals with CMT1A are currently being funded 
 11 
by the Charcot-Marie-Tooth Association (Brennan et al., 2015). 
CMT1B is the second most frequent autosomal dominant inherited 
neuropathy, accounting for 10% of CMT1 cases, and is caused by mutations in 
MPZ, the gene encoding P0 (Shy et al., 2004). P0 is a transmembrane 
glycoprotein with a large amino-terminal extracellular domain and a short 
carboxy-terminal intracellular tail. It is the most abundant protein expressed in 
myelinating Schwann cells, accounting for about 50% of myelin proteins, and is 
critical for stabilizing myelin around peripheral nerves (Nave et al., 2014 and 
Scherer et al., 2002). This is supported by the fact that transgenic mice that lack 
Mpz show uncompaction of myelin early in development, whereas mice with a 
heterozygous disruption of MpZ display late-onset demyelination of peripheral 
nerves (Martini et al., 1995 and Giese et al., 1992).  
More than 120 mutations in MPZ, mostly affecting its extracellular 
domain, have been identified and are known to cause not only CMT1B but also 
two severe neuropathies including childhood-onset Dejerine-Sottas neuropathy 
(DSS) and congenital hypomyelinating neuropathy (Shy et al., 2004). However, 
why certain mutations cause different peripheral neuropathies remains to be fully 
understood. Dominant inheritance and widely varying phenotypes suggest that 
many P0 mutations cause neuropathy through toxic gain-of-function or dominant-
negative mechanisms.  
For example, deletion of serine 63 (S63del) in MPZ results in CMT1B 
while the missense mutation S63C leads to DSS in humans (Hayasaka et al., 1993 
and Kulkens et al., 1993). Furthermore, demyelination within transgenic mice 
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expressing mutant forms of MPZ cannot be rescued by the overexpression of 
wildtype P0 (Wrabetz et al., 2006). One proposed neomorphic mechanism 
suggests that mutant forms of MPZ are retained in the ER, causing high levels of 
ER stress. The latter, in turn, activates the unfolded protein response (UPR) in 
myelinating Schwann cells, ultimately causing apoptosis and demyelination to 
occur. This hypothesis is supported by the fact that mutant MPZ accumulates in 
the ER of Schwann cells and triggers the UPR in two independent mouse models 
of CMT1B that harbor two different MPZ mutations, S63del and R98C (Pennuto 
et al., 2008 and Ikegami et al 1996). Also, the deletion of a transcription factor 
critical for the UPR, CHOP (CAATT enhancer-binding protein homologous 
protein) recuses motor deficits and mitigates demyelination within a mouse model 
of CMT1B that harbors the S63del mutation (Pennuto et al., 2008).  
In response, therapeutic strategies for CMTB and other MPZ-associated 
neuropathies have been centered on relieving ER stress in Schwann cells. For 
example, curcumin, a component of turmeric, is a natural, low affinity, 
sarcoplasmic/ER Ca2+ ATPase (SERCA) inhibitor that can mitigate ER retention. 
Oral administration of curcumin improved Schwann cell differentiation and 
alleviated ER stress, reducing the UPR in the MPZS63del/+ model, although it was 
not successful in alleviating neuropathy in clinical trials (Khajavi et al., 2007 and 
Brennan et al., 2015). Although recent work has shown that pharmacological 
activation of the integrated stress pathway initiated by the phosphorylation of the 
alpha-subunit of eukaryotic translation initiation factor 2 (eIF2) can both prevent 
and mitigate neuropathy in mouse models of this disease. Indeed, Das et al has 
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shown that the small molecule Sephin1, a selective inhibitor of a 
holophosphatase, can prolong the phosphorylation of eIF2 preventing the 
expression of anti-apoptotic genes and prevent the onset of demyelination in 
mouse models of CM1B (Das et al., 2015). As for post-disease onset therapeutic 
effects, pharmacological inhibition of Gadd34 via Salubrinal, an activator of 
CHOP, also increases the phosphorylation of eIF2 as well as improves 
myelination and reduces accumulation of mutant P0 in the ER also within an 
established mouse model of CMT1B (D’Antonio et al., 2013). However, 
treatment salubrinal at concentration higher than 40µM have been identified as 
toxic limited its therapeutic effects and complicating its translation into a 
treatment for the clinic (D’Antonio et al., 2013). 
Mutations in EGR2, a gene that encodes early growth response 2 (EGR2, 
also known as Krox2), cause CMT1D (Brennan et al., 2015). EGR2 is a zinc-
finger transcription factor of the early growth response (EGR) family, which 
regulates gene expression by binding to cis-acting elements of target genes. It is 
highly expressed early in development within migrating neural crest cells and is 
required for both hindbrain development and the myelination of the peripheral 
nervous system directly activating the expression of myelin genes, such as 
PMP22, Cx32, and PRX (Mirsky et al., 2008, Le et al., 2005 and Topilko et al., 
1994). Egr2(-/-) mice display disrupted hindbrain development and 
hypomyelination of the peripheral nervous system with Schwann cells blocked at 
an early stage of development, with the expression of late myelin genes (P0, 
MPZ) either decreased or not expressed at all (Schneider et al., 1993 and Swiatek 
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et al., 1993). Although, mice that are heterozygous for Egr2 are phenotypically 
normal, making it unclear why dominant mutations in EGR2 cause a 
demyelinating neuropathy (Nagarajan et al., 2001).  
Interestingly, most mutations identified in patients with CMT1D are 
located the zinc-finger DNA binding domain (DBD) of EGR2, and subsequent 
studies have shown that zinc-finger mutations affect DNA binding, with the 
amount of residual binding directly correlating with the severity of neuropathy 
(Warner et al., 1999). Like other forms of CMT1, both suggest that mutant forms 
of EGR2 cause neuropathy through a dominant negative mechanism. Indeed, 
Nagarajan et al determined that neuropathy-associated mutant forms of EGR2 
dominantly-negatively inhibit wildtype EGR from initiating the expression of 
essential myelin genes (including MPZ, PMP22, and P0), required for 
myelination. Interestingly, they also determined that the reintroduction of 
wildtype ERG2 into postnatal, Egr2-deficient Schwann cells results in the 
expression of genes critical for myelination, suggesting that EGR2 gene 
replacement therapy may be an efficacious therapeutic approach for CMT1D 
(Nagarajan et al., 2001).  
CMT1X represents the second most frequent form of CMT and results 
from mutations in the gap junction protein beta 1 (GJB1), the gene the encodes 
connexin 32 (Cx32), a gap junction protein that is expressed in Schwann cells 
(Bergoffen et al., 1993). Gap junction proteins are integral membrane proteins 
that form functional gap junctions, or channels that allow the rapid transport of 
ions and small nutrients between contiguous cells in tissues (Kyriakoudi et al., 
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2017 and Goodenough et al., 1996). Gap junctions are formed by two 
hemichannels (or connexons), each made up of six connexin molecules; a 
complete channel is formed when one hemichannel docks with another 
hemichannel in an adjacent cell membrane (Kyriakoudi et al., 2017, Goodenough 
et al., 1996, and Bruzzone et al., 1996).  In Schwann cells, Cx32 forms 
intracellular gap junctions between paranodal loops and Schmidt-Lanterman 
incisures in non-compact regions of myelin, that allow the diffusion of ions and 
small molecules through the myelin sheath (Kyriakoudi et al., 2017 and Scherer et 
al., 1995). Over 400 mutations in Cx32 have been identified in patients with 
CMTX1 that include missense, nonsense, frameshift, and large deletions, all of 
which are evenly dispersed throughout all functional domains of the protein 
(Pareyson et al., 2009 and Kleopa et al., 2006). Mutant forms of Cx32 are thought 
to cause demyelination and neuropathy through a loss-of-function mechanism, as 
mice deficient in Cx32 display reduced nerve conduction velocities and 
hypomyelination that is similar to what is observed in individuals with CMTX1 
(SArgiannidou et al., 2009, Shy et al., 2007, Scherer et al., 1998, Anzini et al., 
1997 and Bruzzone et al., 1994).  
Many Cx32 missense mutants have been studied in vitro and have shown 
abnormal trafficking and intracellular retention in the endoplasmic reticulum (ER) 
and/or Golgi followed by proteasomal or lysosomal degradation (Kleopa et al., 
2002, Yum et al., 2002, VanSlyke et al., 2000, Martin et al., 2000, Deschenes et 
al., 1997 and Omori et al., 1996). Other mutants, both missense and nonsense, can 
traffic to the membrane, but form non-functional channels or channels with 
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altered biophysical properties (Castro et al., 1999, Ressot et al., 1998, and Castro 
et al., 1999). Additional studies in HeLa cells show that some missense mutants 
form nonfunctional chimeric connexons with wildtype connexons that are not 
properly inserted into the cytoplasmic membrane (Omori et al., 1996). Taken 
together, these data suggest, as in other subtypes of CMT1, that protein 
misfolding and/or mislocalization may be involved in pathology along with 
possible dominant-negative activity.  
Overall, all the aforementioned mutations lead to the accumulation of 
mislocalized and/or misfolded proteins within myelinating Schwann cells causing 
deficits in their differentiation and homeostasis, causing subsequent 
demyelination. Thus, much effort has been expended to develop a therapy that can 
promote myelin differentiation and stabilization for patients with a demyelinating 
form of CMT. Along these lines, Fledrich et al identified reduced expression of 
genes required for Schwann cell differentiation within several, preonset Pmp22-
transgenic rodent models of CMT1A. Markers of immature and dedifferentiated 
Schwann cells were also found to be upregulated in sciatic nerves from post-
disease onset rodent models of CMT1A caused by reduced activity of the PI3K-
Akt signaling pathway within myelinating Schwann cells. Based on these 
findings, they determined that treatment with neuregulin-1, a growth factor 
known to enhance PI3K-Akt signaling, can drive undifferentiated Schwann 
cells to mature in early-onset rodent models of CMT1A, and preserves 
myelination throughout adulthood (Fledrich et al., 2014). Although the 
therapeutic window of this therapy is short, neuregulin-1 supplementation 
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might be able to treat childhood onset CMT1A, or, if one of the mentioned 
CMT1-causing mutations is known to affect a family, before the onset of 
disease.  
CMT2: Impaired Mitochondria Function & Axonal Transport  
Mitochondria are unique organelles that provide every cell with energy, in 
the form of ATP, by oxidative phosphorylation. Due to high-energy requirements 
and low intrinsic energy reserves, neurons require continual delivery of ATP to 
maintain excitability and protein phosphorylation reactions that mediate 
neurotransmission and synaptic integrity. Thus, not surprisingly, the dysregulation 
of mitochondrial function has been implicated in a number of neurodegenerative 
disorders, such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease, in 
addition to CMT (Johri et al., 2012). In fact, over 50 different mutations in 
mitofusion 2 (MFN2), an outer mitochondrial membrane protein, together are the 
most common cause of axonal CMT (CMT2A), identified in ~20% of patients 
with CMT2 and accounting for 4% of all CMT cases (Patzko and Shy, 2011). 
MFN2 is a dynamin family GTPase involved in mitochondrial fusion, although it 
has also been implicated in regulation of mitochondrial oxidative function (Harel 
et al., 2014, de Brito el al., 2008 and Chen et al., 2005). Why mutations in this 
ubiquitously-expressed gene specifically cause axon degeneration is unclear. 
However, most reported MFN2 mutations are classified as missense, have a 
dominant inheritance pattern, are fully expressed, and are localized to 
mitochondria, suggesting that dominant-negative or toxic effects of the mutant 
protein may contribute to disease (Misko et al., 2012, Baloh et al., 2007 and Chen 
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et al 2005). Recent research has shown that mutant forms of MFN2 disrupt axonal 
mitochondrial transport. Considering mitochondria need to be transported to distal 
axon terminals to help maintain synaptic connections, this loss is predicted to 
cause length-dependent axonal degeneration as seen with CMT2 (Jerath et al., 
2015). The accumulation of mitochondria within distal portions of axons within a 
mouse model of CMT2A further supports impairment in mitochondrial transport 
along axons (Misko et al., 2010).  
Indeed, axonal transport (axoplasmic flow), the intraneuronal transport of 
organelles along microtubules within axons, is an essential cellular process for the 
proper function and survival of neurons. Human lower motor neurons have axons 
more than 1 meter in length, making axonal transport critical for anterograde 
delivery of proteins, lipids, and mitochondria, required for proper synaptic 
transmission to distant axon terminals (Millecamp et al., 2013). Axonal transport 
also removes recycled or misfolded proteins, clearing potential neurotoxic protein 
aggregates (Perlson et al., 2010). Several axonal forms of CMT are caused by 
mutations in genes critical for axonal transport (Pareyson et al., 2015). For 
example, similar to CMT2A, CMT2E is caused by dominant mutations in NEFL 
(neurofilament light) that disrupt neurofilament assembly and transport, thereby 
interrupting axonal mitochondrial transport with mitochondria being sequestered 
in the axon initial segment (Prior et al., 2017).  
CMT2B results from mutations in TBC1D15 (TBC1 domain family 
member 15), the gene that encodes RAB7, a GTPase-activating protein critical for 
retrograde axon transport (McCray et al. 2010). RAB7 is part of a large family of 
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ubiquitously-expressed Rab GTPases that regulate the formation, transport and 
fusion of cellular vesicles and are involved in the recruitment of molecular motors 
for vesicular transport and trafficking of ion channels (Amaya et al., 2016, Saraste 
et al., 2016, and Bucci et al., 2014).  Rab7 itself regulates vesicular transport to 
late endosomal and lysosomes in the endocytic pathway (Zhang et al., 2013). This 
includes the lysosome-mediated degradation of epidermal growth factor (EGF) 
and its cognate receptor (EGFR) along with nerve growth factor and tropomyosin 
receptor kinase A. This, axon degeneration in CMT2B may result from disrupted 
neurotrophin trafficking by mutant forms of Rab7 (Liu et al., 2017 and Zhang et 
al., 2013). Indeed, loss of GTPase activity is thought to be the pathological 
mechanism underlying CMT2B as the loss of rab7, but not overexpression of 
CMT-linked mutant forms of rab7 caused adult-onset neurodegeneration in 
Drosophila (Cherry et al., 2013). Although in contrast additional research 
discovered that CMT-causing mutations in Rab7 leave it in a constitutively active, 
GTP-bound conformation (Spinosa et al., 2008). Furthermore, mutant forms of 
Rab7 have been recently identified to abnormally bind to the intermediate 
neurofilament protein, peripherin, in vitro (Cogli et al., 2013). Together, these 
data suggest that these mutations may have multiple neurotoxic effects possibly 
through both loss- and gain- of function mechanisms, including interfering with 
retrograde axonal transport by possibly altering neurofilament assembly and 
depleting neurotrophins needed for neuronal homeostasis.  
Interestingly, axonal transport is also altered in CMT2F, an axonal 
neuropathy caused by HSPB1, encoding heat shock protein ß1 (Evgrafov et al., 
 20 
2004 and Ismailov et al., 2001). Heat shock proteins normally remove misfolded 
protein from cells, among other diverse roles in modulating intracellular redox 
states, cell differentiation, and the assembly of cytoskeleton (Arrigo et al., 2007, 
Dierick et al., 2005, and Xanthoudakis et al., 2000). However, in vitro, in addition 
to the accumulation of intracellular protein aggregates, mutant forms of HSPB1 
disrupt neurofilament networks and axonal transport (Zhai et al., 2007, Ackerley 
et al., 2006 and Evgrafov et al., 2004).  This finding was confirmed in vivo with a 
severe loss of axonal transport within peripheral nerves of two conditional mouse 
models of CMT2F, that harbor missense mutations in HSPB1 within neurons and 
exhibit symptoms of CMT symptoms starting at 6 months-of-age (d’Ydewalle et 
al., 2011). This reduction in axonal transport was found to be initiated by a 
reduction in acetylation of alpha-tubulin, a process that is important for the 
association of molecular motor proteins, including kinesin and dynein, to 
microtubules (d’Ydewalle et al., 2011). Both behavioral and electrophysiological 
symptoms were reversed with pharmacological inhibition of HDAC6 (histone 
deacetylase 6), a microtubule-associated deacetylase that deacetylates acetylated 
alpha-tubulin (d’Ydewalle et al., 2011). In response, there has been much effort 
expended in translating the treatment of HDAC inhibitors for CMT2F into clinical 
practice. Translation has been difficult, as many current HDAC inhibitors exhibit 
transient pharmacokinetics with short half-lives in vivo, and poor selectivity 
causing several adverse off-target related toxicities (Benoy et al., 2017).  
However, more stable and selective HDAC inhibitors are currently being 
developed (Benoy et al., 2017). Improvements in HDAC inhibitors are critical as 
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reductions in acetylated alpha-tubulin and axonal transport have also recently 
been found within the peripheral neurons of several mouse models of CMT2D, an 
axonal neuropathy caused by dominant mutations in GARS (Mo et al., 2018 & 
Benoy et al., 2018). Interestingly, these effects were found to be caused by the 
direct aberrant interaction of mutant GARS to HDAC6, enhancing its 
deacetylation activity on α-tubulin (Mo et al., 2018). Importantly, treatment 
with HDAC inhibitors were effective at reversing deficits in axonal transport as 
well as improving motor function in multiple mouse models of this disease (Mo 
et al., 2018). Considering deficits in axonal transport are implicated in several 
other forms of CMT2, levels of acetylated alpha-tubulin within peripheral nerves 
of other models of CMT2 (i.e., CMT2B, CMT2A, and CMT2E) should be 
evaluated. Improvement in axonal transport by HDAC inhibitors may be an 
effective treatment strategy for several forms of CMT.  
Aminoacyl tRNA Synthetases & Neuronal Homeostasis 
Aminoacyl tRNA synthetases (aaRSs) are ubiquitously-expressed 
enzymes that catalyze the aminoacylation of tRNAs with their cognate amino 
acids, playing an essential, non-redundant role in protein translation (Pang et al., 
2014, Guo et al., 2011 and Ibba et al., 2000). These enzymes are critical for 
fidelity of the genetic code as each tRNA harbors a specific anticodon triplet, and 
mischarging an amino acid to its non-cognate tRNA could cause large, 
detrimental changes to the proteome. Therefore, about half of the aaRSs have 
evolved pre- and/or post-transfer amino acid editing mechanisms to ensure the 
highest level of fidelity during protein synthesis (Mascarenhas et al., 2008). 
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Evolution has also obliged several aaRSs to have additional, idiosyncratic, non-
canonical roles in an array of other biological functions, including glucose and 
amino acid metabolism, angiogenesis, inflammation, cellular stress responses, 
apoptosis, the regulation of transcription and translation, rRNA transcription, 
autoimmunity, tRNA maturation, and mitochondrial RNA splicing (Pang et al., 
2014 and Guo et al., 2010).  
Mutations in as many as five genes encoding aaRSs (GARS, MARS, YARS, 
AARS, & KARS) have been implicated in axonal and intermediate forms of CMT 
(Hyun et al., 2014, McLaughlin et al., 2010, Latour et al., 2010, Jordanova et al., 
2006 and Antonellis et al., 2003). However, why mutations in these ubiquitously-
expressed housekeeping genes specifically cause peripheral neuropathy remains 
unclear. It is proposed that reductions in aminoacylation either by 
haploinsufficiency or dominant-negative activity may contribute to pathology. 
Indeed, loss of canonical activity may deplete aminoacylated cognate tRNAs, 
leading to ribosome stalling at codons for these cognate amino acids, and thereby 
reducing translation of critical proteins. This hypothesis is supported by the fact 
that the majority of the amino acid residues that are mutated in all five CMT-
associated aaRSs are highly conserved during evolution, suggesting that 
disruption of their ancient, essential function, aminoacylation, may contribute to 
the onset of neuropathy (Storkebaum et al., 2016). However, none of the 
mutations in aaRSs identified in patients with CMT result in protein-null 
mutations such as stop codons, frame shifts, splicing defects, or large deletions. 
All reported CMT-linked mutations in aaRSs result in either single amino acid 
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changes or small in-frame deletions that are dispersed throughout all the 
functional domains of the enzyme (Meyer-Schuman et al., 2017). Several in vitro 
aminoacylation assays have also confirmed that not all CMT-associated mutant 
forms of aaRSs have reduced aminoacylation activity, including GARS E71G, 
YARS E196K, and AARS E778A, all of which segregate with disease in family 
pedigrees (Niehus et al., 2015, Mclaughlin et al., 2012, Froelich et al., 2011, 
Storkebaum et al., 2009, Nangle et al., 2007, and Antonellis et al., 2006). 
Furthermore, a reduction in tRNAGly aminoacylation activity is not observed 
within mouse models of CMT2D (GarsC201R/+ and GarsP278KY/+) which harbor 
amino acid substitutions, C201R and P278KY, within Gars (Seburn et al., 2006).  
Similarly, while homozygous Gars knockout mice are embryonic lethal, 
haploinsufficiency is not observed in the heterozygous Gars-null strain, 
GarsXm256/+ (Seburn et al., 2006). Furthermore, mischarging of any CMT-
associated aaRSs has yet to be demonstrated, and only 2 out of the 5 of the aaRS 
loci have editing abilities (Pang et al., 2014 and Stum et al., 2011). Taken 
together, these data suggest that neither the loss nor misregulation of 
aminoacylation contributes to pathology underlying CMT pathogenesis.  A loss of 
a newly-evolved idiosyncratic function is possible, although neither a non-
canonical role of aaRS in neuronal homeostasis nor a common non-canonical 
function among all 5 CMT-linked aaRS loci has been identified. However, one 
non-canonical function of YARS has recently been discovered and involves its 
translocation into the nucleus upon oxidative stress where in plays a role in 
preventing DNA damage. However, it remains unclear if this function occurs in 
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peripheral neurons nor if this non-canonical function is disrupted by CMT-
causing mutations in YARS play any role to the onset of neuropathy (Wei et al., 
2014). 
As for other potential pathological mechanisms, an emerging body of 
research largely supports mutant forms of aaRSs causing neuropathy through a 
toxic gain-of-function (neomorphic) mechanism that specifically affects 
peripheral nerves. For example, both established mouse models of Gars-
associated CMT (GarsC201R/+ and GarsP278KY/+) display a distal axonal neuropathy 
that could not be rescued by overexpression of wildtype Gars; whereas increasing 
the genetic dosage of mutant Gars increased the severity of the neuropathy in 
mouse models expressing either mutant allele (Motley et al., 2011). Furthermore, 
over-expression of several mutant forms of human GARS (E71G, G240R, and 
G526R) and YARS (G41R, 153-156delVKQV, and E196K) within motor and 
sensory neurons results in a cell-autonomous reduction in global protein 
translation within neurons, that, in turn, causes a neuropathy in fully developed 
Drosophila, which cannot be rescued by the overexpression of wildtype aaRS 
(Niehues et al., 2015). These data suggest that mutant forms of aaRS may 
interfere with translational machinery that, though it may occur in all cells, may 
be particularly toxic in neurons, which are high-energy cells that require constant 
production of proteins needed for neurotransmission. 
In contrast, He et al. predicts that mutant forms of GARS cause CMT by a 
non-cell autonomous, possibly systemic, mechanism, involving the abnormal 
binding of mutant GlyRS to neuropilin 1 receptor (nrp1). This aberrant interaction 
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interferes with the binding of vascular endothelial growth factor (VEGF), a 
cognate ligand of nrp1, whose neurotrophic effects are critical for neuronal 
protection and survival (Neufeld et al., 2002). These data are further supported by 
the fact that the motor nucleus of the facial nerve does not migrate caudally in 
GarsP278KY/+ embryos, resembling Nrp1 or Vegf knockout phenotypes (He et al, 
2015). However, deletion of Nrp1 at P10 does not cause neuropathy and does not 
enhance symptoms of neuropathy in adult mouse models of CMT2D (Morelli et 
al., unpublished).  
Interestingly, as previously mentioned, mutant forms of GARS also 
aberrantly bind to HDAC6 causing reductions in axonal transport and subsequent 
neuropathy (Mo et al., 2018). However, both mechanisms may only be 
idiosyncratic to mutant forms of GARS and may not apply to all CMT-associated 
aaRS loci. Nonetheless, taken together, these data strongly suggest that treatment 
strategies aimed at reducing mutant aaRS expression may be of therapeutic 
benefit for patients with aaRS-related forms of CMT. 
Precision Gene Therapy: A Promising Treatment Strategy for CMT 
Advancement in diagnostic DNA sequencing, primarily Next Generation 
Sequencing, has significantly enhanced our understanding of CMT by isolating 
the primary genetic cause of many different subtypes of this disorder. Thus, 
identification and thorough study of such disease-associated genes has helped 
categorize the pathophysiological bases of CMT, such as structural proteins of 
myelin (type 1) and axonal cytoskeleton, axonal transport, and mitochondrial 
dysfunction (type 2), but many forms do not clearly fit these categories, 
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suggesting there are many cellular and molecular routes that lead to 
neurodegeneration. For example, it remains unclear why mutations in so many 
ubiquitously-expressed, often housekeeping genes, specifically cause peripheral 
neuropathy, leaving patients that harbor these mutations without an effective 
treatment.  
Furthermore, many CMT-associated genes have pleiotropic effects, often 
leading distinct mutations within the same gene to have variable effects on 
peripheral nerve function. For example, dominant mutations in NEFL can cause 
either a demyelinating CMT (CMT1F) or an axonal form of the disease 
(CMT2E), as neurofilaments play critical roles in axon-Schwann cell interactions, 
maintenance of the axonal cytoskeleton, and axonal transport. Together, these 
factors conspire against a single effective therapy for all subtypes of CMT, such 
as ascorbic acid or HDAC inhibitors, suggesting that personalized genetic 
approaches may represent a more efficacious therapeutic strategy. 
Gene therapy is a promising treatment strategy for CMT as well as many other 
inherited neuromuscular disorders. This experimental therapy encompasses 
several therapeutic approaches, including gene replacement therapies for 
recessive disorders caused by haploinsufficiency, and anti-sense oligonucleotides, 
that can either inactivate or edit genes contributing to disease. Thus, different 
gene therapies can be designed to target the direct molecular cause underlying 
each specific form of CMT, tailoring treatment to each patient’s specific 
pathology. Here we report several advancements in gene therapy for CMT. For 
example, gene therapy approaches are being successfully deployed to treat rare, 
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recessive genetic disorders by restoring the expression of mutated genes.  
However, the feasibility of these approaches for dominantly-inherited diseases—
where treatment may require reduction in the expression of a dominantly toxic 
mutant protein—is unclear. Here, we use viral vector-delivered, allele-specific 
RNAi in combination with precision mouse models of an autosomal dominant 
form of CMT to demonstrate the effectiveness of allele-specific silencing as a 
long-term treatment for dominantly-inherited forms of CMT. We have designed 
our therapy for a single patient, but this sets an important precedent, as 90% of 
CMT subtypes are inherited in an autosomal dominant inheritance pattern. 
In addition to genetic heterogeneity, patients with CMT also exhibit 
clinical heterogeneity, even within individuals with the same CMT-causing 
mutation. This indicates that in addition to potential environmental factors, genes 
that modify the effects of primary mutations may contribute to the phenotypic 
heterogeneity among patients with CMT. With such epistatic control over primary 
genes, genetic modifiers may contribute to the variation of the age of onset, 
severity, and the progression of CMT. Thus, genetic factors underlying this 
variability may represent targets for therapeutic intervention for multiple 
subtypes of the same NMD or multiple independent disorders. Here we describe 
several potential genetic modifiers of CMT that may one day lead to therapies that 
can mitigate several forms of CMT. 
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CHAPTER 2 
SEVERITY OF BOTH DEMYELINATING AND AXONAL 
NEUROPATHY MOUSE MODELS IS MODIFIED BY GENES 
AFFECTING STRUCTURE AND FUNCTION OF PERIPHERAL NODES 
Abstract 
Charcot-Marie-Tooth disease (CMT) is a clinically and genetically 
heterogeneous group of inherited polyneuropathies. Mutations in 80 genetic loci 
can cause forms of CMT, resulting in demyelination and axonal dysfunction. The 
clinical presentation, including sensory deficits, distal muscle weakness and 
atrophy, can vary greatly in severity and progression. Here we used mouse models 
of CMT to demonstrate genetic interactions that result in a more severe 
neuropathy phenotype. The cell adhesion molecule Nrcam and the Na+ channel 
Scn8a (NaV1.6) are important components of nodes. Homozygous Nrcam and 
heterozygous Scn8a mutations synergized with both an Sh3tc2 mutation, 
modeling recessive demyelinating Charcot-Marie-Tooth type 4C, and mutations 
in Gars, modeling dominant axonal Charcot-Marie-Tooth type 2D. We conclude 
that genetic variants perturbing the structure and function of nodes interact with 
mutations affecting the cable properties of axons by thinning myelin or reducing 
axon diameter. Therefore, genes important for peripheral nodes are candidate 
modifiers of peripheral neuropathy. 
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Introduction 
CMT is considered a Mendelian disorder, with over 80 associated loci in 
humans (Timmerman et al., 2014). However, the severity of neuropathy can vary 
even within alleles (Pareyson and Marchesi, 2009). Therefore, it is likely that 
many pathways can influence the severity of peripheral neuropathy, and one 
presumed basis for the variability is the presence of genetic modifiers (Gonzaga-
Jauregui et al., 2015). Here we have used mouse models of two forms of CMT to 
investigate genetic modifiers of neuropathy. First, we identified a spontaneous 
mutation in Sh3tc2 that creates a model of recessive CMT-4C, a demyelinating 
neuropathy (Arnaud et al., 2009, Senderek et al., 2003). We also use two different 
point mutations in glycyl tRNA synthetase (Gars) (Seburn et al., 2006, Achilli et 
al., 2009) that are models of CMT2D, a dominant axonal neuropathy (Antonellis 
et al., 2003). In the present study, we demonstrate that the phenotype of these 
CMT mouse models becomes more severe in the presence of either of two other 
mutations that cause "subclinical" changes at peripheral nodes.  
The Nav1.6 (Scn8a) sodium channel is the primary voltage-gated sodium 
channel at peripheral nodes of Ranvier and axon initial segments (Caldwell et al., 
2000). The Ig superfamily-member cell adhesion molecule Nrcam (Neuro-glial-
related cell adhesion molecule) is part of a transmembrane complex at nodes. 
During development, NRCAM and gliomedin in the Schwann cell establish a 
heminode in the axon at the boundary of the maturing Schwann cell, which then 
fuses into a mature node (Eshed-Eisenbach and Peles, 2013, Rasband and Peles, 
2015, Feinberg et al., 2010). The loss of Nrcam results in delayed formation of 
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nodes, and occasional "split nodes" in adult peripheral nerves, but no obvious 
signs of neuromuscular dysfunction (Amor et al., 2014, Custer et al., 2003). 
NRCAM’s role is somewhat redundant, as Nrcam and Gliomedin double-mutant 
mice fail to maintain nodes (Amor et al., 2014). Similarly, mutations in the 
paranodal protein CASPR are more severe in combination with Nrcam mutations 
(Feinberg et al., 2010). In the axon, NRCAM binds to ankyrins intracellularly, 
and ankyrins bind sodium channels (Davis and Bennett, 1994, Jenkins and 
Bennett, 2001). Similarly, Scn8a homozygous mice have extensive neurological 
problems, but heterozygotes are behaviorally and histologically normal (Burgess 
et al., 1995). However, we found that introducing either Nrcam homozygous or 
Scn8a heterozygous mutations into our CMT models results in a more severe 
neuropathy. Our results demonstrate that mutations that reduce myelin thickness 
or axon diameter act synergistically with mutations that alter nodes and/or reduce 
sodium currents in peripheral axons. These results have implications for CMT 
genetic diagnosis and prognosis, and suggest possible treatments. 
Results 
The identification of spontaneous Nrcam and Sh3tc2 mutations. 
The synergy of demyelinating peripheral neuropathy and impairments in 
peripheral node organization was made evident in a spontaneous mouse mutation 
identified and characterized at The Jackson Laboratory. This strain –nm4302 – 
arose in the background of a knockout of the cannabinoid receptor 2. Some mice 
displayed impaired hind limb function soon after weaning, which progressed to 
near complete hind limb paralysis and death by five months of age. This was 
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inconsistent with the Cnr2 knockout phenotype (Tschop et al., 2009), and was not 
linked to the knockout allele, indicating a spontaneous mutation had arisen. This 
mutation was recessive, since unaffected parents produced litters with a subset of 
affected offspring. Hind limb muscles in affected mice showed severe atrophy. 
Angular fibers and foci of atrophy without signs of degeneration/regeneration, 
fibrosis, or fatty infiltration were consistent with neurogenic etiology (Figure 1A, 
B).  
Using genetic mapping and exome sequencing, we identified two 
mutations in these mice. Genetic mapping revealed regions on Chrs. 12 and 18 as 
associated with the paralysis phenotype (Figure 1C and methods). Affected mice 
were recovered not at 1:4, but at closer to 1:16 in the mapping cross, consistent to 
two recessive loci, and mildly affected mice were also observed, presumably 
carrying only one of the mutations. We also performed exome sequencing on an 
affected mouse, which revealed a single base pair C to T conversion in exon 3 of 
Sh3tc2 on Chromosome 18, creating a premature stop codon at amino acid 71 
(G71X, Figure 1D). Mutations in Sh3tc2 cause a recessive demyelinating 
neuropathy (CMT 4C), and knockout mice have reduced myelin thickness and 
progressive retraction of Schwann cells from nodes of Ranvier (Arnaud et al., 
2009, Senderek et al., 2003). The Sh3tc2 gene is within the mapping interval on 
Chromosome 18, making Sh3tc2 a strong candidate. On chromosome 12, we 
identified a B2 element insertion in exon 26 of Nrcam (see Methods). The Nrcam 
gene is within our mapping interval, and is a candidate gene for its role in Na+ 
channel localization at nodes of Ranvier and axon initial segments, and for its 
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previously reported genetic interactions with Lpin1, causing transient hind limb 
paralysis (Douglas et al., 2009). The B2 element disrupts coding sequence and 
splicing of Nrcam, resulting in premature stop codons (Figure 1 E). 
NRCAM is 1256 amino acids, with a single transmembrane domain at 
amino acids 1120-1142. Both of the B2-element associated stop codons terminate 
translation before the transmembrane domain, resembling a previously reported 
allele, Q1033X, which is a protein null (Douglas et al., 2009). Consistent with 
this, anti-NRCAM immunolabeling with an antibody raised against the entire 
extracellular domain was eliminated at nodes of Ranvier in the sciatic nerve in 
Nrcam mutant samples (Figure 1F,G), and no NRCAM protein was detected by 
Western blotting from brain homogenates (Figure 1H). 
Demyelinating Sh3tc2 mutations strongly synergize with Nrcam mutations 
The phenotype of the Sh3tc2 mutation on its own is consistent with 
previous reports (Arnaud et al., 2009), and the mice develop a tremor and 
demyelinating neuropathy. The Nrcam mutation on its own is also consistent with 
previous reports, with occasional split nodes, having two distinct bands of NaV1.6 
and AnkyrinG (Figure 1 I, J and supplemental figure 1) (Amor et al., 2014). This 
occurred at 6.6±2.8% percent of the Nrcam-/- nodes, versus zero at control nodes 
(n=4, average of 99 nodes per nerve scored). Levels of NaV1.6 in the sciatic 
nerve were reduced on western blots (Figure 1 K, L). Normalizing to beta-Actin 
as a loading control, NaV1.6 levels in Nrcam-/- mice were reduced to 49% of wild 
type levels (n=3 mutant and 3 C57BL/6J control mice). Since Na+ channels may 
localize to internodal axon membranes (Shrager, 1989), we performed semi 
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quantitative immunofluorescence with NaV1.6 and neurofilament light chain as 
an internal control, but did not detect a decrease in NaV1.6 labeling at nodes of 
Nrcam-/- nerves (supplemental figure 1). Localization of paranodal proteins such 
as CASPR were unaffected (Feinberg et al., 2010, Amor et al., 2014). 
Despite the changes in NaV1.6 localization and abundance, the Nrcam-/- 
mice do not have an overt neuromuscular phenotype or obvious deficits in motor 
behavior. Other axonal parameters, such as the internodal distance were 
unchanged (Figure 1M). The average internodal distance divided by fiber 
diameter was 70.3±12.4 for Nrcam-/- axons and 64.9±10.0 for C57BL/6J control 
mice  
The mild neuromuscular dysfunction of the Nrcam or Sh3tc2 mutant mice 
is further substantiated by phenotyping performed by the knockout mouse 
program, with Nrcam-/- mice having poor performance on a rotarod test and 
Sh3tc2-/- mice having reduced grip strength, but otherwise no significant (p<0.05) 
neuromuscular phenotypes (KOMP2; https://www.mousephenotype.org). 
However, in combination, these two mutations cause paralysis in the spontaneous 
double mutant strain nm4302. 
 34 
 
 
 
 
 
 
 
 35 
Figure 1 Nm4302 mutations in Sh3tc2 and Nrcam A, B) Muscle histology from 
the gastrocnemius of control (A) and an affected Nm4302 mouse (B) demonstrate 
signs of neurogenic atrophy in the mutant, including clusters of angular fibers and 
signs of reinnervation/regeneration. C) Genetic mapping revealed significant 
associations with both Chromosome 12 and 18. The logarithm of the odds score 
(LOD, Y-axis) of single nucleotide polymorphisms (SNPs) is plotted versus their 
chromosomal location (X-axis). D) Chromatograms of sequencing PCR products 
from genomic DNA of a wild type (top), Sh3tc2 heterozygote (middle) and 
Sh3tc2 homozygote (bottom) show the C to T conversion in exon three creating a 
stop codon at residue 71. E) The B2 element insertion in exon 26 of Nrcam results 
in a 259 bp insertion with a duplication of the flanking 15 bp of the exon. Splicing 
from exon 25 to 26 results in a premature stop codon in the B2 element sequence. 
Aberrant splicing into the B2 element itself results in a premature stop codon 23 
bp downstream of the new splice junction. F, G) Immunolabeling of NRCAM 
(red) at nodes of Ranvier in teased sciatic nerve axons from wild type mice (F) or 
Nrcam mutant mice (G) reveals an absence of signal in the mutant, confirmed in 
teased nerves from three mice per genotype. Nodes were double labeled with 
antibodies against KV1.2 potassium channels (green). H) Western blotting protein 
from brain extracts also revealed an absence of signal in Nrcam mutant mice 
(Nrcam-/-). Mice from the KOMP2 program carrying an Nrcam mutation 
(Nrcamk/k) and a strain matched littermate control (NrcamWTB6/N) were used as a 
control. Wild type littermates from each Nrcam mutant strain contain protein at 
the predicted size, and anti-GAPDH was used as a loading control (below). Three 
independent blots were probed, and three mice per genotype were examined. The 
Nrcam mutant phenotype resembles previous reports. I) Wild type nodes of 
Ranvier have a single, colocalized site of NaV1.6 and ankyrinG 
immunoreactivity. J) In Nrcam mutant mice, “split” nodes with two sites of 
NaV1.6 and ankyrinG labeling were observed, although these proteins still 
colocalized. Four mice of each genotype were examined. K) Western blot of 
sciatic nerve lysates probed with antibodies against NaV1.6 revealed reduced 
signal relative to beta actin loading control. Proteins migrated at their anticipated 
molecular weights of ~225 kDa and ~42 kDa for NaV1.6 and beta actin 
respectively. L) Quantification of the NaV1.6:beta actin signal revealed a 51% 
decrease in NaV1.6 intensity (3 Nrcam-/- and 3 C57BL/6J control analyzed, 
p=0.03). M) The relationship between internodal distance and fiber diameter was 
not changed in Nrcam-/- mice compared to C57BL/6 controls (n=3 mice per 
genotype,37 Nrcam-/- and 34 Nrcam+/+ axons measured). Scale bar in J is 7 µm for 
F, G and 14 µm for I, J.  
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The basis for this progressive paralysis was explored by examining 
peripheral nerve anatomy and function in control, Nrcam-/-, Sh3tc2-/-, and double 
mutant mice. Cross-sections of the motor branch of the femoral nerve were 
examined (Figure 2 A-D). No changes in axon diameter, myelin thickness or axon 
number were observed for Nrcam mutant samples (Figure 2B, E-G). As expected, 
Sh3tc2-/- samples had reduced myelin thickness (p<0.0001) and supernumerary 
Schwann cell processes, but no decrease in myelinated axon number, and no 
change in axon diameter (Figure 2C, E-G). Axons in double mutant mice 
essentially mirrored the Sh3tc2-/- reduction myelin thickness (p<0.0001 vs. control 
and p=0.27 vs. Sh3tc2-/-), but no change in axon number or size (Figure 2 D, E-
G). Thus, the Nrcam mutation does not exacerbate the demyelinating effects of 
Sh3tc3-/-. In functional assays, nerve conduction velocity (NCV) was slightly 
decreased in Nrcam-/- mice (p=0.04). A previous study of Nrcam mutant mice 
reported normal NCV, but at P2, early the process of myelination, whereas we 
studied adult mice (Custer et al., 2003). NCV was more decreased in Sh3tc2-/- 
mice (p<0.001), and even more severely reduced in double mutant animals 
(p<0.001) (Figure 2 H). Myelin packing was examined by transmission electron 
microscopy (Supplemental figure 2). Myelin wraps on Nrcam-/- axons were 
slightly closer (12.9±1.4 nm between wraps) than control and Sh3tc2-/- axons 
(14.7±1.6 and 14.1±0.7 respectively, P<0.05), but this was not additionally 
reduced in the double mutant mice (12.3±2.0). The reduced overall myelin 
thickness in Sh3tc2-/- and double mutant mice was therefore due primarily to a 
reduced number of myelin wraps, not changes in myelin packing. The relationship 
 37 
between axon diameter and myelin thickness (the “g ratio”) is comparably 
reduced compared to control in both Sh3tc2-/- and double mutant mice, but 
unchanged in Nrcam mutant nerves (Supplemental figure 2). 
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Figure 2. Peripheral nerve anatomy and function in Sh3tc2 and Nrcam 
mutations (A-D) Cross sections of the motor branch of the femoral nerve from 
wild type (A), Nrcam-/- (B), Sh3tc2-/- (C), and double mutant (D) mice are shown. 
E) A cumulative histogram of axon diameters indicates no change in the single or 
double mutants. F) Cumulative histograms of myelin thickness reveal no change 
in Nrcam-/- nerves, a significant decrease in Sh3tc2-/- nerves, but no additional 
decrease in double mutant nerves. G) Axon number was not changed in any 
genotype. H) Nerve conduction velocity was reduced in Nrcam-/- mice, was 
reduced to a greater degree in Sh3tc2-/- mice, and was further reduced in double 
mutant mice. Data from eight mice per genotype are presented in E-G, H includes 
10 control, 14 Nrcam-/-, 10 Sh3tc2-/-, and 14 double mutant mice. Values in G, H 
are mean ± S.D. Mice were from 73-145 days old (average 104 days) in E-G, and 
57-125 days old (average 103 days) in H. * = p<0.05, **=P<0.01  Scale bar in D 
is 50 µm for A-D. 
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Nrcam mutant nerves have no changes in myelination, axon diameter, or 
internodal distance, so their reduced NCV may result from Na+ channel 
dysfunction at nodes. However, NRCAM also interacts with paranodal proteins 
such as CASPR, and Sh3tc2 mutations also cause the Schwann cells to retract 
from the node, so changes in other nodal properties and channel types could also 
contribute to the phenotype of both mutants. 
Changes such as axon loss do not explain the muscle atrophy and paralysis 
in double mutant mice. Examining neuromuscular junctions (NMJs) did not show 
evidence of denervation or die-back neuropathy (Seburn et al., 2006, Spaulding et 
al., 2016), but NMJs did show a phenotype. The NMJ morphology of the plantaris 
muscle in Nrcam-/- and Sh3tc2-/- single mutant animals was normal (Figure 3 A-
C). However, in double mutant mice by 3.5 months of age (~100 days), NMJs 
showed extensive fragmentation, sprouting of nerve terminals, and extrasynaptic 
acetylcholine receptor expression (Figure 3 D,E). These changes were not evident 
at 2.5 months of age (Supplemental figure 3).  
Nerve terminal sprouting and extrasynaptic AChR expression are also 
seen when peripheral nerves are silenced by chronic application of tetrodotoxin to 
the axon or botulinum toxin to the nerve terminal (Duchen and Strich, 1968, 
Pestronk and Drachman, 1978, Brown and Ironton, 1977). Consistent with motor 
neuron action potentials not reaching presynaptic terminals in the double mutant 
mice, we saw evidence of conduction block (Mallik and Weir, 2005) in our NCV 
studies (Figures 2H, 3F). Normally, the integrated compound muscle action 
potential (iCMAP) amplitudes of the distally (ankle) and proximally (hip) evoked 
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EMG are equal, but with conduction block, the proximally evoked EMG is 
reduced. Clinically, decrements of at least 20% are classified as conduction block 
(Mallik and Weir, 2005). Conduction block was present in the double mutant 
mice, with the proximal iCMAP reduced compared to distal (-35%) (Fig. 3F). 
Interestingly, Nrcam and Sh3tc2 mutant mice had intermediate effects (~ -25%) 
and conduction block was not present in control nerves (-12%).  
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Figure 3. Neuromuscular junction sprouting and fragmentation in 
Nrcam;Sh3tc2 double mutant mice A) Normally, the motor nerve terminal 
(green) completely overlays the postsynaptic acetylcholine receptors (red). B, C) 
Mice with mutations in Nrcam (B) or Sh3tc2 (C) did not show abnormal NMJ 
morphology or nerve occupancy. D) Double mutant mice showed profound NMJ 
defects after 3.5 months of age, with sprouting nerve terminals, sites of partial and 
complete denervation, aneural puncta of AChRs, and fragmentation of NMJs. 
Few if any normal NMJs persist, as shown at a lower magnification (E). 
Sprouting and NMJ dysmorphology (D, E) were observed in all double mutant 
mice >3 months of age (n=5) and were never observed in control or single mutant 
mice. F) The integrated compound muscle action potential evoked from distal 
stimulation was larger than when evoked by proximal stimulation in double 
mutant mice. The mice in F are the same as those analyzed in Figure 2H. Scale 
bar in E represents 14µm in A-D and 84 µm in E. 
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Statistically, the variability inherent in CMAP amplitude with 
transcutaneous stimulation resulted in no significant changes by ANOVA 
(p=0.07), but double mutant mice had significant conduction block when 
compared to control in pairwise comparisons (ttest p=0.01 double mutant vs. 
control). The duration of the proximal iCMAPs was increased by less than 10% 
compared to the distal in all genotypes. Thus, temporal dispersion is not 
pronounced. Taken together, the immunofluorescence and conduction block data 
are consistent with failures in action potential propagation with distance in the 
double mutants.  
To further investigate this, one double mutant mouse was examined for 
synaptic transmission at the NMJ by two-electrode voltage clamp. In this muscle, 
five of the ten fibers recorded produced normal postsynaptic responses following 
nerve stimulation (EPC) (Supplemental figure 4). However, no evoked response 
was produced by nerve stimulation in the other five fibers despite the presence of 
spontaneous mini excitatory postsynaptic currents (mEPCs). Recently, we 
examined 184 NMJs in wild-type mice, only 4 (2%) had mEPCs without a 
corresponding EPC, and within single experiments where 6-11 NMJs were 
examined, an mEPC without an EPC never occurred more than once (Spaulding 
et al., 2016). Thus, the finding that 50% of double mutant terminals showed 
spontaneous release without an evoked response is consistent with neuromuscular 
transmission being relatively normal at active synapses (supplemental figure 4), 
but that action potentials fail to reach some nerve terminals.  
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These effects are completely recessive. The progressive paralysis 
phenotype was only observed in double homozygous mice. Mice heterozygous for 
either or both the Nrcam and Sh3tc2 mutations were normal (supplemental figure 
5). Furthermore, if mice were homozygous for one mutation, being heterozygous 
for the second did not make the phenotype worse (supplemental figure 5). 
Therefore, many of the control values reported are pooled data from heterozygous 
and homozygous wild-type mice.  
Together, these results led us to hypothesize that mutations that 
compromise the axonal length constant will synergize with mutations that 
compromise depolarization, and specifically Na+ currents at nodes. However, 
since Nrcam mutations potentially affect more than Na+ currents, and since 
Sh3tc2 mutations also impact nodes as well as myelination, we performed 
additional experiments compromising the length constant by reducing axon 
diameter, and directly compromising NaV1.6. 
Gars dominant axonal neuropathy is exacerbated by loss of Nrcam 
We used a dominant mutation in glycyl tRNA synthetase (Gars) to specifically 
decrease axon diameter (Achilli et al., 2009). The GarsC201R/+ mice have smaller 
diameter axons than wild type mice, but no axon loss. Thus, in GarsC201R/+ mice, 
the axonal length constant is compromised, and we would predict that diminished 
function at nodes would worsen the phenotype. We bred GarsC201R/+ mice into an 
Nrcam-/- background and repeated our analysis of nerve and muscle histology and 
function. Cross-sections of the motor branch of the femoral nerve confirmed the 
reduced axon size in the GarsC201R/+ mice (p<0.0001), which was not exacerbated 
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by the additional loss of Nrcam (Figure 4 A-D). Axon number was unchanged in 
any genotype (Figure 4E). Nrcam-/- muscles were of normal size, but GarsC201R/+ 
muscles were smaller, and muscles from Nrcam-/-;GarsC201R/+ mice were smaller 
still (p<0.001), as assessed by the ratio of the muscle weights to total body weight 
(Figure 4F). NCV was further reduced in double mutant mice compared to either 
single mutant (p<0.001) (Figure 4 G). In examining NMJs, no partial innervation 
or denervation was observed in Nrcam-/- mice alone (p=0.56), but significant 
innervation defects were seen in GarsC201R/+ (p<0.05) and were worsened by the 
loss of Nrcam (Figure 4H). The double mutant mice were also overtly more 
affected based on size, tremor, and poor motor performance. However, the mice 
did not progress to paralysis and premature death. These studies support the 
hypothesis that the introduction of defects at nodes caused by the Nrcam mutation 
synergize with the GarsC201R/+ mutation to cause a more severe phenotype. 
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Figure 4. Axonal neuropathy is exacerbated by loss of Nrcam (A-C) Cross 
sections of the motor branch of the femoral nerve were examined for three month 
old wild type (A), GarsC201R/+ (B), and GarsC201R/+;Nrcam-/- mice. D) Axon 
diameters were reduced in GarsC201R/+ compared to wild type and Nrcam-/- mice, 
with no further reduction in double mutants. E) Axon number was not reduced in 
any genotype. F) Muscle size was assessed by the ratio of muscle weight (g) to 
total body weight (g) (MW/BW*100) for the triceps surae. No change was 
observed in Nrcam-/- mice, but GarsC201R/+ mice showed reduced MW:BW. 
Double mutant mice showed the largest reduction in MW:BW ratio. G) NCV was 
more severely reduced in double mutant mice than in either single mutant. H) The 
GarsC201R/+ mice have reduced NMJ occupancy, with more partial innervation of 
NMJs, and some instances of complete denervation. NMJ occupancy was more 
severely reduced in double mutant mice, whereas Nrcam-/- mice had no change in 
NMJ occupancy compared to controls. D, E are based on 8 mice per genotype, F 
on 7 control, 7 Nrcam-/-, 9 GarsC201R/+, and 8 double mutant mice, G on 8 control, 
7 Nrcam-/-, 9 GarsC201R/+, and 9 double mutant mice, and H on 8 control, 6 Nrcam-
/-, 7 GarsC201R/+, and 4 double mutant mice. Values for E-H are mean ± S.D. 
Animals were 3 months of age, and an approximately equal mix of male and 
females were used. *=p<0.05, **=p<0.01, ***=p<0.001. Scale bar in C is 50µm 
for A-C.  
 46 
Heterozygosity for Scn8a (NaV1.6) also exacerbates Gars-associated axonal 
neuropathy 
Next we directly compromised NaV1.6 to assess their possible 
contribution. Since homozygous mutations in Scn8a cause a variety of 
neurological phenotypes in mice and humans (O'Brien and Meisler, 2013), we 
used mice heterozygous for a spontaneous point mutation in Scn8a, R914S, which 
produces a pronounced med-like phenotype as a homozygote (Duchen, 1970) but 
no overt symptoms as a heterozygote. GarsC201R/+ mice were bred to Scn8a+/- 
mice, and offspring of all subsequent genotypes were analyzed. The Scn8a+/- mice 
did not show a reduction in axon size or axon diameter, and the reduced axon size 
observed in GarsC201R/+ was not exacerbated by heterozygosity for Scn8a (Figure 
5 A-F). NCV was reduced in the Scn8a+/- mice, and the NCV in Gars;Scn8a 
double heterozygous mice was lower than in either single mutant alone (Figure 
5G). Although additional muscle atrophy was not seen in the heterozygous mice, 
NMJ innervation status was worse than GarsC201R/+ alone, whereas Scn8a+/- mice 
did not have NMJ defects (Figure 5 H,I). Thus, Scn8a heterozygosity produced no 
phenotype on its own beyond a modest reduction in NCV, but made the 
GarsC201R/+ phenotype more severe both for NCV and for NMJ innervation. The 
GarsC201R/+;Scn8a+/- double heterozygous mice were also overtly more severe. 
These data support our conclusion that the Nrcam effects are largely through 
NaV1.6 mislocalization or decreased NaV1.6 channel function. 
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Figure 5. Axonal neuropathy is exacerbated by partial impairment of 
NaV1.6/Scn8a+/- (A-D) Cross sections from the motor branch of the femoral 
nerve for control (A), Scn8a+/- (B), GarsC201R/+ (C), and double heterozygous mice 
(D). (E) Axon diameters were not changed in Scn8a+/-, and double heterozygous 
mice did not show a greater reduction in axon diameters than GarsC201R/+ alone. F) 
Axon number in the motor branch of the femoral nerve was unchanged in any 
genotype. G) Nerve conduction velocity was mildly reduced in Scn8a+/- mice, and 
double heterozygotes had conduction velocities reduced below either single 
mutant. H) No muscle atrophy was observed in Scn8a+/- mice, and no additional 
muscle atrophy beyond the effects of GarsC201R/+ was observed in double 
heterozygotes. I) Scn8a+/- mice did not show changes in innervation at the NMJ, 
but double heterozygous mice had more partial innervation and denervation at 
NMJs than GarsC201R/+ mice. Values are mean ± S.D. Analyses were performed 
on eight mice per genotype at three months of age with an approximately equal 
mix of males and females. *=p<0.05, **=p<0.01. Scale bar in D is 50µm for A-D. 
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The GarsC201R/+;Scn8a+/- double heterozygous mice also did not progress 
to paralysis and death, consistent with the slow progression of the GarsC201R/+ 
phenotype. However, we also mated Scn8a+/- mice to mice with a more severe 
allele of Gars, P278KY/+. These mice develop a similar, but more severe, motor 
and sensory neuropathy, and also lose 20 to 30% of their peripheral axons by a 
few months of age (Seburn et al., 2006, Motley et al., 2011). We saw a similar 
increase in the severity of the double heterozygous phenotype over GarsP278KY/+ 
alone by 2.5-3.5 months of age (Figure 6). The GarsP278KY/+ mice did not have 
more severe axon atrophy or axon loss when heterozygous for Scn8a (Figure 6 
A,B), but did have more severe reductions in nerve conduction velocity (p<0.01), 
muscle atrophy p<0.01), and NMJ occupancy (p<0.0001) (Figure 6 C-E). 
Eventually, these mice did become severely impaired in motor ability by six 
months of age and were not maintained longer. 
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Figure 6. Scn8a heterozygosity enhances a more severe axonal neuropathy 
model, GarsP278KY/+ (A) There was no additional reduction in axon diameter in 
the motor branch of the femoral nerve over GarsP278KY/+ in mice also 
heterozygous for Scn8a. (B) The GarsP278KY/+ mice have fewer myelinated axons, 
but this reduction was not exacerbated by Scn8a heterozygosity. (C) Nerve 
conduction velocity was further reduced in double heterozygotes, beyond the 
effects of GarsP278KY/+ alone. (D) Additional muscle atrophy was present in 
double heterozygous mice. (E) Additional defects were present at NMJs, with 
increased denervation and partial innervation, and virtually no fully innervated 
junctions. Analyses were performed on eight mice of each genotype between 2.5 
and 3.5 months of age, except C, in which 8 control, and 9 Scn8a+/- mice were 
used and results from 1 GarsP278KY/+ and 2 double heterozygous mice were not 
included because a reliable EMG signal and conduction velocity could not be 
ascertained. Values in B-E are mean ± S.D. *=p<0.05, **=p<0.01 ***=p<0.001, 
****=p<0.0001. 
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Discussion 
 
Our results indicate that mutations that subtly compromise nodes of 
Ranvier and sodium channel function in peripheral axons can be relatively 
innocuous on their own, but synergize with mutations that cause thinner myelin or 
smaller diameter axons in the peripheral nervous system to cause a much more 
severe phenotype. Homozygous mutations in Nrcam or heterozygous mutations in 
Scn8a result in a minor reduction in NCV, and occasional mis-localization and 
reduced numbers of sodium channels in peripheral nerves (Nrcam homozygotes). 
These mutations do not cause overt neuromuscular phenotypes. Furthermore, 
Nrcam-/- or Scn8a+/- mutations do not result in muscle atrophy or histological 
changes in nerve, muscle, or neuromuscular junctions. However, in combination 
with either demyelinating (Sh3tc2 homozygous) or axonal (Gars heterozygous) 
models of CMT, the Nrcam homozygous and Scn8a heterozygous mutations 
exacerbate the phenotype. With Gars mutations, this results in an additional 
reduction in NCV, additional muscle atrophy (in GarsP278KY/+), and additional 
denervation at the NMJ. With Sh3tc2, the effect is particularly severe, resulting in 
progressive paralysis and muscle wasting, leading to death by five months-of-age. 
These results are consistent with peripheral nerve biophysics. Saltatory 
conduction results from depolarizing action potentials opening voltage-gated 
sodium channels localized to nodes. This local depolarization is propagated very 
rapidly from node to node by the passive “cable properties” of the axon. The 
depolarization decays over distance, but as long as it is suprathreshold and opens 
sodium channels at the next node, saltatory conduction continues. The “length 
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constant” of the axon describes the passive decay in potential with distance, and 
depends on the resistance of the membrane (Rm), the axial resistance along the 
axon (Ra), and the capacitance of the membrane (Cm), largely determined by 
myelin thickness (Figure 7).  
 
 
 
 
 
Figure 7. Compromised axonal length constants synergize with compromised 
Na+ conductance Action potentials occur only at nodes of Ranvier in myelinated 
peripheral axons. Depolarization spreads to the next node by passive cable 
properties of the axon, determined by the membrane capacitance (Cm), the 
membrane resistance (Rm), and the axial resistance (Ra). The decay in the passive 
propagation of depolarization with distance is the axonal length constant (l). 
Increasing Cm through thinner myelin or increasing Ra through smaller axons 
both decrease l (dashed line), resulting in less depolarization at the next node. 
Due to the safety factor, this is usually still sufficient to cause suprathreshold 
depolarization at the next node. However, if the amplitude of the action potential 
is also decreased, the same change in the length constant could result in a failure 
to reach the action potential threshold at the next node.  
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The peripheral nerve normally has a "safety factor," such that the length 
constant is ~5 times longer than necessary to sustain saltatory conduction (Li, 
2015). Thus, as predicted, our Nrcam homozygous or Scn8a heterozygous 
mutations that only slightly compromise sodium currents, produce a very mild 
phenotype. The modest reduction in nerve conduction velocity observed in both 
Nrcam homozygous and Scn8a heterozygous nerves is also consistent with a 
reduction in sodium currents at the nodes. The rapid passive propagation of 
depolarization has to overcome the capacitance current. If Cm is increased, or if 
current is decreased, the rate of change in potential will decrease (following the 
equation: ∂V /∂T = i/C). The reduced sodium influx may also slow the time to 
reach threshold depolarization and initiate an action potential. 
To explore the feasibility of our hypothesized interaction, we used a 
simple mathematical model of myelinated axons (Moore JW, Stuart AE. Neurons 
in Action 2: Tutorials and Simulations in NEURON. 
(2007) file:///Applications/NIA2.app/Contents/X_NIA2/splash.htm), with default 
settings for Cm and Na+ current density based on Hodgkin and Huxley parameters 
for a standard myelinated axon. We used 8 µm for a large diameter axon (see 
Figures 2E, 4D, and 5E, as well as (Seburn et al., 2006, Motley et al., 2011)), and 
obtained a nerve conduction velocity of 40 m/s, closely matching our 
experimental results. The 17% decrease in NCV in the Nrcam-/- mice requires 
only a 33% decrease in Na+ current density, less than our estimated loss measured 
by western blotting (Figure 1K, L); although we did not detect a sodium channel 
decrease specifically at nodes by immunofluorescence. The 60% reduction in 
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myelin thickness in Sh3tc2-/- axons produces an NCV of 28.6 m/s in this model, 
closely matching our experimental value. The combined effect of the Sh3tc2 and 
Nrcam mutations using the model is an NCV of 22 m/s, which underestimates the 
effects we see in vivo. A number of additional factors not considered by this 
model may also be involved. First, the axon initial segment may also be affected 
by the loss of NRCAM (Xu and Shrager, 2005). Our distal sciatic nerve 
stimulation circumvents this, but for normal physiological function, it is clearly a 
consideration. Second, in addition to thin myelin, the retraction of the Schwann 
cells from nodes in Sh3tc2 mutant mice may also be increasing K+ conductances 
and shunt current (Arnaud et al., 2009). Nrcam mutant axons do not have 
disrupted paranodes ((Custer et al., 2003, Amor et al., 2014) and not shown), but 
loss of Nrcam interacts with loss of paranodal CASPR to create a more severe 
phenotype (Feinberg et al., 2010). Therefore, we cannot rule out that 
Nrcam;Sh3tc2 double mutant mice have even more severely disrupted paranodes. 
However, whether the effect is decreased Na+ currents or increased K+ currents, 
our hypothesis and the effect on saltatory conduction is fundamentally unchanged. 
Third, peripheral axons typically conduct action potential trains, and propagation 
failures may become more widespread at higher frequency. Finally, 
demyelination or aberrant channel function may alter the resting potential of the 
axon (Kuwabara and Misawa, 2004).  
Nonetheless, the schematic in Figure 7 illustrates the point that a change in 
the length constant that is still within the safety factor, and a change in the 
amplitude of depolarization that is still within the safety factor, could additively 
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result in subthreshold depolarization and action potential failure, as seen in double 
mutant mice. This reflects the functional interdependence of these processes and 
does not require physical interaction between the proteins.  
These results can also be considered in the context of CMT genetics. Since 
virtually all CMTs compromise the axonal length constant, through demyelination 
or axon atrophy, we would anticipate any mutations that compromise nodes to be 
synergistic. Both Gars/CMT2D and Sh3tc2/CMT4C are reported to be influenced 
by genetic modifiers (Sivakumar et al., 2005, Colomer et al., 2006), but 
identifying modifiers is difficult in rare diseases. The SCN8A gene in humans is 
associated with cognitive impairment with and without cerebellar ataxia, and 
early infantile epileptic encephalopathy, and in mice it causes the motor endplate 
degeneration (med) phenotype (Burgess et al., 1995, Trudeau et al., 2006, 
Veeramah et al., 2012, O'Brien and Meisler, 2013). Nrcam mutations are 
associated with neurodevelopmental disorders and addictive behaviors in humans 
(Bonora et al., 2005, Sakurai et al., 2006, Ishiguro et al., 2006, Kim et al., 2009, 
Marui et al., 2009, Yoo et al., 2012). However, our point is not to make a direct 
case for NRCAM or SCN8A as human disease modifiers for CMT, indeed, their 
clinical associations are more severe than the “subclinical” mouse mutations we 
are describing, but instead to use them as a demonstration of the principle that 
variants that impact nodes will lead to more severe CMT phenotypes. Such 
variants may include any of the key components of the node of Ranvier (see 
(Rasband and Peles, 2015) for review). Although the frequency of such modifiers 
is currently unknown, as genetic diagnostic sequencing improves variants in such 
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genes in patients diagnosed with CMT can be tested for correlation with the 
disease severity, which could improve the prognostic accuracy for disease 
severity and progression. 
Finally, these results may also suggest a treatment strategy. Sodium 
channels are generally antagonized by more slowly gated potassium channels, 
which attenuate and truncate the sodium-mediated depolarization. Thus, if 
decreased sodium currents are detrimental, then perhaps reduced potassium 
currents would be beneficial. This is readily testable in these mouse models. 
 In summary, genetic analyses in mice have led to the general hypothesis 
that mutations compromising the axonal length constant will synergize with 
mutations that alter nodes and/or reduce Na+-channel mediated depolarization in 
peripheral axons. These findings are consistent with our understanding of axonal 
action potential propagation, and have implications for the diagnosis and 
treatment of diseases resulting in neuropathy, such as CMT. 
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CHAPTER 3 
ALLELE-SPECIFIC RNA INTERFERENCE: PRECISION GENE 
THERAPY FOR DOMINANTLY-INHERITED PERIPHERAL 
NEUROPATHIES 
Abstract 
 
Recent advances in personalized medicine have given rise to effective, 
targeted therapeutic interventions for diseases ranging from cancers to human 
airway disease. Furthermore, personalized gene therapy approaches are being 
successfully deployed to treat rare, recessive genetic disorders by restoring the 
expression of mutated genes. However, the feasibility of these approaches for 
dominantly-inherited diseases—where treatment may require reduction in the 
expression of a dominantly toxic mutant protein—is unclear. Here, we use viral 
vector-delivered, allele-specific RNAi in combination with precision mouse 
models of an autosomal dominant neurodegenerative disease to demonstrate the 
effectiveness of allele-specific silencing as a long-term treatment for dominantly-
inherited neuromuscular disorders. 
Introduction 
Personalized medicine seeks to provide the optimized treatment for an 
individual based on the molecular characteristics of their specific disease. For 
example, cancer treatments are customized to the genetics of the patient and the 
tumor (Reck et al., 2016 and Capdeville et al., 2002). However, in rare Mendelian 
diseases, the genetic basis or DNA variant effects may be uncertain or, even when 
defined, chronic, effective treatments may be unavailable (Chong et al., 2015). 
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Animal models recapitulating molecular lesions offer a means for validating the 
causality of new human mutations and can serve as surrogates in preclinical 
therapeutic development studies (Robinson et al., 2014). Furthermore, gene 
therapy approaches can address the primary cause of genetic conditions without a 
detailed understanding of the genetic model, systems biology or pathophysiology 
of the disease (Naldini et al., 2015). Gene therapy approaches are being 
successfully deployed to treat recessive conditions often resulting from loss-of-
function (LoF) alleles, by restoring the expression of the mutated genes (Mendell 
et al., 2017 and Bainbridge et al., 2015).  However, the feasibility of these 
approaches for dominantly-inherited, monoallelic mutations—where treatment 
may require reduction in the expression of a toxic mutant protein resulting from a 
gain-of-function (GoF) allele—is unclear. Here, we combine precision models of 
a dominant inherited neuropathy [Charcot-Marie-Tooth Disease Type 2D 
(CMT2D), MIM#601472, caused by mutations in glycyl-tRNA synthetase, GARS 
MIM#600287] with allele-specific knockdown by viral-vector delivered gene 
therapy to demonstrate the effectiveness of this strategy. We designed our therapy 
for a single patient, but this sets an important precedent as 90% of inherited 
peripheral neuropathies-and the majority of familial amyotrophic lateral sclerosis 
cases- are inherited in an autosomal dominant manner (Boylan et al., 2015 and 
Saprta et al., 2013). 
Charcot-Marie-Tooth Disease Type 2D (CMT2D), also known as distal 
spinal muscular atrophy V (dSMAV), is a rare, progressive, inherited axonal 
neuropathy caused by dominant mutations in GARS, an essential, housekeeping 
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gene encoding glycl-tRNA synthetase (Antonellis et al., 2003). There is no 
treatment for CMT2D or any of the over 80 genetic forms of inherited peripheral 
neuropathy.  To date, at least thirteen individual mutations in GARS have been 
identified in patients with CMT2D, all of which result in single amino acid 
changes in different functional domains of glycl-tRNA synthetase (Lee et al., 
2012, Abe et al., 2009, Rohkamm et al., 2007, James et al., 2006). However, the 
mechanisms through which mutant forms of GARS cause axon degeneration 
remain unclear, limiting the development of a targeted therapy.  
All disease-associated GARS variants studied to date cause impaired 
enzymatic activity in charging glycine onto tRNAGly in vitro and/or decreased 
cellular viability in yeast complementation assays, consistent with a LoF effect 
(Griffin et al., 2014 and Antonellis et al., 2006). However, protein null alleles in 
mice and humans do not cause dominant neuropathy, ruling out 
haploinsufficiency and suggesting a dominant- negative GoF (antimorph) 
mechanism (Lek et al., 2016, Motley et al., 2011, and Seburn et al., 2006). 
Furthermore, transgenic overexpression of wild-type GARS does not rescue the 
neuropathy in mouse models, suggesting that mutant forms of GARS gain toxic 
GoF (neomorph) activity that the wild-type protein cannot out compete (Motley et 
al., 2011). One proposed toxic gain-of-function mechanism involves the abnormal 
binding of mutant GARS to the developmental receptor neuropilin 1 (NRP1).  
This interaction interferes with the normal binding of vascular endothelial growth 
factor (VEGF), an endogenous ligand of NRP1, whose neurotrophic effects are 
critical for neuronal development and survival (He et al., 2015). 
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The aggregate data support the contention that suppression of the mutant 
allele of GARS should be beneficial, whereas enhancing normal GARS function is 
of questionable benefit in the continued presence of the mutant protein. We 
hypothesized that for a GoF mutant allele, suppression would have a 
therapeutically beneficial effect. To achieve this suppression, we developed a 
gene therapy strategy for CMT2D that reduces the levels of mutant Gars 
transcripts through allele-specific RNAi, triggered through the delivery of mutant 
Gars-targeted artificial microRNA expression cassettes packaged within self-
complementary adeno-associated viral vectors, serotype 9 (scAAV9).  
                                           Results  
To determine whether our approach could be translational, we sought to 
demonstrate the therapeutic efficacy of a patient-specific RNAi based gene 
therapy in a “humanized” mouse model expressing a patient-specific GARS 
mutation introduced into the mouse Gars gene. We chose a GARS variant that we 
recently identified in a now six-year-old female who presented clinically by 
displaying decreases in muscle tone, head lag, axillary slippage, mild tongue 
atrophy, ligamentous laxity in the hands and feet, and excessive retraction of the 
chest wall starting at 13 months of age. Muscle biopsy at 15 months was 
indicative of neurogenic changes consistent with neuropathy. This included 
marked atrophy of type I and II fibers, and no evidence of myofiber necrosis, 
degeneration, or regeneration, nor of dystrophic or inflammatory myopathy. EMG 
and nerve conduction studies were also consistent with motor neuron disease. 
After negative tests for spinal muscular atrophy, whole-exome sequencing 
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analysis revealed that the patient is heterozygous for an in-frame deletion of 12 
nucleotides in exon 8 of the glycyl-tRNA synthetase (GARS) gene (c.894_905del; 
NM_002047.2), resulting in the deletion of four highly conserved amino acids in 
the GARS protein (p.Glu299_Gln302del; NP_002038.2) hereafter, referred to as 
∆ETAQ. No other potentially pathogenic variant was identified at another locus 
that could potentially explain the severity of the neuropathy by a dual molecular 
diagnosis. Neither parent carries the identified GARS mutation, nor does the 
patient’s twin brother, indicating a de novo mutation. GARS functions as a dimer 
to ligate glycine onto cognate tRNA molecules. The substrate glycine is bound 
within a pocket of each monomer, and one tRNA molecule associates with each 
half of the dimer. Importantly, the ∆ETAQ GARS mutation results in the deletion 
of four amino-acid residues that are conserved from human to bacteria and that 
reside within the glycine-binding pocket (Figure 8 A) (Qin et al., 2014). 
To determine if the ∆ETAQ GARS mutation affected mRNA expression or 
stability, we performed RNA-seq to assess the expression of wild-type and mutant 
alleles in patient primary dermal fibroblasts. These analyses revealed an even 
distribution of wild-type (53.7%) and ∆ETAQ (46.3%) RNA-seq reads indicating 
that ∆ETAQ GARS does not dramatically affect transcript levels (Supplemental 
figure 6 A). To determine if ∆ETAQ GARS impacted GARS protein levels, we 
performed western blot analysis on whole-cell lysates from these cells compared 
to a control primary dermal fibroblast cell line (i.e., bearing no GARS mutations). 
These experiments did not reveal an observable difference in total GARS protein 
levels in the affected fibroblasts compared to the control cell line, consistent with 
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the mutant protein being expressed and stable (Supplemental figure 6 B). We next 
performed two experiments to assess if ∆ETAQ GARS affects the primary 
function of the enzyme: aminoacylation assays and yeast complementation tests. 
Analysis of the initial rate of aminoacylation as a function of the tRNA substrate 
concentration showed that ∆ETAQ GARS retained less than 0.01% 
aminoacylation activity (Figure 8 B, Supplemental table 1) compared to wild-type 
GARS indicating that it is a functional null allele.  Although the P234KY allele 
showed activity in assays with saturating tRNA and glycine substrate 
concentrations, a re-evaluation of kinetic properties under Michaelis-Menton 
conditions also showed a marked decrease in enzyme activity, making ETAQ 
GARS analogous to P234KY GARS (equivalent to the mouse P278KY mutation, 
numbered without the mitochondrial targeting sequence included) (Figure 8 B). 
The reduced function of the ∆ETAQ allele was further supported by the failure of 
this mutant protein to complement ablated cellular growth associated with 
deletion of the yeast ortholog GRS1 (Figure 8 C).  Data from this latter assay also 
support the LoF effect associated with P278KY Gars (Figure 8 C) and was 
consistent with the failure of the mouse P278KY allele to complement an RNA-
null allele of Gars (Seburn et al., 2006).  
Previous studies showed that neuropathy-associated GARS mutations 
cause inappropriate binding to neuropilin-1 (NRP1), which leads to impaired 
NRP1/VEGF signaling in motor neurons (He et al., 2015). To directly test for 
binding between ∆ETAQ GARS and NRP1, we expressed V5-tagged wild-type, 
P234KY, and ∆ETAQ GARS in the mouse motor neuron cell line NSC-34. After 
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immunoprecipitation with an anti-NRP1 antibody, proteins were subjected to 
western blot analysis using an anti-V5 antibody. These studies revealed strong V5 
signal associated with P234KY GARS, very weak V5 signal associated with 
∆ETAQ GARS, and no V5 signal associated wild-type GARS (Figure 8 D). The 
lack of an interaction between ∆ETAQ GARS and NRP1 was also demonstrated 
in unbiased mass spectrometry analyses of proteins immuno-precipitated from 
mouse neuroblastoma (MN1) cells expressing FLAG-tagged wild-type or V5-
tagged ∆ETAQ GARS (Supplemental figure 7).  In sum, ∆ETAQ showed changes 
in activity characteristic of other neuropathy-associated GARS mutations, 
supporting the pathogenicity in the phenotype described above. However, the 
particularly severe phenotype of the and the lack of an interaction between 
∆ETAQ GARS and NRP1 warrant further studies on the link between this 
mutation and peripheral nerve dysfunction. 
To validate the pathogenicity of ∆ETAQ GARS in vivo, we engineered a 
mouse model in which the mutation was introduced into exon 8 of the mouse 
Gars gene (Gars∆ETAQ/+) using CRISPR/Cas9 genome-editing technology (see 
Methods for details). For subsequent preclinical studies, Gars∆ETAQ/+ mice were 
crossed to GarshuEx8/huEx8, a second mouse model we engineered that harbors a 
“humanized” wild-type Gars exon 8. The Gars gene is highly conserved, 
including intron/exon structure, and the fifty amino acids encoded by exon 8 are 
100% identical between mouse and human, although there are some silent single-
nucleotide differences that could affect allele-specificity of gene silencing, 
thereby necessitating humanizing the wild-type exon.  
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This breeding produced a cohort of Gars∆ETAQ /huEx8 mice with GarshuEx8/+ 
littermate controls. Reverse transcriptase-PCR using cDNA isolated from sciatic 
nerve of heterozygous mice revealed co-expression of ∆ETAQ and wild type 
Gars (Supplemental figure 8 A). At the protein level, a western blot analysis of 
brain homogenates using a polyclonal anti-GARS antibody confirmed that 
∆ETAQ Gars did not alter GARS protein levels, suggesting that a stable 
transcript and protein products are produced from the ∆ETAQ allele similar to our 
results with patient fibroblasts (Supplemental figure 8 B). 
At 12 weeks-of-age, Gars∆ETAQ/huEx8 and GarshuEx8/+ littermates were 
evaluated for features of primary neuropathy, as observed in other mouse models 
of CMT2D (Achilli et al., 2009 and Seburn et al., 2006). Like these previous 
models, Gars∆ETAQ/huEx8 mice displayed overt neuromuscular dysfunction and a 
significant reduction in body weight (p = 0.0006) and grip strength (p = 0.0002) 
compared to huEx8/+ controls (Figure 8 E-F). Histological changes in 
Gars∆ETAQ/huEx8 mice were observed in cross sections of the motor branch of the 
femoral nerve, including an overall decrease in axon number (p = 0.0293) and 
axon diameter (p = <0.0001) (Figure 8 G-I). Nerve conduction velocities (NCV) 
were also reduced by 62%, falling from 35 ± 6.29 m/s in control animals to 13.5 ± 
4.1m/s (p =0.0002) in the sciatic nerve in mutant mice (Figure 8 J). This decrease 
was consistent with NCVs observed in other mouse Gars neuropathy models and 
in some patients with GARS-mediated peripheral neuropathy (CMT2). The loss of 
motor axons resulted in a concomitant disruption of neuromuscular junctions 
(NMJs) in distal muscles. While postsynaptic receptor fields of NMJs in the 
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plantaris muscle were fully occupied by motor nerve terminals in control 
littermates, 60% ± 14.2% of NMJs were partially occupied and 8.5% ± 9.9% were 
completely denervated in mice that expressed the ∆ETAQ mutation (Figure 8 K-
M). Thus, Gars∆ETAQ/huEx8 mice display primary features of peripheral neuropathy 
similar to those observed in established mouse models of CMT2D, confirming 
that the ∆ETAQ GARS mutation was indeed pathogenic and causative of the 
neuropathy (Morelli et al., 2017, Bais et al., 2016, Achilli et al., 2009 and Seburn 
et al., 2006). 
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Figure 8. In vitro and in vivo characterization of the ∆ETAQ GARS variant  
(A) The position and evolutionary conservation of the ∆ETAQ (red) and P234KY 
(green) GARS mutations are shown, along with flanking amino acid residues. (B) 
Initial aminoacylation rates (pmole/min) of wild-type, P234KY, and ∆ETAQ 
(blue) GARS were plotted against tRNA concentrations and fit to the Michaelis-
Menten equation. Error bars indicate standard deviations. (C) Representative 
cultures of yeast strains lacking GRS1, the yeast ortholog of glycyl tRNA 
synthetase, were plated on solid growth medium containing 5-FOA to induce 
expression of transfected vectors containing no insert (Empty pYY1), or 
containing either a wild-type or mutant (∆ETAQ or P234KY) human GARS open-
reading frame. Before inoculating on medium containing 5-FOA, each strain was 
either undiluted, or diluted 1:10 or 1:100 in water. Two independently generated 
expression constructs were employed for each mutation. (D) Wild-type (WT), 
P234KY, or ∆ETAQ GARS were expressed in mouse motor neuron cells. 
Subsequently, immunoprecipitation with an anti-NRP1 antibody was performed 
to detect aberrant interactions. Western blots were performed with anti-NRP1 and 
anti-V5 antibodies. (E) The body weight of Gars∆ETAQ/huEx8 mice and littermate 
controls was measured at 12 weeks. Gars(∆ETAQ/huEx8) mice were significantly 
lighter, weighing 19 ±1.9 grams (p=0.0006, n=8) compared to GarshuEx8/+ 
controls, which weighed 27.4 ±4.84 grams (n=7). (F) Gross motor performance in 
Gars∆ETAQ/huEx8 mice was quantified using a wire hang test. While GarshuEx8/+ 
mice averaged 55 ±9.57 seconds before letting go, Gars∆ETAQ/huEx8 mice (n=8) fell 
after only 17.3 ±11.3 seconds. (G) Axon number in the motor branch of the 
femoral nerve was reduced by 21% from 551 ±45 axons in littermate controls to 
438 ±92 axons in Gars∆ETAQ/huEx8 (n=6 mice per genotype). (H) Axons were also 
smaller in diameter, as shown in a cumulative histogram of axon diameters 
(p<0.0001), with a complete absence of large diameter axons in Gars(∆ETAQ/huEx8) 
mice (average diameter =1.6 ±0.8 µm, n= 6) compared to Gars(+/huEx8) littermates 
(3.3 ±2.198 µm n=6). (I) These changes are evident in images of nerve cross 
sections. (J) Nerve conduction velocity (NCV) was significantly reduced from 35 
±6.29 m/s in littermate controls to 13.5 ±4.1m/s in Gars∆ETAQ/huEx8 mice 
(p=0.0002, n=6 Gars∆ETAQ/huEx8, n=7 GarshuEx8/+). (K) In addition, neuromuscular 
junctions (NMJs) from the plantaris muscle showed partial innervation and 
denervation, scored based on the overlap between pre- and post-synaptic staining. 
While 98.0% of control NMJs were fully innervated, only 32.6% were fully 
innervated in Gars∆ETAQ/huEx8 mice, with 60% being partially innervated and 8.5% 
completely denervated. Representative images of NMJs morphology and 
innervation are shown (L, M) after labeling with antibodies against neurofilament 
and synaptic vesicles and alpha-bungarotoxin. Differences between body weight, 
grip strength, conduction, axon number between genotypes were statistically 
evaluated using a two-way student’s t test, while axon diameter was evaluated by 
a KS test. Significant difference in overall % NMJ innervation was determined by 
two-way ANOVA with Tukey’s HSD posthoc comparisons. For all analyses 
*=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001 represents posthoc 
significance between genotypes. Values are mean ± S.D. All scale bars = 100 µm. 
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To test whether the allele-specific knockdown of mutant GARS using 
RNAi would be efficacious in the context of a pathogenic human GARS mutation, 
we first engineered a miRNA shuttle designed to specifically target ∆ETAQ 
transcripts for degradation (Figure 9 A-B, Supplemental figure 9) in the 
Gars∆ETAQ/huEx8 mice. Specifically, we designed six different mir-30 based 
artificial microRNAs shuttles (mi.∆ETAQ1-6) with a mature guide strand 
designed to specifically target both human and mouse mutant Gars ∆ETAQ 
mRNA for degradation (Figure 9 B, Supplemental figure 9). To identify our lead 
microRNA shuttle, we cloned each mi.∆ETAQ sequence into an U6-promoter-
driven expression cassette.  These were used in an initial in vitro dual-luciferase 
screening assay (Boudreau et al., 2011) in which we cloned the ∆ETAQ or 
wildtype Gars target sequences into the 3’ UTR of sea pansy (Renilla reniformis) 
luciferase and used firefly luciferase as a standard. Knockdown efficiency and 
disease-allele specificity were tested following co-transfection of the reporter 
plasmid and each U6.mi.∆ETAQ shuttle (or a control vector) into HEK293 cells. 
The most effective construct (mi∆.ETAQ-5, now referred to as mi.∆ETAQ) 
(Figure 9 B) was cloned into a self-complementary adeno-associated viral vector 
(serotype 9, scAAV9) for in vivo delivery (Figure  9 B, Supplemental figure 9). 
To first establish the proof-of-principle of this approach in vivo, we tested 
whether the reduction of mutant Gars expression before disease onset could 
prevent the onset of neuropathy in Gars∆ETAQ/huEx8 mice. A total dose of ~2.6x1011 
vg of scAAV9.mi.∆ETAQ or scAAV9.mi.LacZ (expressing a control microRNA 
targeting the E. coli LacZ gene) were delivered with an intracerebroventricular 
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(ICV) injection at postnatal day 0-1 (P0-1) to Gars∆ETAQ/huEx8 and littermate 
control (GarshuEx8/huEx8) pups. All mice were evaluated for established signs of 
neuropathy at 4-weeks-of-age, ~1.5 weeks after the initial onset of overt signs of 
neuropathy. Gars∆ETAQ/huEx8 mice treated with scAAV9.mi.∆ETAQ showed 
significant improvement in a wire hang test of grip strength, increased muscle to 
body weight ratios (MW:BW), and improved sciatic nerve conduction velocity 
(NCV) compared to control-treated ∆ETAQ mice (Figure 9 C-E).  Examination of 
cross-sections of the motor branch of the femoral nerve revealed that 
scAAV9.mi.∆ETAQ treatment prevented the axon loss and lessened the decrease 
in axon diameters observed in untreated and vehicle control-treated ∆ETAQ mice 
(Figure 9 F-H). Importantly, injection with scAAV9.mi.∆ETAQ (or 
scAAV9.LacZ) did not cause adverse effects in control mice by any of these 
outcome measures or by observation for overt reactions. Collectively, these data 
show that allele-specific knockdown of mutant ∆ETAQ Gars expression prior to 
disease onset has a significant therapeutic effect and almost completely prevents 
behavioral, physiological, and histological signs of neuropathy, providing proof-
of-concept data that allele-specific knockdown using virally delivered RNAi may 
be an effective approach for treating CMT2D. 
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Figure 9. scAAV9.mi∆ETAQ prevents of the onset of neuropathy in Gars(∆ETAQ/huEx8) 
mice (A) Therapeutic miGARS microRNAs utilize naturally occurring RNAi biogenesis 
and gene silencing pathways in target cells.  Each miGARS or control sequence was 
cloned as a DNA template downstream of a U6 promoter and then delivered to cells via 
plasmid transfection (in vitro) or within scAAV9 particles in vivo (depicted here). Once 
in the target cell nucleus, primary microRNA constructs are transcribed and then 
processed by the RNAses Drosha and Dicer and the nuclear export factor Exportin-5 
(Exp5).  The mature antisense strand (red line) incorporates into the RNA-Induced 
Silencing Complex (RISC) to elicit sequence-specific degradation of the mutant Gars 
mRNA. (B) MiRNAs were efficacy tested in vitro by co-transfecting HEK293 cells with 
individual U6-miGARS, or control, plasmids miRNA and a dual-luciferase reporter 
plasmid containing one of four target genes cloned into the 3’ UTR of Renilla luciferase: 
wild type Human GARS, human ∆ETAQ GARS, wild type mouse Gars, or the mouse 
Gars gene containing the same ETAQ deletion. Target gene silencing was then 
determined by measuring the ratio of Renilla to Firefly luciferase. The values are reported 
as mean ratios ±SEM, and the significance of knockdown efficiency was analyzed using 
a two-way ANOVA. Also shown is the sequence of the guide strand of the lead 
mi∆ETAQ and its complementarity to both the wild type and ∆ETAQ GARS gene. The 
four amino acid deletion is shown in red. Base pairing between the miRNA and target 
genes is shown with vertical lines, with red lines indicating wobble G-U bonds present in 
RNA duplexes. (C-F) scAAV9.mi∆ETAQ treatment in vivo deliver ICV to 
neonatal mice significantly prevented deficits at four weeks of age in gross motor 
performance quantified by the wire hang test (p= 0.0001) as well as reductions in 
MW:BW ratios (p = 0.0315) and NCVs (<0.0001), compared to vehicle-treated 
Gars(∆ETAQ/huex8) mice. (F-H) Furthermore, quantification of axon number and 
axon size indicated that scAAV9.mi∆ETAQ could partially prevent axon loss (p= 
0.0272) and reductions in axon diameter (p = <0.0001) compared to 
scAAV9.miLacZ-treated ∆ETAQ mice as displayed in cross sections of the motor 
branch of the femoral nerve. Axon diameter was analyzed using a KS normality 
test while all other outcomes measures were analyzed using a two-way ANOVA 
with Tukey’s HSD posthoc comparisons. *=p<0.05, **=p<0.01, ***=p<0.001, 
****=p<0.0001 represents posthoc significance between scAAV9.mi∆ETAQ- 
and scAAV9.miLacZ- treated ∆ETAQ mice. Values are mean ± S.D. All scale 
bars = 100 µm. Untreated Gars(huEx8/huEx8) n=4,  miLacZ-treated Gars(huEx8/huEx8) 
n=3, scAAV9.mi∆ETAQ-treated Gars(huEx8/HuEx8) n=5, mi.LacZ-treated 
Gars(∆ETAQ/huEx8) n=5, and scAAV9.mi∆ETAQ-treated Gars(∆ETAQ/huEx8) n=5. 
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To practically establish the translational potential of our strategy, we next 
delivered scAAV9.mi.∆ETAQ to cohorts of both early- (5-week-old) and late- (9-
week-old) symptomatic Gars∆ETAQ/huEx8 mice and littermate controls via a single 
intrathecal (IT) injection into the lumbar spinal cord. When left untreated, 5-week 
old early symptomatic Gars∆ETAQ/huEx8 mice are undergo active axon loss, while 
axon loss has slowed and muscle atrophy accelerates in 9-week old late 
symptomatic ∆ETAQ mice. These time point were chosen to determine if 
scAAV9.mi.∆ETAQ could halt the progression of axons loss during early stages 
of neuropathy as well as have therapeutic effects in late stages of neuropathy after 
axon loss has ceased.  
The scAAV9.mi.∆ETAQ-treated early-symptomatic Gars∆ETAQ/huEx8 mice 
displayed enhanced grip strength and significant increases in body weight starting 
at ~5 weeks post treatment compared to untreated controls (Figure 10 A). When 
analyzed for primary signs of neuropathy at 7 weeks post treatment, early-
symptomatic Gars∆ETAQ/huEx8 mice also exhibited significant increases in MW:BW 
ratios, nerve conduction velocity, NMJ innervation and a reduction in axon loss, 
but no improvement in axon size compared to untreated Gars∆ETAQ/huEx8 mice 
(Figure 10 B-D, F). When treated with scAAV9-mi.∆ETAQ at 9 weeks of age, 
Gars∆ETAQ/huEx8 mice gained weight and displayed enhanced grip strength starting 
at 5-7 weeks post treatment (Figure 10 A). While MW:BW ratios were not 
improved and axon loss and atrophy were not prevented, scAAV9.mi.∆ETAQ did 
improve nerve conduction velocity and NMJ innervation (Figure 10 B, E-F). 
Analysis of mRNA from sensory dorsal root ganglia (DRGs) via pyrosequencing, 
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which were also transduced by scAAV9, indicated that mutant Gars mRNA levels 
were significantly reduced in scAAV9.mi.∆ETAQ treated mice compared to 
vehicle-treated controls (Supplemental table 2).  
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Figure 10. Post-Onset therapeutic effects of scAAV9.mi∆ETAQ 
(A-B) Reduction in mutant Gars expression improves grip strength and increases 
body weight in early- and late- symptomatic Gars∆ETAQ/huEx8 mice. (A) 
Mi.∆ETAQ-treated early-and late-symptomatic Gars∆ETAQ/huEx8 mice exhibit 
enhanced grip strength and significant increases in body weight starting at ~5 
weeks post treatment. (B) When evaluated at 7 weeks post treatment for primary 
signs of neuropathy, these data correlate with trending increases in MW:BW 
ratios and significant improvements in nerve conduction velocity in mi.∆ETAQ-
treated late-symptomatic Gars∆ETAQ/huEx8 mice. (B) In addition, early-symptomatic 
Gars∆ETAQ/huEx8 mice treated with mi.∆ETAQ displayed significantly higher 
MW:BW ratios and faster nerve conduction velocity most likely resulting from 
the greater number of motor axons observed in cross-sections of the motor branch 
of the femoral nerve although significant in axon diameter was not observed 
displayed in C-D. In contrast, reversal of axon atrophy was not observed in 
mi.∆ETAQ-treated late-symptomatic Gars∆ETAQ/huEx8 mice (E). Although both 
early- and late- symptomatic overall displayed significant increases in NMJ 
innervation (F). Data was analyzed using a one-way ANOVA followed by 
Tukey’s HSD posthoc comparisons. Significant changes within axon diameter (E) 
were determined with a Kolmogorov-Smirnov test.  *=p<0.05, **=p<0.01, 
***=p<0.001, ****=p<0.0001 represents posthoc significance between miLacZ-
treated and scAAV9.mi∆ETAQ-treated Gars∆ETAQ/huEx8 mice. A = significant 
difference in fully innervated NMJs, B = significant difference in partially 
innervated NMJs, & C = significant difference in denervated NMJs. Late-
symptomatic Cohort: MiLacZ-treated Gars(huEx8/huEx8) n=5-7, scAAV9.mi∆ETAQ-
treated Gars(huEx8/HuEx8) n=3-5, mi.LacZ-treated Gars(∆ETAQ/huEx8) n=6, and 
scAAV9.mi∆ETAQ-treated Gars(∆ETAQ/huEx8) n=7. Early-symptomatic Cohort: 
Gars(huEx8/huEx8) n=6-7, scAAV9.mi∆ETAQ-treated Gars(huEx8/HuEx8) n=3-5, 
mi.LacZ-treated Gars(∆ETAQ/huEx8) n=7, and scAAV9.mi∆ETAQ-treated 
Gars(∆ETAQ/huEx8) n=9-11. Values are mean ± S.D. All scale bars = 100 µm. 
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Given that ∆ETAQ GARS is a de novo mutation and may function through 
a different mechanism than other GARS mutants (i.e. independent of NRP1 
binding), we sought to confirm the generality of our approach in a second mouse 
model of CMT2D, GarsP278KY/+ (Seburn et al., 2006). A miRNA shuttle targeting 
the mouse P278KY allele was optimized in our luciferase assay and packaged into 
scAAV9, as before (Supplemental figure 10).  Similar improvements were also 
observed in neonatal, early- and late- symptomatic GarsP278KY/+ mice that were 
treated with 1x1011 viral genomes of scAAV9.mi.P278KY delivered by ICV 
(neonates) or IT (adults) injection (Figure 11, Supplemental figure 11). 
Furthermore, the therapeutic effects of scAAV9.mi.P278KY were dose-dependent, 
and were greater with ICV delivery compared to a systemic, intravenous injection 
delivering the same total dose (Supplemental figure 12). The beneficial effects of 
ICV delivery of the high dose (1x1011 v.g.) of scAAV9.mi.P278KY at P0 lasted at 
least one year (Supplemental figure 13).  
The outcomes in post-onset studies in both genotypes were variable, likely 
because of the challenges in intrathecal delivery in mice. However, the 
knockdown efficacy of mutant Gars transcripts within dorsal root ganglion 
strongly correlated with therapeutic outcomes within both post-onset studies 
(Supplemental figure 14 A-B, E-F). This correlation was stronger with DRGs than 
when outcomes were compared to mutant Gars mRNA levels in liver, another 
peripheral tissue transduced by scAAV9 (Supplemental figure 14 C-D, G-H). This 
is consistent with mutant forms of GARS causing neuropathy through a cell-
autonomous mechanism. These data indicate that allele-specific knockdown may 
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be a general therapeutic strategy for patients with CMT2D, and suggest that 
delivery needs to effectively target peripheral neurons. Taken together, these data 
confirm that allele-specific RNAi-based gene therapy can improve symptoms of 
neuropathy in two mouse models of CMT2D—including a “humanized” model—
and even at post-onset phases of the disease.  
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Figure 11. Reduction of mutant Gars by RNAi prevents neuropathy in 
Gars(P278KY/+) mice (A) scAAV9.miP278KY treatment by ICV delivery neonatally 
significantly prevented deficits in gross motor performance quantified at four weeks-of-
age by the wire hang test (p= 0.0001) and (B) reductions in MW:BW ratios (p= 0.0463) 
compared to untreated and vehicle-treated P278KY mice. (C) Nerve conductions 
velocities were also significantly improved (p= <0.0001) in treated P278KY mice. (D) 
Quantification of axon number within cross sections of the motor branch of the femoral 
nerve showed that while axon number was reduced by 17% in control-treated P278KY 
mice, axon counts in scAAV9.miP278KY-treated P278KY mice (589±15 axons) were 
similar to untreated control littermates (600±11 axons). (E) As shown in a cumulative 
histogram of axon diameters, scAAV9.miP278KY treatment also restored the presence of 
large diameter axons, with average axon diameter within control-treated P278KY mice 
being 1.98±4.47 µm, 2.71±3.71 µm for scAAV9.miP278KY-treated P278KY mice, and 
3.84±3.74 in untreated Gars(+/+) . The prevention of axon atrophy is evident in 
representative images of cross sections of the motor branch of the femoral nerve isolated 
from untreated Gars(+/+) and Gars(P278KY/+) mice as well as scAAV9.miP278KY-treated 
P278KY mice (F). Representative images of neuromuscular junction (NMJ) morphology 
isolated from plantaris muscle are shown (G) after labeling with antibodies against 
neurofilament and synaptic vesicles (green) and alpha-bungarotoxin (red). While over 
70% of the NMJs are partially or completely denervated in control-treated Gars(P278KY/+) 
mice by 4 weeks of age (H) less than 30% of NMJs show any degree of denervation 
scAAV9.miP278KY-treated Gars(P278KY/+) mice. Ns for the all outcome measures include; 
untreated Gars(+/+) n=5, control-treated Gars(+/+) n=4, scAAV9.miP278KY-treated 
Gars(+/+) n=8, untreated Gars(P278KY/+) n=6, control-treated Gars(P278KY/+) n=5, 
scAAV9.miP278KY-treated Gars(P278KY/+) n=7. Significance in (A-D, H) was determined 
by two-way ANOVA with Tukey’s HSD posthoc comparisons. Significant changes 
within axon diameter (E) were determined with a Kolmogorov-Smirnov test.  
*=p<0.05,**=p<0.01, ***=p<0.001, ****=p<0.0001 represents posthoc significance 
between miLacZ-treated and scAAV9.miP278KY-treated GarsP278KY/+ mice. Values are 
mean ± S.D. All scale bars = 100 µm. 
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Conclusion 
To date, all data from patients with CMT2D and mouse models of 
CMT2D are consistent with the selective silencing of mutant GARS expression 
being the best strategy for treating this disease. The gene therapy strategy we 
developed reduces the expression of mutant Gars transcripts through allele-
specific RNAi.  The efficacy of this treatment was demonstrated in vivo in a 
“humanized” mouse model of CMT2D that expresses a patient-specific GARS 
mutation, including benefit with post-onset treatment, and results were confirmed 
by showing similar benefits with a different vector targeting an independent 
Gars/CMT2D mouse mutation. These studies demonstrate how precision animal 
modeling can be used to engineer improved “humanized” preclinical models for 
testing personalized therapies for rare and orphan diseases, and set an important 
precedent for the use of a RNAi-based gene therapy for this dominant 
neuromuscular disease.  This approach could conceivably be applied to other, 
related disorders including other dominantly inherited peripheral neuropathies or 
motor neuron diseases. 
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CHAPTER 4 
 
GENE THERAPY GAINS STRENGTH: THE PATH FROM GENETIC 
DISCOVERY TO MEDICINE FOR INHERITED NEUROMUSCULAR 
DISORDERS 
 
Gene Therapy: An Innovative Treatment Strategy for Inherited 
Neuromuscular Disease 
Although each individual form may be rare, in aggregate, over 400 
clinically- and genetically-diverse inherited neuromuscular disorders (NMDs) that 
lead to muscle weakness and immobility affect an estimated 1:3500 individuals 
worldwide (Emery, 1991). To date, not one NMD is currently curable, likely due 
to their genetic and clinical heterogeneity, making treatment development for 
NMDs an extremely difficult endeavor. Although, with the amazing 
advancements in Next Generation sequencing, genome-editing technologies, and 
other innovative genetic tools, the direct genetic cause of, or genes that contribute 
to the severity of a neuromuscular disorder, have been identified. In response, the 
research community has put much effort into developing cutting-edge, innovative 
gene-targeting therapies for these devastating diseases. Here we review both the 
success of current FDA-approved treatments as well as promising preclinical 
support for prospective gene therapy approaches for a number of NMDs. We also 
highlight several considerations that must be taken when engineering future gene 
therapies for the clinic. All told, gene therapies have the potential to provide a 
powerful and effective treatment strategy for many deserving individuals affected 
by a NMD.  
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Escalating SMN Expression for Spinal Muscular Atrophy 
Spinal muscular atrophy (SMA) represents a group of autosomal-recessive 
neurodegenerative disorders generally characterized by progressive muscle 
weakness and paralysis within proximal limb muscle resulting from the 
degeneration of lower motor neurons (Mendell et al., 2017). Its estimated 
incidence is 1 in 10,000 to 1 in 6,000 live births, with a high carrier frequency of 
~1 in 54 (Sugarman et al., 2012). The clinical presentation of this disorder can 
vary, and is further classified, based on the age of onset and clinical progression, 
into SMA Type I-IV (D’Amico et al., 2011 and Wang et al., 2007). About 60% of 
patients are diagnosed with SMA I, also known as Werdnig-Hoffmann disease, 
the most severe form of SMA and the leading genetic cause of infant death 
(D’Amico et al., 2011, Dubowitz., 1999 and MacLeod et al., 1999). It presents 
very early in life, with most patients diagnosed at 6 months of age with an average 
survival of 3 years (Hoyert et al., 2011).  Type II SMA is intermediate in severity, 
with onset before 18 months of age and patients never gaining the ability to walk. 
Types III & IV SMA are relatively mild, with onsets after 18 months and in late 
adulthood, respectively (D’Amico et al., 2011and Wang et al., 2007).  Patients 
with either Type III or IV only experience mild muscle weakness and often retain 
the ability to walk (Wang et al., 2007).  
All cases of SMA are caused by mutations within the survival motor 
neuron (SMN) gene (Lefebvre et al., 1995). In humans, SMN is located within an 
inverted duplication on chromosome 5q13 that contains four genes present in both 
telomeric and centromeric copies that can vary from 0-4 copies per chromosome, 
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making it prone to rearrangements and deletions (Tisdale et al., 2015). Indeed, 
variants within this region are often caused by unequal crossing over between the 
repeated units during paternal meiosis, increasing carrier frequency of this disease 
(Tisdale et al., 2015). Both telomeric (SMN1) and centromeric (SMN2) copies of 
SMN share 99.8% sequence homology and encode the same protein. SMN1 can 
be distinguished from SMN2 by only five nucleotide differences: one within 
intron 6, exon 7, and exon 8, and two within intron 7 (Kashima et al., 2000). The 
nucleotide exchange within exon 8 lies within the 3’ untranslated region, while 
the C to T transition is in an exon splice enhancer site in exon 7 that, while 
translationally silent, alters splicing, and often results in the exclusion of exon 7 
within SMN2 transcripts (Kashima et al., 2000 and Lorson et al., 1999). As a 
result, while SMN1 always yields full-length transcripts, SMN2 primarily 
produces a truncated transcript lacking exon 7 (~60%) and a relatively small 
number of full-length transcripts (~40%) (Cho and Dreyfuss, 2010 and Lorson 
and Androphy, 2000). Considering exon 7 of the SMN genes encodes a functional 
domain that is responsible for self-oligomerization, SMNΔ7 protein oligomerizes 
less efficiently, is unstable, and rapidly degrades (Vitte et al., 2007). Not 
surprisingly, homozygous deletion or mutations in exon 7 of SMN1 have been 
identified in 94% of patients with SMA yielding a significant reduction in SMN 
protein (Wirth, 2000). There is a slightly higher frequency of homozygous 
absence of SMN1 in types I and II (96% and 94%, respectively) as compared to 
type III SMA (86%) (Wirth, 2000). Also, copy number of SMN2 correlates with 
disease severity, with patients with a higher copy number often displaying milder 
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symptoms, indicating the loss of SMN protein largely accounts for disease onset 
(Gavrilov et al., 1998 and Lefebvre et al., 1997). 
SMN is a ubiquitous 38 kDa polypeptide that is highly expressed in spinal 
motor neurons (Tisdale et al., 2015). Recent research has shown that plays an 
essential role in spliceosomal snRNP biogenesis and pre-mRNA splicing (Li et 
al., 2014 and Fischer et al., 2011). It is expressed in both the cytoplasm and in 
compartments within the nucleus called gems (Tisdale et al., 2015). However, 
why the absence of this housekeeping protein results in specific lower motor 
neuron loss remains unclear. Nevertheless, therapeutic strategies have been 
centered on increasing total levels of SMN in motor neurons of the spinal cord. 
The first FDA-approved treatment for SMA, Nusinersen, a modified 2’-O-
methoxyethyl phosphorothioate antisense oligonucleotide (ASO), is designed to 
increase the inclusion of exon 7 into SMN2 transcripts, and thus increase 
production of a functional, stable SMN protein, which can compensate for the 
disease-causing null and loss-of-function mutations in the SMN1 gene (Finkel et 
al., 2016).  This is accomplished by 10 arginine-serine dipeptide repeats within 
the ASO that drive the artificial recruitment of splicing enhancer factors to exon 7 
of SMN2 (Finkel et al., 2016 and Singh et al., 2006). Interim analysis of a phase 
III, double-blind, sham-procedure controlled clinical trial showed the post-onset 
benefit of Nusinersen for infantile-onset SMA patients who had two or more 
copies of the SMN2 gene (Finkel et al., 2016).  Indeed, 40% of treated patients 
achieved critical developmental motor milestones compared to sham-procedure 
controls (Finkel et al., 2016). This treatment was found to be so beneficial that all 
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subjects within the placebo group were switched to Nusinersen (Finkel et al., 
2016). Similar effects of this SMN2-targeting ASO were identified when given to 
later-onset SMA patients with 2-4 copies of SMN2 (Parente et al., 2018). This 
study was stopped prematurely, based on a highly significant treatment effect 
based on the Hammersmith Functional Motor Scale – Expanded (Parente et al., 
2018). Both studies imply that this treatment strategy may be therapeutically 
beneficial for all SMA patients across its phenotypic scale; however, both studies 
had non-responders, indicating possible variable effects.   
Although highly efficacious, the effects of Nusinersen are transient, 
requiring patients to receive four intrathecal injections of the ASO within the first 
few weeks of treatment, and every 6 months thereafter (Parente et al., 2018, 
Mendell et al., 2017, Finkel et al., 2016). This type of injection is invasive and 
could cause adverse effects in patients. In response, an alternative gene therapy 
has been developed that involves a one-time intravenous delivery of SMN1 
complementary DNA under the control of a hybrid cytomegalovirus enhancer-
chicken beta-actin promoter with the use of a recombinant viral delivery vehicle: 
self-complementary adeno-associated viral vector (scAAV9) (Dominguez et al., 
2011, Foust et al., 2010, Valori et al., 2010, and Foust et al., 2009). This therapy 
is designed for rapid and sustained expression of SMN, not only in motor 
neurons, but other peripheral tissues that contribute to SMA symptoms, including 
the autonomic and enteric nervous systems, the heart, and the pancreas. In a phase 
1 clinical trial, 15 treated SMA patients exhibited longer survival, greater 
achievement of motor milestones, and significant improvements in motor function 
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compared to historical cohorts. Although additional studies will be required to 
confirm both safety and efficacy of this gene therapy approach, preliminary data 
show that phenotypic improvement can be achieved with a single, noninvasive, 
intravenous injection regardless of SMN2 copy number within each patient 
(Mendell et al., 2017).  
Due to the success of SMN gene replacement therapy, an analogous 
therapeutic approach has been developed for patients with a similar infantile-onset 
motor neuron disease known as spinal muscular atrophy with respiratory distress 
type 1 (SMARD1) (Eckart et al., 2012 and Grohmann et al., 2001). This 
autosomal recessive neuromuscular disorder is caused by the haploinsufficiency 
of another housekeeping gene encoding the immunoglobulin µ-binding protein 2 
(IGHMBP2) (Jankowsky et al., 2011 and Guenther et al., 2009). IGHMBP2 is an 
adenosine triphosphatase/helicase motif-containing DNA-binding protein that 
regulates several nuclear, RNA, and translation processes (Nizzardo et al., 2015). 
However, as in SMN1, it is unclear why the loss of this ubquitous housekeeping 
gene leads to selective loss of motor neurons. Recent studies have shown that a 
single, systemic delivery of IGHMBP2 transgene via scAAV9 can largely prevent 
motor neuron loss, increase survival, and improve motor function in the nmd 
mouse model of SMARD1 when delivered at the preonset age of postnatal day 1 
(Nizzardo et al., 2015). This model harbors a splice site mutation in Ighmbp2 and 
exhibits a neuromuscular phenotype similar to patients (Cox et al., 1998). 
Furthermore, the delivery of wild-type IGHMBP2 rescued the disease phenotype 
in human SMARD1 motor neurons in vitro (Nizzardo et al., 2015). Both 
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experiments yield the premise for future clinical trials testing gene replacement 
therapy for SMARD1, although its postonset effects in vivo remain unclear.  
Exon Skipping Methods for Duchenne Muscular Dystrophy 
Muscular dystrophy (MD) represents an entire heterogeneous group of 
inherited myogenic disorders characterized by progressive muscle wasting and 
weakness that affects limb, axial, and facial muscle, although severity, age of 
onset, and the overall progression can vary greatly among different forms. 
Additionally, in some cases, the diaphragm, cardiac smooth muscle, and 
swallowing muscles can also be affected (Mah et al., 2016).  
Duchenne and Becker MDs are both X-linked, recessive forms of MD, 
together affecting 1 in 3,500 to 5,000 newborn males worldwide. Both disorders 
are caused by mutations in the dystrophin gene (DMD), the longest human gene, 
consisting of 2.4 megabases, or 1% of DNA within chromosome X (Koenig et al., 
1987 and Kenwrick et al., 1987). It contains at least seven independent, tissue-
specific promoters and two polyA-addition sites, producing 17 different isoforms 
that are named based their lengths and splicing patterns (Rumeur., et al 2015). 
The full-length isoform is expressed in all striated skeletal muscle and consists of 
an N-terminal domain that binds to actin filaments (encoded by exons 1-8), a 
central rod domain (exons 9-61), and a C-terminal cysteine-rich domain (exon 62-
80) that help anchor dystrophin to the plasma membrane, where it interacts with 
many integral muscle proteins, including cytoskeletal actin, microtubules, and 
intermediate filaments to the extracellular matrix (Ervasti et al., 2007). Thus, 
dystrophin acts as scaffolding protein that is critical for sarcolemmal integrity. 
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Any disruption of dystrophin’s scaffolding network can lead to either Duchenne 
or Becker MD.  
Over 2/3 of patient of patients with either Duchenne or Becker MD harbor 
mutations that delete one or more exons in DMD (Rumeur., et al 2015). 
Duchenne, the more severe of the two disorders, is caused by frameshift 
mutations that disrupt the open reading frame of DMD, resulting in the complete 
loss of dystrophin (Rumeur et al., 2015 and Monaco et al., 1988). Patients with 
this form of MD exhibit severe, progressive muscle wasting causing the loss of 
ambulation within the first decade of life, and suffer from cardiomyopathy often 
leading to premature death (Kohler et al., 2005).  Becker MD, meanwhile, is 
caused by in-frame deletions that result in a truncated but partially-functional 
dystrophin that often retains its N-terminal and C-terminal domains (Rahimov et 
al., 2013 and Davies et al., 2006). Patients with this disorder have a milder 
clinical pathology and normal lifespan (Bushby et al., 1993). Even individuals 
lacking more than 60% of the central rod domain are diagnosed with mild Becker 
muscular dystrophy (Rahimov et al., 2013 and Davies et al., 2006). This implies 
that even a DMD gene with large in-frame deletions can yield partially functional 
dystrophin and ameliorate the severity of the disease. Thus, treatment 
development has been centered on altering splicing in an effort to restore the open 
reading frame within DMD genes affected by nonsense mutations. The goal is to 
turn a frameshift mutation into an in-frame deletion, in the hopes of converting 
severe forms of Duchenne MD to a milder Becker phenotype.  
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For example, a series of ASOs designed to skip 20 different exons have 
been developed (exons 2, 8, 17, 19, 29, 40-46, 48-53, 55 and 59) and found to 
restore the reading frame of DMD, subsequently producing truncated dystrophin 
in various in vivo and in vitro models of Duchenne MD (McClorey et al., 2006, 
Goyenvalle et al., 2004, Aartsma-Rus et al., 2004, Surono et al., 2004, Aartsma-
Rus et al., 2003, vanDeutekom et al., 2001, and Takeshima et al., 2001). Exondys 
51 (eteplirsen), an ASO designed to skip exon 51 within DMD, is currently being 
tested for safety and efficacy in clinical trials (Mendell et al., 2013). Specifically, 
this ASO binds to exon 51 in DMD and masks the exon inclusion signals that are 
used for splicing. Removal of exon 51 from an exon 45 to 50, 47 to 50, 48 to 50, 
49 to 50, 50, 52 or 52 to 63 deleted transcript allows restoration of the open 
reading frame and synthesis of an internally-truncated, semi-functional dystrophin 
protein. By targeting exon 51, approximately 13% of patients with Duchenne 
could potentially be treated, the largest proportion of patients that could benefit 
from targeting a single dystrophin exon (Mendell et al., 2013). In 2016, the Food 
and Drug administration accelerated approval for the use of Exondys 51, based on 
its ability to increase the expression of dystrophin in skeletal muscle within 
patients affected by Duchenne, although the extent of its efficacy and long-term 
effects on motor function are still being determined (Aartsma-Rus et al., 2017).  
            Considering ASOs exhibit variable tissue transduction efficacies and 
transient effects, several exon-skipping approaches based on clustered regularly 
interspaced short palindromic repeats (CRISPR)-Cas9 genome editing are 
currently being developed (Long et al., 2018, Juliano et al., 2016, Tabebordbar et 
 92 
al., 2016, Ousterout et al., 2015). This direct genome editing approach would only 
require a one-time treatment that would result in an irreversible genomic 
modification and production of exon-deleted mRNA, which would, in turn, 
produce a semi-functional dystrophin protein. In addition, this method could 
potentially eliminate the disease from being inherited by future generations, if the 
germline were also allowed to be modified. In a proof-of-concept study, AAV9-
delivered CRISPR/Cas9 endonucleases and paired guide RNAs were shown to 
excise a nonsense mutation in exon 23 of the dmd gene within adult mdx mice, an 
established model of DMD (Tabebordbar et al., 2016). This restoration of the 
gene’s reading frame initiated the expression of dystrophin and partially 
recovered muscle function (Tabebordbar et al., 2016). However, the disease-
causing mutation in the mdx mouse is a point mutation that leads to a premature 
stop codon and subsequent disruption of dystrophin expression. Point mutations 
have only accounted for 5-9% cases of DMD, while over 3000 different 
frameshift mutations in DMD have been reported to cause Duchenne muscular 
dystrophy (Rumeur et al., 2015). Thus, there is a great need to develop an exon-
skipping or alternative gene therapy that can treat wider populations of patients.  
In response, an alternative gene therapy approach that consist of a virally-
delivered truncated dystrophin transgene with non-essential regions of the gene 
deleted known as ∆R4-R23/∆CT and is often referred to as micro-dystrophin (µ-
dys). Remarkably, both intramuscular and intravenous administration of AAV 
vectors containing µ-dys expression cassettes significantly improves muscle 
membrane integrity and function in the mdx mouse and greatly extended the 
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lifespan of dystrophin/utrophin double knockout mice (Gregorevic et al., 2006, 
Yue et al., 2006, Liu et al., 2005, Gregorevic et al., 2004, Yue et al., 2003, Harper 
et al., 2002). This therapy, now fornally being tested in clinical trials for efficacy 
and safety (https://clinicaltrials.gov/ct2/show/NCT03375164) has a major 
advantage over exon-skipping methods as this treatment can treat any individual 
with Duchenne’s MD regardless of their distinct mutation in DMD. Furthermore, 
recent studies have shown that 60% of DMD mutations are clustered in two 
“hotspots” within the human DMD gene: one within exons 45 to 55 and another 
between exons 2 and 10 (Aartsma-Rus et al., 2009). In response, several research 
groups have developed a CRISPR/Cas9-based therapy that eliminates a 336-kb 
genomic region flanking exons 45 to 55 in the human DMD gene with the use of 
multiplexed single-guide RNAs (Ousterout et al., 2015). This technique could 
restore dystrophin expression in human DMD myoblasts, yet it did exhibit off-
target effects, including chromosomal rearrangements (Ousterout et al., 2015). To 
avoid the elimination of large genomic regions and in order to treat patients with 
mutations within exon 2-10, Long et al have recently developed a series of single 
guide RNAs designed to excise the 12 most common affected exons in DMD and 
induce the expression of dystrophin in both patient-derived iPSCs and derivative 
cardiomyocytes (Long et al., 2018). Remarkably, these single guides could even 
restore muscle force and contraction within a three-dimensional engineered heart 
muscle derived from treated DMD patient-derived induced cardiomyocytes (Long 
et al., 2018). However, long-term efficacy and safety have yet to be determined in 
a formal preclinical study.  
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In future, personalized CRISPR/Cas9 based gene therapies should be 
developed not just to convert a DMD mutation to a BMD mutation but to engineer 
a complete DMD transcript. This way, a fully-functional dystrophin protein will 
be expressed, treating both Becker and Duchenne muscular dystrophies. This 
could potentially be accomplished by delivering a specific DNA donor template 
with an RNA guide designed to excise the specific DMD mutations alongside 
Cas9 mRNA. Consequently, the mutation would be replaced with the 
corresponding wildtype DMD sequence provided by the DNA template via 
homology-directed repair, and the entire transcript would be fixed, eliminating 
disease.  
Targeting Genetic Modifiers: A Gene Therapy Approach for Treating 
Heterogeneous Groups of Neuromuscular Disorders 
Although the symptoms of all NMDs are quite similar, most have a range 
of clinical presentation, with variance even between siblings with the same 
disease-causing mutation (Lamar et al., 2014). This indicates that in addition to 
potential environmental factors, genes that modify the effects of primary disease-
causing mutations may contribute to the phenotypic heterogeneity among NMDs. 
With such epistatic control over primary genes, genetic modifiers may contribute 
to the variation of the age of onset, severity, and the progression of one or more 
NMDs. Thus, genetic factors underlying this variability may represent targets 
for therapeutic intervention for multiple subtypes of the same NMD or multiple 
independent disorders. 
Amyotrophic lateral sclerosis (ALS) is a prime candidate for a modifier-
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based gene therapy. Age of onset is typically around 50 years, and most patients 
die within 2–5 years of diagnosis (Lamar et al., 2014). However, the clinical 
presentation of ALS is quite variable, both in age of onset and disease duration 
(Lamar et al., 2014). Similar to SMA, ALS is a progressive motor neuron disease, 
although the genetic cause of ALS is far more diverse than that of SMA, with a 
primary disease-causing mutation identified in only 10% of cases (Chen et al., 
2013). Thus, there is a great need for identifying possible genetic modifiers of 
ALS in hopes of uncovering a therapeutic target for this heterogeneous disease. 
Mutations in Cu/Zn superoxide dismutase 1 (SOD1) is one identified 
genetic cause of ALS, accounting for 20% of familial forms and several 
spontaneous cases (Czaplinski et al., 2006). Interestingly, mouse models of ALS 
that harbor mutations in SOD1 not only develop motor neuron disease, but, like 
humans, exhibit variation in both disease onset and progression, depending on the 
genetic background of the model (Riboldi et al., 2011). This indicates that genetic 
modifiers may contribute to phenotypic severity of ALS. In response, several 
genome-wide association studies (GWAS) have been conducted in an effort to 
identify potential genetic loci that may contribute to the difference in disease 
onset in multiple mouse models of ALS (Sher et al., 2014, Nardo et al., 2013, 
Mancuso et al., 2012, and Kunst et al., 2000).  Interestingly, a strong linkage was 
identified on chromosome 13 within a locus containing Smn, the known genetic 
cause of SMA (Kunst et al., 2000). Further studies have shown lower levels of 
SMN protein within spinal cords in both mice and human ALS patients that 
harbor mutations in SOD1 (Turner et al., 2014 and Turner et al., 2009). In 
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addition, Turner et al showed that SMN deficiency enhances phenotypic severity 
while its overexpression improves both neuromuscular function and motor neuron 
survival in SOD1 mouse models of ALS (Turner et al., 2014). These data do not 
only show that SMN may be a genetic modifier of both ALS and SMA but 
existing gene therapies for SMA designed to increase SMN expression may also 
help reduce the severity of ALS caused by mutations in SOD1.  
Furthermore, other studies have identified EPHA4, the gene that encodes 
Ephrin type A receptor 4 (EPHA4) as a genetic modifier of ALS and SMA (Van 
Hoecke et al., 2012). EPHA4 is a tyrosine kinase receptor that modulates axonal 
repulsion and synapse formation in the developing nervous system through ephrin 
signaling (Klein et al., 2009). Reductions in Epha4 expression by genetic or 
pharmacological inhibition increase motor performance and lengthen survival in 
SOD1 zebrafish and mouse models of ALS, as well as zebrafish models of SMA 
(Van Hoecke et al., 2012). Interestingly, knockdown of Epha4 also rescues the 
axonopathy within zebrafish induced by expression of mutant TAR DNA-
binding protein 43 (TDP-43), another gene linked to both familial and sporadic 
forms of ALS (Van Hoecke et al., 2012 and Sreedharan et al., 2008). 
Importantly, human GWAS studies have determined that EPHA4 expression 
inversely correlates with disease onset and survival, and loss-of-function 
mutations in EPHA4 are associated with long term survival in patients with ALS 
(Van Hoecke et al., 2012). Taken together, these data highlight a possible 
molecular connection between different forms of ALS and SMA, as well as the 
importance of ephrin signaling for the general homeostasis of motor neurons; and 
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it suggests that gene therapies designed to reduce EPHA4 expression may be 
effective at slowing the progression of multiple forms of ALS and SMA.  
In addition to motor neuron disorders, several genetic modifiers that may 
contribute to the phenotypic variability in patients with muscular dystrophy have 
been identified. For example, when overexpressed, several genes that are integral 
for the extracellular matrix and the structural integrity of skeletal muscle—
including alpha-7 integrin, laminin-alpha7, biglycan, sarcospan, galectin-1, and 
osteopontin—have been found to improve dystrophic phenotypes in several 
animal models of Duchenne muscular dystrophy (Marshall et al., 2015, Van et al., 
2015, Wuebbles et al., 2013, Pegoraro et al., 2011, Guo et al., 2006, and Rooney 
et al., 2006). Considering the loss of dystrophin disrupts the link between the 
cytoskeleton and extracellular matrix within muscle, a therapy designed to 
increase the expression of one or more of the aforementioned genes may help 
prevent the loss of or help rebuild muscle integrity in patients suffering from a 
dystrophy. A successful modifier-based gene therapy would substantially improve 
treatment options for individuals with Duchenne muscular dystrophy: as 
previously mentioned, the current gene therapy approved for the treatment of this 
disease is therapeutically efficacious for only 13% of patients (Mendell et al., 
2013). 
One of the first genetic modifiers of Duchenne muscular dystrophy was 
identified in two distinct Brazilian Golden Retriever muscular dystrophy (GRMD) 
dogs, who, though dystrophin-deficient, displayed a mild dystrophy phenotype 
and normal lifespan, a phenotype never reported in typical GRMD dogs whose 
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survival is only around two years of age (Zatz et al., 2015 and Ambrosio et al., 
2008). Whole-genome sequencing and transcriptome analysis of muscles from 
both traditional GRMD canine models and the two Brazilian “escaper” GRMD 
dogs showed that this mild phenotype was correlated with higher levels of 
Jagged-1 (Jagged-1) (Vieira et al., 2015). Subsequent studies showed that the 
overexpression of Jagg-1 can alleviate muscle atrophy in both canine and 
zebrafish models of DMD, confirming its modifying capability and therapeutic 
potential (Vieira et al., 2015). 
Jagged-1 is a critical ligand for several Notch receptors (Lindsell et al., 
1995). In addition to its role in regulating gene expression patterns required for 
proper embryonic muscle development, the notch signaling pathway is critical for 
muscle regeneration in adults (Wen et al., 2012 and Conboy and Rando et al., 
2003). Although Notch signaling was found to be dysregulated in both muscle 
satellite cells and dystrophin-deficient muscles within the mdx mouse model, the 
exact role of Jagg-1 in the maintenance of adult skeletal muscle has yet to be fully 
elucidated (Jiang et al., 2014). Interestingly, mutations that lead to 
haploinsufficiency of Jagged-1 cause Alagille syndrome, a multi-organ disorder 
negatively affecting liver, heart, and kidney function, but which leaves skeletal 
muscle intact, further complicating the role of Jagg-1 in muscle physiology 
(McCright et al., 2002). Nonetheless, considering the function of Jagg-1 does not 
seem to have a direct link to dystrophin and/or the extracellular matrix of muscle, 
understanding the impact of Jagg-1 in muscle regeneration may help discern 
further therapeutic targets for other forms of muscular dystrophy. Future studies 
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aimed at determining if the overexpression Jagged-1 mitigates multiple forms of 
muscular dystrophy should be completed.  
Dok7 is another potential gene therapy target that may treat multiple forms 
of NMD. Dok7 is a gene that encodes the cytoplasmic protein, downstream of 
tyrosine kinase 7 (DOK-7). DOK-7 is an activator of MuSK, a receptor tyrosine 
kinase required for the formation and maintenance of the neuromuscular junction 
(Okada et al., 2006). NMJs do not form in mouse models that lack Dok-7, and 
partial loss-of-function mutations in Dok-7 have been determined to cause 
familial, autosomal recessive limb-girdle myasthenia (DOK-7 myasthenia), a 
NMD characterized by muscle weakness and small NMJs (Inoue et al., 2009 and 
Selcen et al., 2008). The overall size of NMJs can impact synapse function by 
limiting synaptic transmission of acetylcholine, a neurotransmitter required for the 
initiation of muscle contraction, leading to subsequent muscle weakness (Beeson 
et al., 2006). Such structural defects have been identified in multiple NMDs, 
including muscular dystrophy, ALS, SMA, and age-related sarcopenia (Beeson et 
al., 2006). Indeed, Arimura et al report that the administration of an AAV vector 
that expresses human DOK-7 results in an enlargement of NMJs and improved 
muscle strength within mouse models of both DOK-7 myasthenia and autosomal 
dominant Emery-Dreifuss muscular dystrophy, a completely different NMD 
characterized by small NMJs Arimura et al., 2014). These results suggest that 
DOK-7 gene therapy could help ameliorate multiple forms of NMDs that result 
from compact NMJS.  
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Treating Neuromuscular Disorders Caused by The Expansion of 
Microsatellite Repeats 
Instability of repetitive DNA sequences within the human genome is 
associated with numerous disorders. The expansion of unstable, microsatellite 
repeats, often consisting of 2-9 base pairs, is a major cause of many NMDs with 
the type of repeat and its location within the gene defining each disorder. In 
addition to disrupting the canonical function of the gene, tandem nucleotide 
repeats in non-coding regions typically cause the formation of toxic, nuclear RNA 
foci and/or aberrant dipeptide-repeat (DPR) proteins through repeat-associated 
non-AUG dependent (RAN) translation, having noxious effects on motor neurons 
and skeletal muscle. Examples include the most common familial form of ALS, 
Friedreich ataxia, myotonic dystrophy (types 1 and 2) and Huntington’s disease-
like 2 (Todd et al., 2010 and Gatchel et al., 2005).  
In response, an array of ASOs have been designed to eliminate nucleotide 
repeat-containing RNA foci and protein aggregates by base pairing with target 
mRNAs, subsequently catalyzing degradation mediated by RNase-H, an 
endogenous enzyme within mammalian cells. For example, Wheeler et al 
developed several ASOs designed to target and degrade CTG repeats within the 3’ 
UTR of human DMPK (dystrophia myotonica protein kinase) a mutation that 
causes myotonic dystrophy type 1 (DM1). In addition to DMPK 
haploinsufficiency, this triplet repeat expansion initiates RNA toxicity with 
CTGexp-containing transcripts folding into dsRNA hairpins that remain in the 
nucleus, forming ribonuclear foci. Muscle degeneration results when these RNA 
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foci bind to and sequester Muscleblind-like (MBNL) proteins, a family of tissue-
specific RNA splicing regulators, leading to their accumulation within nuclei of 
skeletal myocytes and causing a misregulation in alternative splicing, and 
subsequent detrimental changes in the muscle transcriptome. The ASOs 
developed were phosphorothioate–modified chimeric ASOs synthesized with a 
2’-O-methoxyethyl (2’ MOE) modification in order to enhance nuclease 
resistance, and a central region of unmodified nucleotides to improve RNase-H-
mediated degradation of transcripts—collectively referred to as a “MOE gapmer”.  
Subcutaneous administration of the MOE gapmer ASO significantly reduced the 
expression of disease-causing triplet repeat-containing mRNA within several 
hindlimb muscles in an established mouse model of DM1 (HSALR transgenic 
mice). In addition, alternative splicing of several MBNL1-dependent exons was 
normalized, and symptoms of mytonia were partially reversed, with therapeutic 
effects lasting for one year post-treatment. However, the reduction in mutant 
transcripts was not uniform within all hindlimb muscles, and the ASO did 
gradually degrade over time (by ~50%), limiting its therapeutic potential 
(Wheeler et al., 2012).  
Jauvin et al recently developed a similar ASO that contains a different 
phosphodiester backbone modification consisting of 2’-4’-constrained ethyl (cET) 
gapmer and that targets the 3’ UTR of the human DMPK. Upon subcutaneous 
injection, this ASO (ISIS 486178) displayed enhanced bioavailability, reducing 
triplet repeat-containing mRNA and foci by 70% in multiple skeletal muscles and 
by 40% in the heart muscle of DMSXL mice, a transgenic mouse model of MD1 
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that expresses the human DMPK gene. Systemic treatment also improved body 
weight and muscle strength and reduced skeletal muscle maturation in post-onset 
DMSXL mice, although the long-term effects and pharmacokinetics still need to 
be established (Jauvin et al., 2017). 
In addition to DM1, an ASO with a similar chemistry was recently 
developed as a potential treatment for a familial form of ALS caused by a 
hexanucleotide GGGGCC repeat expansion within intron 1 of the C9ORF72 gene 
(Jiang et al., 2016). This allele-specific ASO was designed to target sequences 5’ 
to the microsatellite expansion only within mutant transcripts. This treatment 
yielded significant reductions in RNA foci and several DPRs in the cortex and 
spinal cord of C9 transgenic mice expressing 450 GGGGCC repeats in the 
C9ORF72 gene, while preserving wildtype C9ORF72 expression. However, 
considering C9 transgenic mice do not exhibit motor deficits, the therapeutic 
efficacy of this treatment has yet to be determined (Jiang et al., 2016).  
Compared to non-coding repeats, nucleotide repeat expansion within exons often 
results in expanded polyglutamine or polyalanine tracts in translated proteins, 
causing them to form toxic protein aggregates. Examples of this type of NMD 
include Huntington’s disease, as well as spinal bulbar and muscular atrophy. 
Although expanded nucleotide repeats within the coding region drive a different 
outcome, similar therapeutic strategies to those developed for NMDs caused by 
intronic tandem repeats are currently being developed (Todd et al., 2010 and 
Gatchel et al., 2005). For example, another ASO was developed as a prospective 
gene therapy for Huntington’s disease (HD), a neurodegenerative disease 
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characterized by progressive chorea, dystonia, incoordination, and cognitive 
decline with selective neuronal loss in the striatum (Kordasiewicz et al., 2012). 
This autosomal dominant NMD is caused by the expansion of a CAG triplet 
within the first exon of the huntingtin gene (HTT), that leads to an elongated 
glutamine tract in the N-terminus of the huntingtin protein. Normally, this CAG 
segment is repeated 10 to 35 times within exon 1 of HTT, while individuals with 
Huntington’s disease have approximately 40 or more (Todd et al., 2010 and 
Gatchel et al., 2005). 
In an effort to reduce the accumulation of toxic huntingtin protein, 
Kordasiewicz et al developed a MOE gapmer-containing ASO complementary to 
human huntingtin mRNA. Therapeutic efficacy was assessed in several 
established mouse models of HD (BACHD, YAC128, & R6/2) all of which 
express a fragmented or full-length human HTT gene with 97-125 CAG repeats 
within exon 1. Each line also develops motor deficits, hypoactivity, cognitive 
dysfunction, and brain atrophy at various time points, recapitulating both the 
genetics and phenotypes implicated in the human form of the disease. Direct 
administration of the ASO into the central nervous system led to a significant—
though transient—reduction in human huntingtin mRNA within neurons of the 
striatum and many other brain regions, as well as a partial reversal of the HD-
associated phenotype or extended survival within each symptomatic HD mouse 
model. Since the ASO used was designed to target both wildtype and mutant HTT 
transcripts, and since reducing huntingtin by 75% throughout the central nervous 
system did not exacerbate the HD phenotype in any model, it is evinced that 
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normal huntingtin may not be required for normal adult brain function 
(Kordasiewicz et al., 2012). This is an important insight into the pathogenesis of 
HD, as it remains unclear why this ubiquitously-expressed gene leads to selective 
neurodegeneration. Hence, this study further demonstrates the use of gene 
therapies as tools that can help us learn more about the pathology underlying 
complex NMDs. Excitingly, ASOs designed to reduce human HTT are currently 
in clinical trials and in early stages of possible FDA approval for the treatment of 
HD (https://clinicaltrials.gov/ct2/show/NCT02519036). Taken together, these 
studies highlight innovative modifications in ASO chemistry and examples of 
some of the first translatable gene therapies designed to treat expansion repeat 
disorders.  
ASO-based gene therapies do not represent the only therapeutic strategy 
currently being developed for tandem nucleotide repeat disorders. In an effort to 
obviate the required continuous administration and limited bioavailability of 
ASOs, an RNA-targeting CRISPR/Cas9 system has been designed to eliminate 
several NMD-associated RNA foci containing microsatellite expansions. A study 
completed by Batra et al determined that a nuclease-dead Cas9 (dCas9) fused to a 
non-specific RNA endonuclease domain (PIN-deCas) from SMG6 (nonsense-
mediated mRNA decay factor), or a dCas9 alone along with a cognate gRNA, can 
destabilize microsatellite repeat-containing toxic RNA foci within COS-M6 cells 
transfected with different plasmids encoding either CTGexp (DM1), CCTGexp 
(DM2), CAGexp (HD), or GGGGCCexp (C9ORF72-ALS) expansions. This PIN-
Cas9 system also eliminated CTGexp- and CCTGexp- containing RNA foci in 
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myoblasts and fibroblasts derived from DM1 patient biopsies, restoring the 
splicing abilities and localization of MBNL1. Furthermore, for potential 
translation, a truncated, AAV compactible version of PIN-Cas9, capable of 
reducing toxic RNA foci in vitro, was developed. Taken together, these data 
support the proof-of-concept of a new gene therapy aimed at eliminating toxic 
tandem nucleotide repeats, although their potential therapeutic effects in vivo need 
to be established before further therapeutic development (Batra et al., 2017). 
Human disorders caused by tandem nucleotide repeats often demonstrate genetic 
anticipation, meaning the number of nucleotide repeats in the disease-causing 
gene continues to expand with each subsequent generation. Considering that the 
number of repeats positively correlates with earlier disease onset and increased 
phenotypic severity—although technically difficult—gene therapies designed to 
eliminate toxic nucleotide repeats within DNA and, hence, the germline would 
significantly advance treatment for these disorders. Preliminary support for this 
potential gene therapy strategy was recently described. Van Agtmaal et al 
designed a CRISPR/Cas9 gene editing system with the ability to precisely excise 
tracts of triple repeats within the 3’ UTR of the DMPK gene and remove toxic 
RNA foci within DM1-affected human myoblasts (van Agtmaal et al., 2017). 
However, its potential to revere disease in vivo without adverse, off-target effects 
has yet to be established. Nonetheless, taken together, all studies here mentioned 
have significantly contributed to the extraordinary advancements in therapeutic 
development for the number of currently incurable NMDs caused by tandem 
nucleotide repeat disorders. 
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Precision Gene Therapy for Charcot-Marie-Tooth Disease 
Many different NMDs display high degrees of genetic and phenotypic 
heterogeneity among individual patients. For example, Charcot-Marie-Tooth 
disease (CMT) is a NMD that encompasses a collection of 80 different inherited 
peripheral neuropathies Gonzaga-Jauregui et al., 2015, Sivakumar et al., 2005, 
and Shy et al., 2004). Remarkably, over 1000 distinct genetic mutations in 80 
different loci within the human genome can cause individual forms of CMT, with 
only a small percentage of loci having a direct link to peripheral nerve function 
(Timmerman et al., 2014). Together, these factors conspire against a single 
effective therapy for all subtypes of CMT, suggesting that personalized genetic 
approaches may represent a more efficacious therapeutic strategy.  
The first potential gene therapy for this kind of inherited neuropathy was 
developed for giant axonal neuropathy (GAN), a very rare form of CMT. GAN is 
an autosomal recessive NMD characterized by progressive muscle weakness and 
premature death caused by enlarged axons with densely packed and disordered 
microtubules and intermediate filaments (Nalini et al., 2008 and Demir et al., 
2005). It is caused by loss-of-function mutations in GAN1, the gene that encodes 
gigaxonin, an E3 ubiquitin ligase adaptor involved in intermediate filament 
processing in neural cells (Bomont et al., 2000). Over 40 different mutations in 
GAN1 have been identified in patients with GAN (Houlden et al., 2007 and Koop 
et al., 2007). They consist of in-frame deletion, insertion, missense, and nonsense 
mutations, all of which disrupt Gan1 function. However, both human and murine 
carriers of GAN1 mutations not only produce half the normal amount of 
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endogenous GAN1, but are not affected by neuropathy or any other abnormalities 
(Mussche et al., 2013). This suggests that enhancing the expression of GAN1 in 
the nervous system may be of therapeutic benefit for patients with GAN. The 
proof-of-concept of this gene therapy approach was described in Mussche et al. 
Here, a GAN1 gene replacement therapy, consisting of GAN1 transgene delivered 
by AAV, not only enhanced the expression of GAN1, but eliminated intermediate 
filament aggregates within a series of patient fibroblasts harboring different 
GAN1 mutations. Furthermore, virally-delivered GAN1 has been shown to reduce 
neuronal intermediate filaments in the brain stem and spinal cord within Gan1 
knockout mice (Mussche et al., 2013). In fact, therapeutic safety and efficacy of 
scAAV9/jeT-GAN are currently being evaluated in clinical trials with the first 
patient having been treated in 2015 
(https://clinicaltrials.gov/ct2/show/NCT02362438).  
Yet 90% of inherited peripheral neuropathies are dominantly-inherited, 
requiring a gene therapy approach that reduces the expression of a toxic mutant 
protein (Timmerman et al., 2014). In response, an ASO was developed for 
autosomal dominant CMT type 1A, a demyelinating peripheral neuropathy 
resulting from a 1.4 Mb duplication on chromosome 17 that contains the 
peripheral myelin protein 22 (PMP22) gene (Lupski et al., 1992). This gene 
encodes PMP22, a protein within Schwann cells that contributes to the lipid 
organization and distribution in peripheral myelin (Garbay et al., 2000) While the 
overexpression of PMP22 results in CMT type 1A, the deletion of this genomic 
region and, thus, the loss of PMP22 results in a different neuropathy referred to as 
 108 
hereditary neuropathy with liability to pressure palsies (HNPP) (Lupski et al., 
1992). This indicates that genetic dosage of PMP22 is critical for myelin 
homeostasis and, thus, peripheral nerve function, complicating the development 
of a gene therapy, as the expression of PMP22 needs to be maintained to a certain 
level. The ASO was designed to target the 3’UTR of PMP22, reducing 
endogenous human PMP22 by ~50% in symptomatic C22 mice, a mouse model 
of CMTA that harbors 7 copies of the human PMP22 gene, causing a severe 
demyelinating neuropathy without exhibiting any overt adverse effects. Weekly, 
subcutaneous injections of this ASO improved myelination of peripheral nerves, 
leading to increases in muscle endurance and motor nerve conduction velocity. 
Similar therapeutic effects were also seen when a post disease-onset rat model of 
CMT1A, which harbors 3 copies of a cosmid containing Pmp22 in addition to its 
2 biological copies, was treated with another ASO designed to exclusively target 
rat Pmp22 (Zhao et al., 2018). Although these preclinical data clearly show the 
efficacy of ASOs for the treatment of CMT1A, the long-term effects of this 
treatment need to be evaluated. Even though a ~60% and 35% reduction of total 
PMP22 were tolerated by C22 and wildtype mice, respectively, HNPP, the 
neuropathy caused by the loss of PMP22 may develop with continuous treatment 
of ASOs over time. Nonetheless, this study demonstrates the efficacy of the ASO 
as a potential therapy for CMT1A and additional NMDs caused by copy number 
variations, such as familial forms of Parkinson’s disease caused by duplications or 
triplications of SNCA (synnuclein alpha) (Chartier-Harlin et al., 2004).  
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Considering more than 1000 distinct mutations cause individual forms of 
CMT, an allele-specific gene therapy that can specifically reduce a mutant allele 
would be beneficial for many patients with a dominant form of CMT, regardless 
of their disease-causing mutation. In response, Morelli et al recently developed 
the first single-dose allele-specific gene therapy approach for dominant peripheral 
neuropathies. This therapy, developed to treat CMT2D, an axonal neuropathy 
caused by dominant mutations in GARS (glycl-tRNA-synthetase), consists of a 
specific mutant Gars-targeting artificial microRNA expression cassette packaged 
within self-complementary AAV serotype 9. Remarkably, this therapy both 
prevented and treated symptoms of neuropathy in two independent mouse models 
of CMT2D. These included a spontaneous mouse model harboring a mouse-
specific missense mutation (GarsP278KY/+), as well as the first humanized mouse 
model of CMT that harbors an in-frame 12 base-pair deletion in Gars, a mutation 
recently identified in a current patient with CMT2D (Gars∆ETAQ/+). These studies 
demonstrate how precision animal modeling can be used to engineer improved 
“humanized” preclinical models for testing personalized therapies for rare and 
orphan diseases, and set an important precedent for the use of RNAi-based gene 
therapy for this dominant NMD (Morelli et al., in preparation). This gene therapy 
strategy has extremely broad implications, and could conceivably be applied to 
other, related disorders, including other dominantly-inherited peripheral 
neuropathies or motor neuron diseases. 
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Considerations for Clinical Translation 
All of the progressive translational research mentioned in this review 
together represent the recent great advancements in therapeutic development for 
NMDs. However, several caveats should be mentioned to further the clinical 
translation of novel gene therapies and in order to deliver the most effective gene 
therapies to patients. For example, many lessons have been learned from the 
development and translation of several gene therapies developed for both SMA 
and GAN. Both NMDs primarily affect either lower motor neurons, in the case of 
SMA, or both lower motor and sensory neurons, in GAN. Thus, inquiry into the 
route of delivery has been focused on methods that deliver each therapy directly 
to the central nervous system and dorsal root ganglia. However, likely due to the 
ubiquitous expression of SMN, some SMA1 patients also exhibit symptoms from 
the periphery, arising from the autonomic and enteric nervous systems, 
cardiovascular systems, and pancreas (Mendall et al., 2017). In fact, recent 
clinical data have shown that the systemic infusion of SMN1 gene replacement 
therapy has more efficacious outcomes compared to its intrathecal delivery 
(Mendall et al., 2017). And although it is thought to be, primarily, a sensorimotor 
peripheral neuropathy, symptoms arising from the autonomic nervous system 
(ANS) have been reported by adolescent patients with GAN, including lactose 
intolerance, constipation, obstipation, heat intolerance, and blood pressure 
instability with orthostatic hypotension. Neuronal perikaryal inclusions within 
neurons of the enteric ANS and in postganglionic neurons of the sympathetic and 
parasympathetic ANS, in addition to peripheral motor and sensory neurons, have 
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also been identified in GAN1 knockout mice (Armao et al., 2016). These data 
suggest that a systemic delivery may be more efficacious, despite the current 
intrathecal route of delivery for the Phase I GAN1 replacement therapy clinical 
trial, wherein only neurons within the central nervous system and dorsal root 
ganglia will be reached. Additional preclinical studies must be conducted to 
establish the most effective and safest route of delivery, with administration 
methods based on what is reported from the clinic.  
A major hurdle in gene therapy development is ensuring that the therapy 
targets each affected tissue as efficiently as possible without causing off-target 
toxicities. For example, ASOs do not cross the blood brain barrier well, limiting 
their ability to target both the central nervous system and the periphery upon 
systemic delivery (Juliano et al., 2016). Also, when injected intravenously, ASOs 
accumulate in liver, kidney, and lymph nodes, causing hybridization-independent 
toxicities and limiting their administration to local injections (Frazier et al., 2015). 
This strictly limits their therapeutic potential for a NMD caused by cell-
autonomous and non-cell-autonomous mechanisms, such as SMA or GAN. In 
contrast, self-complementary AAVs (scAAVs) have an excellent safety profile 
and have a broad tissue tropism, meaning they have a high transduction efficiency 
with the ability to transduce many different cell types and tissues. In addition, in 
contrast to ASOs, certain serotypes such as scAAV9 can cross the BBB. 
However, while suitable for short artificial microRNA, scAAV vector delivery is 
limited to transgenes that are 2.7 Kb in length or less. This severely restricts the 
number of full-length genes that can be used for gene replacement therapies by 
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scAAV (McCarty et al., 2008). 
However, the delivery of abridged transgenes by scAAVs that express 
truncated proteins may be effective at alleviating disease caused by null and/or 
loss-of-function mutations. For example, although the full-length cDNA sequence 
of DMD cannot be delivered by scAAVs, a truncated version can be. This 
therapeutic strategy, similar in outcome to the exon skipping gene therapies for 
Duchenne muscular dystrophy, may convert a severe dystrophy to a milder 
Becker-like case, regardless of the patient’s specific mutation. Another 
compensation for limited transgene capacity is the newly developed dual scAAV 
vector system (McClements et al., 2017). This delivery system involves splitting a 
large transgene expression cassette into two (one with a 5’ end and one with the 
3’ end) with each half of the cassette packaged into a single scAAV vector. The 
re-assembly of the full-length transgene occurs upon co-infection of the same cell 
by both scAAV vectors harboring different halves of the transgene and 
subsequent homologous recombination between the 5’ and 3’ genome. This 
method can occur in vivo and has been tested in various animal models, although 
its transduction efficiency is lower in comparison to canonical scAAV delivery 
(McClements et al., 2017). However, this delivery system may still be efficacious 
in cases where the delivery of a truncated transgene may not be effective at 
mitigating disease. 
Systemic injections also increase the probability of adverse off-target 
effects of gene therapies. For example, CMTX is a peripheral neuropathy caused 
by a loss-of-function mutation in connexin 32, a gap junction protein within the 
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paranode of peripheral nerves that conducts ions necessary for the depolarization 
of action potentials. The off-target expression of this protein may interfere with 
the membrane potentials of other cell types, causing detrimental effects 
(Sargiannidou et al., 2015). Incorporating cell-specific promotors within viral 
delivery vehicles may help reduce the chances of such side effects (Sargiannidou 
et al., 2015). Together, all are important considerations, as many NMD-causing 
mutations are within ubiquitously or widely expressed genes. Many mutations 
have even been reported in housekeeping genes whose function relative to 
neuronal or muscle physiology remain enigmatic, and/or how they cause inherited 
NMDs is unclear.  
Many preclinical studies describing the effects of gene therapies for 
NMDs assert that the earlier the therapeutic intervention, the better the outcome 
for patients. One reason is that axon regeneration can only occur within a very 
narrow time-period. This is due to the fact that many motor neuron disorders and 
axonal neuropathies cause rapid distal-to-proximal axonal degeneration or “dying-
back neuropathy,” with degenerating axons moving farther and farther away from 
postsynaptic targets on muscle as disease progresses (Dadon-Nachum et al., 
2011).  
 Thus, even if pathology is ceased by gene therapy, in humans, axons need 
to regrow over long distances, and the distal portions of peripheral nerves 
progressively lose their ability to regenerate. This is largely due to the loss of 
terminal Schwann cells and the Schwann cell basal lamina tube that occurs during 
dying-back neuropathy, resulting in an extracellular environment that is inhibitory 
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to nerve regeneration (Yaron et al., 2016 and Stoll et al., 2002). Furthermore, 
damaged neuromuscular junctions progressively lose their ability to form a fully 
functional synapse as disease progresses (Yaron et al., 2016). Thus, gene 
therapies for these NMDs have a limited therapeutic window. This needs to be 
taken into consideration when translating such gene therapies to the clinic.  
Furthermore, many preclinical studies are being conducted with animal models 
that do not fully recapitulate genetic mutations in human patients. For example, as 
previously mentioned, the mdx mouse model used to study the effects of many 
different gene therapies for Duchenne muscular dystrophy harbors a point 
mutation in the dystrophin gene, while only a small fraction of patients have a 
similar mutation. Also, many gene replacement therapies have been tested in 
simple knockout mouse models and not within models that harbor disease-causing 
mutations similar to those identified in patients. Thus, only a loss-of-function 
disease mechanism is assumed, when, in reality, the mutation can contribute 
pathology through multiple mechanisms, confounding preclinical testing of a gene 
therapy approach. Using precision mouse models developed with efficient 
genome-editing techniques, such as that used in Morelli et al to test a novel 
therapy for CMT2D, may facilitate the successful transition from preclinical 
testing to the clinical use of a gene therapy. 
Conclusion 
Here we review some of the major advancements for gene therapies for 
many currently incurable NMDs. We also highlight the advent of direct genome-
editing therapies and other innovative approaches that may improve existing gene 
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therapy options and/or prevent NMDs from being inherited in future generations. 
We also share the importance of enhancing the bioavailability and pharmokinetics 
of gene therapy vectors as well as how to improve preclinical efficacy studies to 
further advance the clinical translation of additional gene therapy approaches for 
NMDs. Taken together though, it is amazing to think that a treatment may be just 
around the corner for so many deserving families affected by these disorders. 
                                                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 116 
CHAPTER 5 
ADDITIONAL CONTRIBUTIONS TO THE FIELD 
Metabolite profiling for a mouse model of Charcot-Marie-Tooth type 2D: 
implications for disease mechanisms and interventions. (2016) Biology Open 
Bais P, Bebee K, Morelli KH, Norberg S, Currie M, Esokov A, Miers KE, Seburn 
KL, Jordanova A, Bult CJ, Burgess RW. 
How autosomal dominant mutations in GARS (glycyl tRNA synthetase) 
cause Charcot-Marie-Tooth Disease Type 2D (CMT2D) remains controversial. In 
effort to identify changes in metabolite abundance that may be indicative of the 
pathophysiology underlying CMT2D, we compared metabolites isolated from the 
spinal cord of Gars mutant mice and littermate controls. A profile of altered 
metabolites that distinguish the affected and unaffected tissue was determined. 
The metabolite with the largest systemic decrease in the mutant samples was 
carnitine whereas glycine showed a modest increase. Thus, my role in this project 
was to determine the ability of dietary supplementation with either metabolite to 
alleviate symptoms of neuropathy in mouse models of CMT2D. Supplementation 
with either glycine or acetyl-L-carnitine did not mitigate primary features of 
neuropathy such as axonal atrophy or nerve conduction velocity. Carnitine 
supplementation was modestly beneficial in gross motor performance as assayed 
in the wire hang test. These data suggest that even though acetyl-L-carnitine 
supplementation did not directly prevent or reverse symptoms of neuropathy, it 
did improve muscle strength and endurance in mouse models of Gars-linked 
neuropathy. Therefore, carnitine supplementation may be considered as a 
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complimentary therapy used to enhance gross muscle strength in patients with 
CMT2D.  
Synaptic deficits at neuromuscular junctions in two mouse models of 
Charcot-Marie-Tooth Type2D. Journal of Neuroscience. (2016) Spaulding EL, 
Sleigh JN, Morelli KH, Pinter MJ, Burgess RW, Seburn KL 
Mutations in GARS (glycyl tRNA synthetase) cause autosomal dominant 
Charcot-Marie-Tooth type 2D (CMT2D), a currently incurable axonal neuropathy 
that leads to progressive distal muscle weakness. Although, the mechanism(s) 
through which mutant forms of GARS cause CMT2D remains controversial. 
Based on reported clinical observations, and studies of mouse models of CMT2D, 
we sought to determine whether weakened synaptic transmission at the 
neuromuscular junction (NMJ) contributes to the pathophysiology underpinning 
CMT2D. Indeed, electrophysiological studies including quantal analysis and 
voltage-clamp of neuromuscular junctions within two mouse models of CMT2D 
(GarsP278KY & GarsC201R) revealed synaptic deficits that caused reduced 
presynaptic release of neurotransmitters at the NMJ. As a result, my primary role 
in this study was to determine if drugs that modify either pre/post-synaptic 
efficacy could improve muscle strength of GarsP278KY & GarsC201R mice. With the 
use of the wire hang test, a behavioral test used to evaluate gross motor 
performance, we determined that physostigmine treatment, a cholinesterase 
inhibitor that enhances current duration at postsynaptic receptors, was able to 
improve overall muscle strength in both mouse models of CMT2D. Overall, our 
data suggests that synaptic deficits in NMJS contributes to the pathophysiology of 
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CMT2D and that therapeutics that enhance synaptic strength may be a treatment 
option for improving motor function in patients with this disorder.  
Lack of neuropathy-related phenotypes in hint1 knockout mice. J 
Neuropathol Exp Neuropathol. (2014) Seburn KL, Morelli KH, Jordanova A, 
Burgess RW. 
Mutations in HINT1, the gene encoding histidine triad nucleotide-binding 
protein 1 (HINT1), cause a recessively inherited axonal neuropathy with 
neuromyotonia prolonged nerve impulses from the peripheral nerves that result in 
continuous muscle contraction. Affected individuals often experience progressive 
muscle stiffness and cramping in distal muscles. Considering several lines of 
evidence suggest that HINT1 mutations cause neuropathy and neuromyotonia 
through a loss-of-function mechanism, we analyzed Hint1 knockout mice for their 
relevance as a disease model to in turn investigate proposed mechanisms 
underpinning this disorder. Hint1 knockout mice were examined for abnormal 
neuromuscular behaviors; nerve, muscle, and neuromuscular junction anatomy; 
and conduction nerve impulses. However, evidence of axon degeneration or 
neuromyotonia could not be detected in any of the latter tests. Therefore, we 
conclude that Hint1 knockout mice may be useful for studying the biochemical 
activities of HINT1, but do not provide a disease model for investigating the 
pathophysiology underlying HINT1-associated neuropathy and neuromyotonia. 
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APPENDIX A: Chapter 2: Supplemental Data 
 
 
Figure 12. Effects of Nrcam mutations on nodes of Ranvier A) In wild type 
teased sciatic nerve axons, ankyrinG (ANKG) is found at nodes. Occasionally, a 
slight offset between the labeling and the apparent center of the node based on the 
Schwann cell morphology (arrowhead) is observed. This was not quantified 
because it is observed in wild type mice and may be an artifact of either fixation 
or sample preparation. An example of this is shown. B-D) examples of ANKG 
labeling Nrcam-/-
 
nodes show minor separation in the labeling (B), unequal 
“splitting” of the labeling (C), or a normal node, but with some offset from the 
Schwann cell center (D). Sodium channel (NaV1.6) density at nodes was assessed 
by semiquantitative immunofluorescence using labeling of neurofilament light 
chain as an internal control. The ratio of NaV1.6 to NEFL labeling intensity in 
wild type and Nrcam-/- nerves is shown as box and whisker plots (E). No change 
in NaV1.6 density was detected by this method (p=0.98, >20 nodes per genotype 
from three animals were analyzed).  
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Figure 13. Myelin structure in peripheral axons A-D) Electron micrographs of 
femoral motor nerves collected at 50,000X magnification show the myelin 
structure of control (A), Nrcam-/- (B), Sh3tc2-/- (C), and double mutant (D) axons. 
E) The spacing of myelin wraps was evaluated by measuring the total myelin 
thickness, counting the number of wraps, and dividing. Nrcam-/-  myelin was more 
tightly packed than control or Sh3tc2-/-  myelin. Double mutant mice were not 
worse than Nrcam-/- alone. F) The relationship between axon diameter and myelin 
thickness is referred to as the g-ratio, calculated as the inner diameter of a nerve 
fiber (the axonal diameter), divided by the outer diameter (the axon plus the 
myelin thickness). The g-ratio was not changed in Nrcam-/- nerves, whereas Sh3tc-
/-
 
nerves had an increased g-ratio due to thinner myelin, as anticipated. Double 
mutant mice were not different from Sh3tc2-/- alone. A-E are based on myelin 
measurements from 9 control axons, 9 Nrcam-/-  axons, 10 Sh3tc2-/-  axons, and 8 
double mutant axons. F is based on measurements from 8 control, 7 Nrcam-/-, 7 
Sh3tc2-/-, and 8 double mutant mice. Scale bar in D represents 100 nm. * = 
p<0.05, ***=p<0.001. Values are mean ± S.D.  
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Figure 14. NMJ morphology in double mutant mice A, B) Additional examples 
of NMJ dysmorphology in Nrcam-/- ;Sh3tc2-/- double mutant mice. C A control 
neuromuscular junction labeled with anti-neurofilament/anti-SV2 to label nerve 
(green), anti-S100 to label terminal Schwann cells (red), and Alexafluor647-
αBungartoxin to label acetylcholine receptors (purple). C’ shows the S100 only, 
with terminal Schwann cells being restricted to the synaptic region. D) A double 
mutant NMJ at 2.5 months of age shows normal morphology. D’) The S100 
channel reveals terminal Schwann cell processes extending beyond the synaptic 
region at this age. Scale bar in D’ represents 14µm in A, C-D and 19 µm in B.  
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Figure 15. Two electrode voltage clamp data from NMJs of a double mutant 
mouse Synaptic activity was recorded in ten muscle fibers from an Nrcam-/- 
;Sh3tc2-/-  double mutant mouse under two-electrode voltage-clamp conditions. 
All fibers showed spontaneous activity (minis), but only 5 showed evoked 
activity. A) The mini- amplitude was not different between the active (EPC) and 
the silent (no EPC) fibers, and both were similar to previously reported control 
values (~1.7 na). B) The frequency of spontaneous release was elevated in silent 
fibers, consistent with previous studies (Snider and Harris, 1979). C, D) In fibers 
that showed an evoked response, the amplitude (C), and quantal content (D), were 
well within the normal range we have observed previously (quantal content 
ranging from ~20 to ~80, with a median value of ~45). Thus, active synapses have 
relatively normal synaptic transmission, but many synapses show a failure of 
evoked release despite relatively normal spontaneous release. This is consistent 
with a failure in action potentials to reach the nerve terminal following 
stimulation of the distal nerve. Other explanations, such as a failure of presynaptic 
Ca2+ channels are also possible, but such changes would have to occur rapidly 
since active synapses show relatively normal function.  
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Figure 16. Effects of Nrcam and Sh3tc2 mutations are recessive  In all graphs, the 
Nrcam genotype is abbreviated to Nr the Sh3tc2 genotype to Sh in the X-axis 
labels. A) Nerve conduction velocity was examined in Nrcam heterozygotes, 
Sh3tc2 heterozygotes, and double heterozygotes, and compared to control. Nerve 
conduction velocity was chosen as the parameter because both Nrcam and Sh3tc2 
homozygous mice had a significant reduction in this measure. No changes in 
nerve conduction velocity were seen in any heterozygous combination. B) The 
reduction in nerve conduction velocity seen in Sh3tc2-/- mice wild type for Nrcam 
(+/+; -/-) was not made worse by heterozygosity for Nrcam (+/-; -/-) C) The 
reduction in nerve conduction velocity seen in Nrcam-/-  mice wild type for Sh3tc2 
(-/-; +/+) was if anything improved by heterozygosity for Sh3tc2 (-/-; +/-); 
however, this statistical difference is likely explained by the small sample number 
(n=3) for the (-/-; +/-) animals Nonetheless, this change makes it clear that Sh3tc2 
heterozygosity does not enhance the effects of Nrcam homozygosity. For (A), 10 
wild type, 6 Nrcam+/- , 9 Sh3tc2+/-, and 7 double heterozygous mice were used. 
For (B) 16 Nrcam+/- and 10 Nrcam+/+ mice were examined. For (C), 14 
Sh3tc2+/+mice three Sh3tc2+/- were examined.  
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APPENDIX B:  Chapter 2: Materials & Methods 
Mice: Mice were housed in PIV racks in the research animal facility at The 
Jackson Laboratory and provided food and water ad libitum. All mouse husbandry 
and experimental procedures were conducted according to the NIH Guide for 
Care and Use of Laboratory Animals and were reviewed and approved by The 
Animal Care and Use Committee of The Jackson Laboratory. Mice carrying 
mutations in Gars have been previously described (Achilli et al., 2009; Seburn et 
al., 2006), and their official strain designations are: CAST;B6-GarsNmf249/Rwb 
and C3.C(CBA)-GarsC201R/HRwb. The official strain designations of the newly 
identified mutations in Sh3tc2 and Nrcam are: B6(129P2)-Sh3tc2m1J/GrsrRwb 
and B6(129P2)-Nrcamm1J/GrsrRwb. For validation we also examined mice 
carrying null alleles of each gene (B6N(Cg)-Nrcamtm2e.1(KOMP) Wtsi /J and 
B6N(Cg)–Sh3tc2tm1b(KOMP)Wtsi/J) that were obtained from the NIH 
repository for knockout mice (KOMP; https://www.komp.org/). The Scn8a mice 
carry a C to A transversion, changing arginine at amino acid 914 to serine 
(R914S). These mice are officially designated Scn8am10J and are Jackson strain 
23609 (https://www.jax.org/strain/023609). Unless otherwise noted, all 
experimental cohorts used for direct comparisons consisted of littermate animals 
to match strain and age to the greatest extent possible.  
Mapping: The nm4302 mice were initially ascertained in a mixed B6.129 strain 
background carrying a knockout allele of the cannabinoid receptor 2 (Jackson 
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strain 5786, Cnr2tm1Dgen). Two spontaneous mutations were identified in this 
strain by a combination of genetic mapping and exome sequencing. The mutations 
were mapped by out crossing an affected mouse to BALB/cByJ mice to generate 
obligate heterozygous F1 offspring. These F1 mice were inter-crossed, and 
produced affected offspring not at the expected 1:4, but closer to 1:16, consistent 
with two recessive genes being required to produce the phenotype. Mapping with 
129 SNPs spanning the entire genome in 11 affected mice compared to 16 
unaffected littermates revealed two peaks of significant association on 
chromosomes 12 and 18. Testing additional polymorphic markers in these regions 
narrowed the intervals to between D12Mit222 (12:39503,868) and rs3724069 
(12:79,259,640) on Chromosome 12, and between D18Mit124 (18:57,617,140) 
and D18Mit183 18:64,987,826) on Chromosome 18 in mm9 NCBI Build 37.  
Exome sequencing: Genomic DNA from an affected mouse was isolated and 
fragmented. Pre-capture libraries were constructed using the methods described in 
Hodges, E. et al. (Hodges et al., 2009), with 9 cycles of PCR done on the pre-
capture library. The pre- capture library was hybridized to the alpha version of the 
Roche NimbleGen Mouse Exome capture probe set (Roche NimbleGen, Madison, 
WI, USA) according to the manufacturer’s instructions. The sequencing library 
was quantified by QPCR and sequenced on a single lane of an Illumina HiSeq 
GAIIX (Illumina, San Diego, CA, USA) using a 75 base single end sequencing 
protocol. Sequences were aligned to the mouse reference genome (mm9, NCBI 
Build 37) using Burrows-Wheeler transformation (BWA) version 0.5.8a, and 
variants were identified using SAMtools version 1.0 (Li and Durbin, 2009; Li et 
 156 
al., 2009). A C>T conversion on Chr. 18 at 62,127,702 (18:61,968,048 in mm38) 
creating a stop codon at G71X in Sh3tc2 was the best candidate variant and 
aligned with mapping data. No candidate variants were identified in the Chr. 12 
mapping interval; however, Nrcam was deemed a strong candidate based on a 
previous characterization (Douglas et al., 2009). Analysis of Nrcam transcripts by 
RT-PCR and Sanger sequencing revealed abnormal splicing events between 
exons 25 and 26 and the presence of a B2 element insertion into exon 26. High 
throughput sequencing reads confirming this event were subsequently identified, 
but were initially filtered out of the analysis because the B2 element is an 
endogenous sequence that does not map uniquely in the genome, and because the 
insertion results in a 15 bp duplication of the flanking exon 26 sequence 
(12:44,576,700-44,576,714 in mm38), allowing reads from upstream and 
downstream of the insertion to align with apparently uninterrupted overlap.  
Genotyping:  Genomic DNA was prepared from tail-tip or toe-tip biopsy lysed 
with proteinase K incubation. Primers NM4302Nrcam-F (5’- 
AAATTCCTGCCAACAAGACC-3’) and NM4302Nrcam-R (5’- 
TCCTCTGTGATCTGACTGCC-3’), which anneal to exon 26 and span the B2 
insertion were used in a PCR reaction to identify the NM4302 Nrcam mutation. 
The wildtype allele yields a PCR product of 115 bps and the mutant allele, 374 
bps. NM4302Sh3tc2F (5’ GTG GAG GAC ACC AAT TCA GG 3’) and 
NM4302Sh3tc2R (5’ CAC CCT CTG TCA GCC AGT TG 3’), with subsequent 
Sanger sequencing with NM4302Sh3tc2F to detect the single base pair C to T 
conversion in exon 3 of Sh3tc2. Mu-KOMPNrcam- F (5’-CGG TCG CTA CCA 
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TTTA CCA GT-3’), Mu-KOMPNrcam-R (5’-TGC CAA TCA AGC GAA TTA 
CT-3’), WT-KOMPNrcam-F (5’-CTA CTA TCA GCT AGC ATA ATG G-3’) 
and WT-KOMPNrcam-R (5’-CTT GTA CTA TGC CAA TCA AGC G- 3’) 
primer sets were used to detect the KOMP mutant and wildtype NrCAM allele, 
respectively. Mu-KOMPSh3tc2-F (5’-GGG GGA AAA GAT ACT TCT GAGG-
3’), Mu- KOMPSh3tc2-R (5’-CGG TCG CTA CCA TTA CCA GT-3’), WT-
KOMPSh3tc2-F (5’- GTG CCA CAC TGG GCT TGA-3’), and WT-
KOMPSh3tc2-R (TTC CAA ACT GAA GGG AAT GTG-3’) primer sets were 
used to identify the mutant and wildtype Sh3tc2 alleles, respectively.  
Tissue lysate preparation:  Whole brain samples were isolated from animals 
immediately after they were euthanized by CO2 inhalation. The tissues were 
frozen in liquid nitrogen and stored at -80 ̊C. Samples were homogenized using a 
mortar and pestle followed by a Dounce homogenizer in 1% NP-40 in phosphate 
buffered saline supplemented with Protease Inhibitor Cocktail Tablets (Roche, 
Basal, Switzerland) then centrifuged at 14,000 g twice for 5 minutes at 4 ̊C. 
Cleared homogenates were then sonicated at 4 ̊C and centrifuged again at 14,000 
g for 5 minutes. Sciatic nerve lysates were prepared similarly, except they were 
homogenized in 3% Triton X-100, 25 mM Tris, 1 mM EDTA, 5% glycerol, 150 
mM NaCL, 1% NP-40 in phosphate buffered saline supplemented with Protease 
Inhibitor Cocktail Tablets Protein concentrations were assessed using a Bradford 
assay (BioRad, Hurcules, CA). 20 µg of protein for brain, and 10 µgs for sciatic 
nerve were then analyzed by immunoblot. 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Western blot – Protein lysates were resolved on Mini-PROTEAN 4-15% Tris-
Glycine gels (BioRad, Hurcules, CA) and transferred to an Invitrolon & 
Immobilon-P PVDF membrane for western blot analysis. Membranes were 
blocked with 5% skim milk in TBST (1x Tris-buffered saline, 0.1% Tween-20), 
and incubated overnight with anti- NRCAM (rabbit, Abcam, 1:1000 dilution) and 
anti-GAPDH (mouse monoclonal, Cell Signaling, 1:1000) or anti-SCN8A (rabbit 
polyclonal, Abcam), followed by Anti-Actin (rabbit polyclonal, Sigma) diluted in 
blocking solution at 4 ̊C. Following three 10 minute washes in TBST, the blots 
were incubated with the appropriate horseradish peroxidase- conjugated 
secondary antibodies (PerkinElimer, Boston MA) diluted in blocking solution. 
After three 10 minute washes in TBST, the blots were developed using Western 
Lightening Plus-ECL, Enhanced Chemiluminescence Substrate (Perkin Elmer, 
Waltham, MA). Immunohistochemistry and histology – The entire triceps surae 
(medial and lateral gastrocnemius, soleus, and plantaris) were dissected free from 
both hind legs and weighed. Detailed methods for immunolabeling and histology 
are available elsewhere (Burgess et al., 2010; Motley et al., 2011; Seburn et al., 
2006; Sleigh et al., 2014). For basic muscle morphology some muscles were fixed 
in Bouin’s fixative, paraffin- embedded, and sectioned for standard histology with 
hematoxylin and eosin stain. Neuromuscular junction staining and innervation 
analysis. Muscles used for NMJ immunohistochemistry were fixed for 30 minutes 
in ice-cold 4% paraformaldehyde diluted in phosphate buffered saline. NMJ 
morphology was evaluated blind to genotype following labeling of the 
acetylcholine receptors with Alexa-594 conjugated alpha- bungarotoxin 
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(Invitrogen, Carlsbad, CA) and a cocktail of anti-neurofilament (2H3) and anti-
SV2 to label the motor axon and terminal (Developmental Studies Hybridoma 
Bank, Iowa City, IA). Nerves were visualized with an Alexa-488 conjugated anti-
mouse IgG1 antibody (Invitrogen). To quantify the innervation status NMJs 
where the nerve completely overlapped the AChRs on the muscle were defined as 
fully occupied, those with a portion of receptors clearly vacated by the 
presynaptic nerve were defined as partially occupied, and those with AChR 
plaques that had no associated nerve were defined as denervated.  
Axon Histology: The femoral nerves, which include both a motor and sensory 
branch (Scherer et al., 2005) were dissected free and fixed by immersion in 2% 
paraformaldehyde, 2% glutaraldehyde in 0.1M cacodylate buffer for 12 hours. 
Nerves were then plastic embedded, sectioned at 0.5 microns thickness, and 
stained with Toluidine Blue. Images were collected at 40X magnification on a 
Nikon Eclipse 600 microscope with DIC- Nomarski optics. Images were analyzed 
for axon number using an automated method in Fiji/ImageJ that was manually 
confirmed by visual inspection of images for mis- identified axons. Axon 
diameter and myelin thickness were measured in Fiji/ImageJ with the Measure & 
Label Plug-in.  
Myelin analysis: Femoral nerves prepared above were thin sectioned (75nm) and 
post- stained on grids for transmission electron microscopy. Grids were viewed on 
a Jeol 1230 electron microscope and images were captured at 50,000X 
magnification with a Hamamatsu digital camera system. Spacing of myelin wraps 
was determined by measuring the total thickness of the myelin using Fiji (ImageJ) 
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software, and counting the number of wraps in that total distance.  
Nodes of Ranvier Analysis: Sciatic nerves were dissected free, fixed in cold, 
buffered 4% paraformaldehyde for 30 minutes, and teased onto glass slides in a 
drop of PBS. Samples were allowed to dry onto the slides overnight, and then 
extracted in -20 ̊C acetone for 10 minutes. Samples were blocked and 
permeabilized in PBS with 2.5% BSA and 0.5% Triton X-100. For determining 
internodal distances, axons were then viewed under Nomarski DIC optics at 200X 
magnification and fiber diameters and internodal distances were determined using 
Fiji/ImageJ to analyze photomicrographs. For immunofluorescence, primary 
antibodies were diluted in blocking buffer and applied overnight at 4 ̊C. 
Following washes, secondary antibodies were also applied overnight at 4 ̊C. 
Semi-quantitative analysis of NaV1.6 density at nodes was performed by 
collecting confocal images of NaV1.6 and neurofilament labeling on teased 
sciatic nerve axons under standardized imaging parameters. The labeling intensity 
in a region of interest including the NaV1.6 signal was compared to the labeling 
intensity of neurofilament in the adjacent axon in an equivalently sized region. 
Background intensity in an equivalent area of neighboring blank space (no tissue) 
was subtracted from both the neurofilament and NaV1.6 values. The following 
primary antibodies were used: anti-Nrcam (rabbit, Abcam, 1:200 dilution), anti-
NaV1.6 (rabbit, Alamone, 1:200 dilution), anti-NaV1.6  (mouse monoclonal 
IgG1, NeuroMab/Antibodies Inc., 1:5 dilution) anti-Kv1.2 (mouse monoclonal 
IgG2bK, Millipore, Billerica, MA; 1:100 dilution), anti-AnkyrinG (rabbit, Santa 
Cruz, 1:200) anti-neurofilament light chain (mouse IgG1 2H3, Developmental 
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Studies Hybridoma Bank, 1:500). The following secondary antibodies 
(Invitrogen) were used for visualization: anti-mouse IgG1 594, anti-mouse IgG1 
Alexa 488, anti-mouse 488, anti-mouse IgG2bK Alexa IgG2bK 488, and anti-
rabbit Alexa 594.  
Nerve Conduction Analysis: Mice were anesthetized with 1.5-2.0% isoflurane 
and placed on a thermostatically-regulated heating pad to maintain normal body 
temperature. Compound muscle action potentials (CMAP) were evoked by 
subcutaneous stimulation at the sciatic notch and at the ankle. For recording, the 
active needle electrode was inserted in the center of the paw and a reference 
electrode was placed in the skin between the first and second digits. Sciatic nerve 
conduction velocity was determined by measuring CMAP latency and the 
distance between points of stimulation. The presence of conduction block was 
evaluated by integration measuring area under the CMAP (iCMAP) in response to 
distal and proximal stimulation and expressing the difference between the 
proximal and distal iCMAPs as a percentage ((proximal-distal)/distal)/100)). 
Clinically, conduction block is considered present when there is a decrease in the 
proximal amplitude of at least 20% relative to the distal, with less than a 20% 
increase in temporal dispersion of the proximal CMAP waveform relative to distal 
(Mallik and Weir, 2005).  
Voltage-clamp: Detailed methods are available elsewhere (Rich et al., 2002; 
Spaulding et al., 2016; Wang et al., 2004; Wang et al., 2005). Briefly, mice were 
anesthetized and the levator auris longus (LAL) muscle (Angaut-Petit et al., 1987) 
was removed and placed immediately in a recording chamber perfused 
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continuously with Ringer’s solution (20–22°C) comprised of (in mmol/l): 118 
NaCl, 3.5 KCl, 2 CaCl2, 0.7 MgSO4, 26.2 NaHCO3, 1.7 NaH2PO4, and 5.5 
glucose, and equilibrated with 95%O2/5%CO2 to maintain a pH of 7.3–7.4. The 
preparation was then placed under an upright epifluorescence microscope (Leica 
DMLFSA). Synapses were located and fibers were impaled within 100 µm of the 
terminal and voltage clamped to -50 mV. The muscle specific sodium channel 
blocker (µ-Conotoxin GIIIB, Alomone, Israel )(Cruz et al., 1985; Robitaille and 
Charlton, 1992) was introduced (~1 µM) to eliminate muscle action potentials. 
Mini endplate currents (MEPC) were recorded continuously for 1 minute and 
twenty evoked endplate currents (EPC) (when present) were recorded in response 
to single stimuli delivered at 0.5 Hz.  
Statistics: A one-way ANOVA followed by Tukey’s HSD posthoc comparison 
(R- Team, 2008) was used for evaluating differences between genotypes for axon 
counts, conduction velocity, body weight, and muscle-to-body-weight ratio 
(MW:BW). Axon diameters and myelin thickness were compared using the non-
parametric Kolmogorov- Smirnov two-sample test. NMJ innervation status 
between genotypes and categories (fully innervated, partially innervated, and 
denervated) was evaluated with a two-way ANOVA followed by Tukey’s HSD 
and Roy posthoc comparisons (R-Team, 2008). Probability of p<0.05 was used as 
a cutoff for declaring statistical significance in all comparisons.  
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APPENDIX C:  Chapter 3: Supplemental Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. The ∆ETAQ GARS mutation does not affect gene expression (A) RNA 
and cDNA libraries were generated from patient fibroblasts. Subsequently, RT-
PCR products spanning the mutation were subjected to deep-sequencing analysis. 
A cartoon representing the GARS exon7-exon8 junction is shown with the wild-
type (blue) and mutant (red) PCR products indicated. Mapped sequence reads 
were deemed informative if they spanned the nucleotides affected by the 
mutation. Of the informative reads, 53.7% were from wild-type (WT) transcripts 
and 46.3% were from ∆ETAQ GARS transcripts. (B) Western blot analyses were 
performed with total protein lysates from fibroblast cell lines from affected 
(Patient) and unaffected (Control) individuals using an anti-GARS or anti-actin 
antibody, as indicated. Sample names are across the top and protein size markers 
(kDa) are indicated on the left. 
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Figure 18. The ∆ETAQ GARS mutation does cause aberrant binding to NRP1 
 (A) Western blot analyses were performed on total protein lysates from MN1 
cells and human fibroblasts using an anti-NRP1 or anti-actin antibody, as 
indicated. Sample names are across the top and protein size markers (kDa) are 
indicated on the left. (B) Non-normalized spectral counts from mass spectrometry 
experiments are shown for proteins that co-immunoprecipitated with wild-type 
(WT) or ∆ETAQ GARS; data are shown for human GARS, mouse GARS, and 
mouse NRP1. The ratio of human:mouse GARS is also provided. Two 
independent sets of data were generated at two independent institutions, and each 
set contained two or three biological replicates. ND – not detected. (C) Non-
normalized spectral counts from mass spectrometry experiments are shown for 
proteins that co-immunoprecipitated with untagged wild-type GARS; data are 
shown for human GARS, mouse GARS, and mouse NRP1. The ratio of 
human:mouse GARS is also provided. Two independent sets of data were 
generated at two independent institutions, and each set contained two or three 
biological replicates. NA – not applicable. ND – not detected. 
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Figure 19.  mRNA and protein levels in Gars∆ETAQ/huEx8 mice 
RT-PCR using cDNA isolated from sciatic nerve confirmed expression of the 
∆ETAQ mutation and/or the human-specific nucleotides in exon 8 of Gars as 
indicated by the black arrows (n=3 mice per genotype). (A) Chromatograms from 
Sanger sequencing analysis of RT-PCR products showing the first 34 bases of 
GARS exon 8. Human-specific nucleotides expressed within Gars+/huEx8 and 
Gars∆ETAQ/huEx8 are indicated by black arrows. The ∆ETAQ mutation (the 12 bps 
deleted by the ∆ETAQ mutation are hilghlighted in red) is noted by the box in the 
sequence above and is indicated by double sequence starting at base 13. (B) 
Western blot analysis of GARS expression in the indicated mouse strains. The 
blot was re-probed with an anti-NeuN antibody to control for variability in protein 
loading. 
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Figure 20.  All miRNAs targeting ∆ETAQ disease allele tested in vitro (A) The 
five miRNAs hairpins originally tested targeting the ∆ETAQ mutation in the 
human GARS gene. The guide strand is indicated in blue, and the passenger strand 
is in red. Grey and black arrowheads indicate the Drosha and Dicer cut sites 
respectively. (B) The first set of miRNAs tested in a dual-luciferase assay. 
HEK293 cells were cotransfected with a single miRNA and the dual luciferase 
reporter containing either wild type or ∆ETAQ human GARS cloned as the 3’UTR 
of Renilla luciferase. Gene silencing was determined by measuring the ratio of 
Renilla to Firefly luciferase and triplicate data are presented as the average mean 
ratio ± SEM. Based on the efficient knockdown of the human disease-allele and 
preservation of the wild type allele, miEx8D12-1A was chosen as the lead 
candidate. (C) The lead candidate miEx8D12-1A was tested in an additional dual-
luciferase assay against the mouse ∆ETAQ mutant gene. Despite effective 
silencing of the human disease allele, it was unable to target the ∆ETAQ mouse 
Gars mRNA. Triplicate data were averaged and presented as the mean ± SEM. 
(D) The guide strand of the initial lead miRNA and its complementarity to the 
target regions of both human and mouse ∆ETAQ Gars. Base pairing is indicated 
by vertical lines with G-U bonds shown in red. (E) The hairpin structures of six 
variants of miEx8D12-1A. Drosha and Dicer cut sites are indicated with grey and 
black arrowheads. The guide strand is shown in blue, with the changes to the 
original miR sequence indicated in red. G-U base pairing is shown with a red 
vertical line. In vitro testing results for these miRNAs is shown in Figure 2. The 
lead miRNA is marked with an asterisk and was renamed mi.∆ETAQ for all 
further testing 
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Figure 21.  U6.miP278KY microRNAs can specifically knockdown P278KY 
mouse Gars mRNA in vitro (A) Hairpin structures of all pre-miRNAs targeting 
P278KY mouse Gars mRNA. The guide strand is shown in blue, while the 
passenger strand is in red. Drosha and Dicer cut sites are indicated by grey and 
black arrowheads, respectively. The best performing miRNA in vitro is marked 
with an asterisk and the name was shortened to miP278KY for further testing. (B) 
The sequence of the guide strand of the best performing miP278KY and it’s 
complementarity to both wild type and mutant mouse Gars. The P278KY 
mutation is shown in red. Vertical lines indicate the base paring between the 
miRNA and the target genes, with weaker G-U bonds shown in red. Allele-
specificity is achieved by effective base-pairing of the miRNA with the mutant 
allele, while also having much lower complementarity to the wild type. (C) 
miRNAs were tested in vitro by cotransfecting HEK293 cells with a single 
miRNA and a dual-luciferase reporter containing either wild type or P278KY 
mouse Gars cloned as the 3’UTR of Renilla luciferase. Target gene silencing was 
determined by measuring the ratio of Renilla to Firefly luciferase. Triplicate data 
were averaged and presented as the mean ratio ± SEM.   
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Figure 22.  Reduction in Mutant GARS Expression Also Alleviates Neuropathy 
in Post-Disease Onset Gars(P278KY/+) Mice (A-B) mi-P278KY treatment yields 
significant increases in grip strength as determined by the wire hang test starting 
at 5 weeks post treatment in both early- (A) and late-symptomatic (B) 
Gars(P278KY/+) mice. Treated P278KY mice also gain weight starting 3 weeks post 
treatment with early-symptomatic mice (A) and 1 week post treatment with late-
symptomatic mice (B). These data correlate with a significant an increase 
MW:BW within scAAV9.mi.P278KY early- symptomatic Gars(P278KY/+) mice (C) 
although scAAV9.miP278KY treatment was unable to improve NCV within this 
cohort or MW:MW nor NCVs in the late-symptomatic P278KY mice (C-D). 
However, scAAV9.miP278KY treatment significantly prevented further or 
reversed NMJ breakdown in both early- and late- symptomatic Gars(P278KY/+) 
mice. All statistics were completed with a One-Way Anova with Tukey Posthoc 
comparisons. Star represents significance between MiLacZ and MiP278KY-
treated GarsP278KY/+ mice (* = <0.05 ** = <0.005 *** =<0.001). A = significant 
difference in fully innervated NMJs, B = significant difference in partially 
innervated NMJs, and C = significant difference in denervated NMJs. Late-
symptomatic Cohort: MiLacZ-treated Gars(+/+) n=6, scAAV9.miP278KY-treated 
Gars(+/+) n=5-6, mi.LacZ-treated Gars(P278KY/+) n=6, and scAAV9.miP278YK-
treated Gars(P278KY/+) n=7. Early-symptomatic Cohort: miLacZ –treated Gars(+/+) 
n=3, scAAV9.miP278KY-treated Gars(+/+) n=3-4, mi.LacZ-treated Gars(P278KY) 
n=6, and scAAV9.miP278KY-treated Gars(P278KY/+) n=7. Values are mean ± S.D. 
All scale bars = 100 µm. 
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Figure 23. Escalating doses of scAVV9.miP278KY delivered via ICV delivery 
improves peripheral nerve function in Gars(P278KY/+) mice. (A-B) Significant 
improvements in nerve conduction velocity correlate with reductions of mutant 
Gars expression within dorsal root ganglia when scAAV9.miP278KY was 
delivered by ICV compared to IV. (C) In contrast, these gains in peripheral nerve 
function did not correlate with reductions in mutant Gars expression within liver. 
N=5 for all experimental groups. IV = intravenous delivery of 1x1011 vg/mouse, 
ICV = intracerebroventricular delivery, LD = low dose of 8.75x109 vg/mouse, 
MD = median dose of 5.00 x1010 vg/mouse, and HD = 1x1011 vg/mouse. (A) Data 
was analyzed by a One-Way ANOVA followed by Tukey’s posthoc comparisons. 
a = significant from untreated, wildtype control; b = significant from untreated 
P278KY control. (B-C) These data were analyzed with a Two-Way Anova with 
Tukey Posthoc comparisons. Star represents significance between wildtype and 
mutant Gars expression per experimental group (* = <0.05 ** = <0.005 *** 
=<0.001). Values are mean ± S.D.  
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Figure 24. Long term therapeutic effects of neonatal scAAV9.mi.P278KY  
treatment. To access long term effects of scAAV9.mi.P278KY treatment, both 
bodyweight and grip strength as determined by the wire hang test were recorded 
from both Gars(P278KY/+) mice and littermate controls every 6 weeks after being 
injected with scAAV9.mi.LacZ or scAAV9.mi.P278KY at P0 for 1 year post 
injection. Remarkably, scAAV9.miP278KY-treated P278KY displayed 
significant increases in body weight (A,) starting at 24 weeks post treatment and 
grip strength (B) throughout the course of 1 year compared to vehicle control-
treated P278KY mice. When evaluated for primary signs of neuropathy at 1 year 
post-treatment treated-P278KY mice exhibited significantly greater MW:BW 
ratios (C) and faster NCVs (D). Significance in (A-B) was determined by one-
way ANOVA with Tukey’s HSD posthoc comparisons. Significance in (C-D) was 
determined by two-way ANOVA with Tukey’s HSD posthoc comparisons. 
*=p<0.05,  **=p<0.01, ***=p<0.001, ****=p<0.0001 represents posthoc 
significance between miLacZ-treated and scAAV9.miP278KY-treated 
GarsP278KY/+ mice for all analyses. MiLacZ-treated Gars(+/+) n=3, 
scAAV9.miP278KY-treated Gars(+/+) n=3, mi.LacZ-treated Gars(P278KY/+) n= 5, 
and scAAV9.miP278YK-treated Gars(P278KY/+) n=7. Values are mean ± S.D.  
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Figure 25. Improvements in phenotype negatively correlates with reductions in 
mutant Gars expression in dorsal root ganglia (A-B) Scatter plot illustrating the 
negative correlation between the percentage of the ∆ETAQ variant expression 
within dorsal root ganglia and nerve conduction velocities quantified from 
scAAV9.mi.∆ETAQ-treated Gars(∆ETAQ/huEx8)  mice within late- (A) and early- (B) 
symptomatic cohorts. (C-D) Scatter plot illustrating the relationship between the 
percentage of the ∆ETAQ variant expression within liver and nerve conduction 
velocities quantified from scAAV9.mi.∆ETAQ-treated Gars(∆ETAQ/huEx8)  mice 
within late- (C) and early- (D) symptomatic cohorts. (E-F) Scatter plot illustrating 
the negative correlation between the percentage of the P278KY Gars variant 
expression within dorsal root ganglia and nerve conduction velocities quantified 
from scAAV9.mi.P278KY-treated Gars(P278KY/+)  mice within late- (E) and early- 
(F) symptomatic cohorts. (G-H) Scatter plot displaying the association  between 
the percentage of the P278KY Gars variant expression within liver and nerve 
conduction velocities quantified from scAAV9.mi.P278KY-treated Gars(P278KY/+)  
mice within late- (E) and early- (F) symptomatic cohorts. 
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. 
aHuman amino-acid positions correspond to GenBank Accession number 
NP_002038.2 
 
Table 1. Kinetic analysis of mutant GARS proteins 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Varianta kcat (s-1) Km (µM) kcat/Km (s-1 µM-1) Ratio 
Wild-type 0.049 ± 0.014 0.74 ± 0.30 0.066 1 
P234KY 0.0012 ± 4.6 x 10-4 8.8 ± 3.3 1.3 x 10-4 1 / 500 
∆ETAQ 8.7 x 10-6 ± 1.2 x 10-6 1.4 ± 0.085 6.2 x 10-6 1 / 11,000 
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Table 2. Effects of scAAV9.mi.∆ETAQ on in vivo GARS expression in doral 
root ganglia quantification of the percentage of ∆ETAQ Gars expression relative 
to wildtype Gars expression (± standard deviation) as determined by 
pyrosequencing per genotype, treatment, and experimental cohort as noted by the 
age of injection. For the preonset study a total of 5 neonatal animals were used per 
genotype and treatment groups. Late-symptomatic Cohort (injection at 9 weeks): 
MiLacZ-treated Gars(huEx8/huEx8) n=5, scAAV9.mi∆ETAQ-treated Gars(huEx8/huEx8) 
n=3, mi.LacZ-treated Gars(∆ETAQ/huEx8) n=6, and scAAV9.mi∆ETAQ-treated 
Gars(∆ETAQ/huEx8) n=7. Early-symptomatic Cohort (injection at 5 weeks) : 
Gars(huEx8/huEx8) n=6, scAAV9.mi∆ETAQ-treated Gars(huEx8/HuEx8) n=5, mi.LacZ-
treated Gars(∆ETAQ/huEx8) n=7, and scAAV9.mi∆ETAQ-treated Gars(∆ETAQ/huEx8) 
n=8. 
 
 
 
 
Age at Injection Genotype Treatment Average Ratio of 
Mutant: Wildtype Gars 
Expression ( ± SD) 
Neonate (P0-P1) (huEx8/huEx8) Untreated  14.0: 86.0 (± 3.28) 
Neonate (P0-P1) (huEx8/huEx8) sc.AAV9.mi.LacZ 8.0: 92.0 (± 1.275) 
Neonate (P0-P1) (huEx8/huEx8) sc.AAV9.mi.∆ETAQ 9.6: 90.4 (± 2.07)  
Neonate (P0-P1) (∆ETAQ/huEx8) Untreated  62.4: 37.6 (± 0.94) 
Neonate (P0-P1) (∆ETAQ/huEx8) sc.AAV9.mi.LacZ 62.5: 38.6 (± 0.96) 
Neonate (P0-P1) (∆ETAQ/huEx8) sc.AAV9.mi.∆ETAQ 46.9: 53.1 (±4.79) 
5 Weeks  (huEx8/huEx8) sc.AAV9.mi.LacZ 9.6: 90.4 (± 2.53) 
5 Weeks (huEx8/huEx8) sc.AAV9.mi.∆ETAQ 8.3:91.7 (± 2.92) 
5 Weeks (∆ETAQ/huEx8) sc.AAV9.mi.LacZ 63.9: 36.1 (± 3.13)  
5 Weeks (∆ETAQ/huEx8) sc.AAV9.mi.∆ETAQ 47.2: 52.8 (± 7.88) 
9 Weeks (huEx8/huEx8) sc.AAV9.mi.LacZ 10.3: 89.7 (± 3.04) 
9 Weeks (huEx8/huEx8) sc.AAV9.mi.∆ETAQ 6.0: 94.0 (± 1.33) 
9 Weeks (∆ETAQ/huEx8) sc.AAV9.mi.LacZ 59.3:40.7 (± 6.45) 
9 Weeks (∆ETAQ/huEx8) sc.AAV9.mi.∆ETAQ 45.3:54.74 (±6.02) 
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Table 3. Effects of scAAV9.miP278KY on allele-specific GARS expression in 
dorsal root ganglia quantification of the percentage of P278KY Gars expression 
relative to wildtype Gars expression (± standard deviation) as determined by 
pyrosequencing per genotype, treatment, route of delivery and experimental 
cohort as noted by the age of injection. For the preonset study a total of 5 neonatal 
animals per experimental group. ICV = Intracerebroventricular delivery, IV= 
Intravenous delivery, and NA = not available. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genotype Treatment Dose: Route of Delivery  Average Ratio of Mutant:Wildtype 
Gars Expression ( ± SD) 
(+/+) Untreated  NA 1.2: 98.8 (± 0.43) 
(+/+) sc.AAV9.mi.LacZ 1x1011 DRPS/animal: ICV 1.0: 99.0 (± 0.32) 
(+/+) sc.AAV9.mi.P278KY 1x1011 DRPS/animal: ICV 0.2: 99.8 (± 0.22)  
(P278KY/+) Untreated NA 55.8: 44.2 (±9.93) 
(P278KY/+) sc.AAV9.mi.LacZ 1x1011 DRPS/animal: ICV 51.7: 48.3 (± 8.46) 
(P278KY/+) sc.AAV9.mi.P278KY 1x1011 DRPS/animal: ICV 22.2: 77.8 (±16.44) 
(P278KY/+) sc.AAV9.mi.P278KY 5x1010 DRPS/animal: ICV 33.3: 66.65 (± 9.1 
(P278KY/+) sc.AAV9.mi.P278KY 8.75 x109 DRPS/animal: ICV 38.5:62.15 (± 8.91) 
(P278KY/+) sc.AAV9.mi.P278KY 1x1011 DRPS/animal: IV 9.8:90.2 (±8.22) 
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Table 4. Post onset effects of scAAV9.mi.P278KY on in vivo GARS expression 
in doral root ganglia quantification of the percentage of P278KY Gars expression 
relative to wildtype Gars expression (± standard deviation) as determined by 
pyrosequencing per genotype, treatment, and experimental cohort as noted by the 
age of injection. Late-symptomatic Cohort (injection at 9 weeks): MiLacZ-treated 
Gars(+/+) n=5, scAAV9.miP278KY-treated Gars(+/+) n=3, mi.LacZ-treated 
Gars(P278KY/+) n=6, and scAAV9.mi.P278KY-treated Gars(P278KY/+) n=7. Early-
symptomatic Cohort (injection at 5 weeks) : Gars(+/+) n=6, scAAV9.mi.P278KY-
treated Gars(+/+) n=5, mi.LacZ-treated Gars(P278KY/+) n=7, and 
scAAV9.mi.P278KY-treated Gars(P278KY/+) n=5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age at 
Injection   
Genotype Treatment Average Ratio of Wildtype: 
Mutant Gars Expression ( ± SD) 
5 Weeks  (+/+) scAAV9.mi.LacZ 1.6: 98.4(± 2.46) 
5 Weeks  (+/+) sc.AAV9.mi.P278KY                0.7: 99.3 (± 0.55) 
5 Weeks  (P278KY/+) sc.AAV9.mi.LacZ 55.0: 45.0 (± 7.26) 
5 Weeks  (P278KY/+) sc.AAV9.mi.P278KY 36.2: 63.8 (± 14.74) 
9 Weeks  (+/+) sc.AAV9.mi.LacZ 0.9: 99.1 (± 0.27) 
9 Weeks  (+/+) sc.AAV9.mi.P278KY 0.0: 100.0 (± 0.00) 
9 Weeks  (P278KY/+) sc.AAV9.mi.LacZ                52.3:47.7 (± 4.64) 
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APPENDIX D:  Chapter 3: Materials & Methods 
 
Clinical Evaluation and Mutation Analysis: The proband was clinically 
evaluated by P. Mancias and I.J. Butler at Texas Children’s Hospital (Houston, 
TX) under Institutional Review Board approved protocols. Clinical data were 
obtained after written informed consent from the proband’s parents. Diagnostic, 
whole-exome sequencing (XomeDxPlus) was performed by GeneDx 
(Gaithersburg, MD). For allele-specific Sanger sequencing we first isolated DNA 
from patient-derived primary fibroblasts. Cells were treated with trypsin 
according to the Wizard Genomic DNA Purification Kit (Promega) protocol. PCR 
amplification was performed to obtain a 381 bp region including GARS exon 8 
using PCR SuperMix (ThermoFisher Scientific). PCR products were cleaned 
according to the QiaQuick PCR Purification Kit protocol and cloned into the 
pCR4-TOPO vector using the TOPO TA Cloning Kit (ThermoFisher Scientific). 
Vectors were then transformed into One Shot TOP10 Chemically Competent 
E.coli cells (ThermoFisher Scientific) and plated on ampicillin-containing LB 
agar plates. Plasmid DNA from six isolated colonies was purified and Sanger 
sequenced using the PCR primers. Five colonies contained plasmids with the 
amplicon of the wild-type allele and one colony contained plasmids with the 
amplicon of the mutant allele. Primers used for the PCR reaction: forward 
5’GCATTGCCAAAGTAGTACTGC 3’; and reverse 5’ 
CCTGACTCTGATCAGTCCAGATCG 3’. 
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GARS Expression Studies: For RNA expression studies, RNA was isolated from 
patient fibroblasts using the RNeasy Mini Kit (Qiagen) per the manufacturer’s 
protocol. cDNA samples were generated from 1ug of RNA using the High-
Capacity cDNA reverse transcription kit (Applied Biosystems) following the 
manufacturer’s instructions. The resulting cDNA was used to amplify a 224 base-
pair product flanking the region bearing the ∆ETAQ mutation. The reaction was 
column purified and the product was analyzed for quality via gel electrophoresis. 
To prepare the sample for next-generation sequencing, the product was digested 
and “tagmented” using Tn5 transposase. The library was amplified by PCR using 
Kapa Hifi DNA polymerase and Illumina-compatible indexing primers. Final 
library fragment size and purity was determined via gel electrophoresis, and 
fragments were column purified and sequenced on the Illumina MiSeq with 
paired 155 bp reads. All primer sequences are available upon request. 
Overlapping reads were merged using PEAR (v0.9.6) and aligned using bwa mem 
(v0.7.12) to custom references containing the wild-type exon 7-exon 8 junction or 
the ∆ETAQ-containing equivalent. A custom python script (available upon 
request) was used to count reads with higher-scoring alignment to each junction. 
Uninformative reads (e.g., those not spanning the mutation) were disregarded.  
For protein expression studies, cells were cultured and harvested under normal 
conditions. Proteins were isolated in 1 mL cell lysis buffer [ 990 µL RIPA Lysis 
Buffer (ThermoFisher Scientific) + 10 µL 100X Halt Protease Inhibitor 
(ThermoFisher Scientific)]. Protein concentrations were quantified using the 
Thermo Scientific PierceTM BCA Protein Assay Kit (ThermoFisher Scientific) 
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and 10 µg of protein per sample was analyzed via western blot. Each protein 
sample was prepared in 1X SDS-sample buffer (ThermoFisher Scientific) plus 5 
µL 2-me beta-mercaptoethanol (β-ME) and boiled at 99°C for 10 minutes. 
Samples were electrophoresed on pre-cast 4-20% tris-glycine gels (ThermoFisher 
Scientific) at 150V for 1 hour. Proteins were transferred onto a polyvinylidene 
difluoride (PVDF) membrane at 25V for 1.5 hours. The membrane was incubated 
for 1 hour at room temperature with the respective primary antibody at the 
following dilutions in blocking solution: anti-GARS 1:1000, anti-neuropilin-1 
(Abcam) 1:1000, anti-Flag M2 (Sigma Aldrich) 1:10000, and anti-Sema3A 
(Abcam) 1:1000. Membranes were then rinsed 3X in 1X TBST to remove 
unbound antibody and incubated with the respective Hrp-conjugated secondary 
antibody at 1:10,000. Membranes were rinsed in 1X TBST and exposed using 
SuperSignal West Dura substrate and enhancer (ThermoFisher 
Scientific).Expression Construct Development: All GARS expression 
constructs were generated using Gateway cloning technology (Invitrogen). The 
human GARS open-reading frame was amplified from human cDNA using 
primers designed with Gateway sequences attB1 (forward) and attB2 (reverse; 
primer sequences available on request). Entry clones were generated by 
recombining PCR-purified amplicons into the pDONR221 vector using BP 
clonase. After transformation into E. coli, DNA from individual entry clones was 
isolated and subjected to sequencing analysis to confirm the presence of the 
appropriate wild-type gene. Oligonucleotides containing sequences corresponding 
to each GARS mutation studied were generated, and mutagenesis was performed 
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using the QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene). After 
transformation into E. coli, DNA from individual clones was purified and 
sequenced to confirm the presence of each mutation and the absence of any errors. 
Validated entry clones were purified and recombined into the appropriate 
Gateway-compatible vector using LR clonase: pET-21a(+) for aminoacylation 
assays and pTM3xFLAG for co-immunoprecipitation assays. DNA from the 
resulting expression constructs was purified and digested with BsrGI (New 
England Biosystems) to confirm the presence of the insert. For yeast 
complementation assays, yeast GRS1 was expressed from pRS315 and human 
GARS was expressed from the pYY1 expression construct containing 
ΔMTSΔWHEP GARS; the pYY1 constructs were a gift from Chin-l Chien and 
Chien-Chia Wang (National Central University, Taiwan).  
Aminoacylation Assays: Wild-type and mutant GARS proteins were expressed 
in E. coli with a C-terminal His tag and purified with nickel affinity resins 
(Novagen). The T7 transcript of human tRNAGly/UCU (UCU, anticodon) was 
prepared and purified as previously described (26), heat denatured at 85°C for 3 
min, and annealed at 37°C for 20 min before use. Steady-state aminoacylation 
assays were monitored at 37°C in 50 mM HEPES (pH 7.5), 20 mM KCl, 10 mM 
MgCl2, 4 mM DTT, 2 mM ATP, and 50 mM 3H-glycine (Perkin Elmer) at a 
specific activity of 16,500 dpm/pmole. The reaction was initiated by mixing 
GARS enzyme (20–600 nM) with varying concentrations of tRNA (0.3–20 µM). 
Aliquots of a reaction mixture were spotted on filter paper, quenched by 5% 
trichloroacetic acid, washed, dried, and measured for radioactivity using a liquid 
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scintillation counter (LS6000SC; Beckman Coulter Inc.). The amount of 
radioactivity retained on filter pads was corrected for quenching effects to 
determine the amount of synthesis of Gly-tRNAGly. Steady-state kinetics was 
determined by fitting the initial rate of aminoacylation as a function of tRNA 
concentration to the Michaelis-Menten equation (27).  
Yeast Complementation Assays: Yeast complementation assays were carried 
out using the haploid S. cerevisiae strain disrupted for the endogenous GRS1 and 
maintained viable via pRS316 bearing the-wild type GRS1 locus previously 
described (28-29). To assess the ability of wild-type and mutant GARS alleles to 
support cellular growth, the haploid yeast strain was transformed with wild-type 
or mutant constructs (see above), or a constructs bearing no GARS/GRS1 insert.  
Transformed yeast cells were selected for the presence of both the maintenance 
and experimental vectors by growth on solid media lacking leucine and uracil. 
Colonies were grown to saturation in 2 mL liquid medium lacking leucine and 
uracil at 30OC, 275 rpm for 48 hours. Undiluted cultures and dilutions of 1:10, 
and 1:100 were spotted on 0.1% 5-FOA complete solid medium (Teknova, 
Hollister CA) to select for cells that have spontaneously lost the maintenance 
vector (20). Yeast viability was assessed after 4 days of incubation at 30OC. At 
least two colonies per transformation were assayed and each transformation was 
repeated at least twice.  
MN1 Transfections for Immunoprecipitation: MN1 cells were grown at 37°C 
in 5% CO2 and standard growth medium [Dulbecco’s modified eagle medium 
(DMEM) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 
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U/ml penicillin, and 50 µg/ml of streptomycin (Invitrogen, Carlsbad, CA)]. Cells 
were transfected using lipofectamine 2000 (Invitrogen) with 15 µg of a plasmid to 
express wild-type or mutant GARS pTM3xFLAG, per T-175 flask. Cells 
incubated for 48 hours at 37°C in 5% CO2. Cells were then harvested using 0.25% 
trypsin (Invitrogen), centrifuged at 2,000 rpm for 2 minutes, and washed twice 
with 1X PBS.  
Co-immunoprecipitation Analyses: 25 µl of Dynabeads Protein G Magnetic 
beads (Invitrogen) were used for each cell lysate from one T-175 flask. Beads 
were washed twice in 1 mL of wash solution (0.5% bovine serum albumin and 
0.1% Triton X-100 in PBS) and re-suspended in 1 mL of wash solution. Two µg 
anti-Flag M2 antibody (Sigma) was added to the beads and incubated at 4˚C with 
gentle shaking overnight. Harvested, transfected cells were re-suspended in 1.5 
mL lysis buffer [20 mM Tris-HCl (pH7.5) 2.5mM MgCl2, 300mM KCl, 0.1% 
NP-40, 1mM DTT, 0.2mM PMSF, 1x HaltTM Protease Inhibitor Cocktail (EDTA 
free) (Thermo Scientific)] and incubated with gentle rocking at 4°C for 90 
minutes. Cell lysates were centrifuged at 12,000 rpm for 5 min at 4°C. The 
protein-containing supernatant was removed and utilized as the input for the 
subsequent immunoprecipitation (IP) reaction in a clean tube. Protein was 
quantified using the PierceTM BCA Protein Assay Kit (Thermo Scientific) and 1 
mg of protein was used as input for each sample. Western blot analysis using the 
anti-Flag M2 antibody (Sigma) (1:2,500 dilution) was used to confirm expression 
of 3xFLAG tagged protein in input samples. Immediately before use, the αFlag-
conjugated magnetic beads were washed twice with 500 µl of lysis buffer using a 
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magnetic rack, re-suspended in 25 µl lysis buffer and added directly to the protein 
sample. The protein and beads were incubated at 4°C for 2 hours with gentle 
shaking. Tubes were placed on a magnetic rack and the supernatant was removed 
from the beads and discarded. The beads were washed 5 times with 1 mL of wash 
buffer [20 mM Tris-HCl (pH7.5) 2.5mM MgCl2, 300mM KCl, 0.1% NP-40, 1mM 
DTT] and re-suspended in 30 µl of wash buffer per 25 µl of starting beads 
(Proteomics Core at the Fred Hutchinson Cancer Institute) or 50 µl of wash buffer 
per 25 µl of starting beads (University of Michigan Proteomics Resource 
Facility). 200 µg/ml of 3xFlag peptide was added to each sample and incubated at 
4°C with gentle shaking for 3 hours to elute the bound flag-tagged protein. The 
tubes were placed on a magnetic rack and the supernatant was saved and used for 
subsequent analyses. 
Mass Spectrometry and Bioinformatics: For mass spectrometry at the Fred 
Hutchinson Cancer Institute, IP products were separated on a denaturing 4-20% 
Tris-Glycine gel and silver stained using standard protocols. Destained gel slices 
were reduced with 10 mM dithiothreitol (DTT) in 100 mM ammonium 
bicarbonate at 56⁰C for 45 minutes. DTT was removed and alkylation performed 
by adding 55 mM iodoacetamide in 100 mM ammonium bicarbonate to cover the 
gel slices and incubating in the dark at room temperature for 30 minutes. Slices 
were washed with 100 mM ammonium bicarbonate, dehydrated with 50% 
acetonitrile, and then dried by vacuum centrifugation. Slices were then re-
hydrated in an ice-cold solution of 12.5 ng/uL trypsin in 50 mM ammonium 
bicarbonate and incubated on ice for 1 hour. The trypsin solution was removed 
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and replaced with 50 mM ammonium bicarbonate and digestion was carried out 
overnight at 37⁰C. The digestion solution was removed and saved, and peptides 
were extracted from the slices by the addition of 0.1% trifluoroacetic acid (TFA) 
and lightly vortexing for 30 minutes followed by the addition of an equal volume 
of 100% acetonitrile and lightly vortexing for an additional 30 minutes. The 
TFA/acetonitrile wash solution was combined with the original digestion solution 
and the resulting extraction solution was brought to dryness by vacuum 
centrifugation. The extracted peptide material was desalted with a Millipore C18 
Zip-Tip using the manufacturer’s recommended procedure and brought to dryness 
again by vacuum centrifugation. Desalted peptides samples were brought up in 10 
µL of 2% acetonitrile in 0.1% formic acid and 8 µL was analyzed by LC/ESI 
MS/MS using a Thermo Scientific Easy-nLC 1000 (Thermo Scientific) HPLC 
system coupled to a hybrid Orbitrap Elite (Thermo Scientific) mass spectrometer 
using an instrument configuration as described (22). The LC system consisted of a 
reversed-phase trap column (100 µm × 20 mm) packed with Magic C18AQ (5 
µm, 200 Å resin; Michrom Bioresources) followed by peptide separations on a 
reversed-phase column (75 µm × 250 mm) packed with Magic C18AQ (5 µm, 
100Å resin; Michrom Bioresources) directly mounted on the electrospray ion 
source. A 90-minute gradient from 7% to 35% acetonitrile in 0.1% formic acid at 
a flow rate of 400 nL/minute was used for chromatographic separations. The 
heated capillary temperature was set to 310⁰C and a spray voltage of 2300 V was 
applied to the electrospray tip. The Orbitrap Elite instrument was operated in the 
data-dependent mode, switching automatically between MS survey scans in the 
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Orbitrap (AGC target value 1,000,000, resolution 120,000, and injection time 200 
milliseconds) with MS/MS spectra acquisition in the linear ion trap (AGC target 
value of 10,000, and injection time 100 milliseconds). The 15 most intense ions 
from the Fourier-transform (FT) full scan were selected for fragmentation in the 
linear trap by collision-induced dissociation with normalized collision energy of 
35%. Selected ions were dynamically excluded for 30 seconds with a list size of 
500 and exclusion mass width of +/- 10 ppm. 
For mass spectrometry at the University of Michigan, IP products were 
concentrated using a TCA precipitation protocol. 2 µl of 2% sodium deoxycholate 
was added to 200 µl of IP product and incubated on ice for 30 min. 20 µl of 100% 
(w/v) TCA was added (bringing TCA to ~10%) and incubated on ice for 1 hour. 
The IP product was then centrifuged at maximum speed at 4˚C for 10 min. The 
supernatant was discarded and the remaining pellet was washed in 500 µl of 
acetone, and incubated on ice for 10 min. The acetone solution was centrifuged at 
max speed at 4˚C for 10 min. The resulting pellet was re-suspended in 30 µl of a 
solution containing 20 mM HEPES and 8M Urea (pH=8.0). Three independently 
generated IP products for each wild-type, ∆ETAQ, and an untagged wild-type 
GARS control sample were sent for analysis. Tandem mass spectrometry was 
performed using the Orbitrap Fusion Mass Spectrometer (Thermo Scientific) at 
the University of Michigan Proteomics Resource Facility.  
For all mass spectrometry data analyses, the open source proteomics search 
engine X!Tandem (The Global Proteome Machine Organization), was used to 
match tandem mass spectrometry data with peptide spectra. Peptide Prophet was 
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used to validate peptide assignments (30) and Protein Prophet was employed to 
group peptides into proteins (31). ABACUS extracted spectral counts for the data 
for quantitative analysis (32). Finally, interactions were scored to remove 
background and comparisons of interacting proteins was performed to calculate 
the relative fold changes for protein interactions between wild-type and ∆ETAQ 
GARS. 
Targeted Assessment of NRP1 GARS Interactions: The NSC-34 cell line was 
purchased from ATCC and cultured under standard conditions. Cells were grown 
to 70% confluency before transfection. A human wild-type, P234KY, or ∆ETAQ 
GARS cDNA was cloned into the pcDNA6 plasmid to express GARS in-frame 
with a V5 tag. Transfections were performed using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s instruction. For cell lysate 
preparations, NSC-34 cells (36 hours after transfection) were washed twice in 
phosphate-buffered saline (PBS), scraped into PBS, pelleted, and resuspended in 
Pierce IP Lysis Buffer (Thermo Scientific) for 30 min and centrifuged for 7 min at 
12,000×g; the insoluble fraction was discarded. Protein G beads (Invitrogen) were 
pre-incubated with anti-NRP1 antibody (Abcam) or rabbit IgG (Cell signaling) for 
30 min before mixed with the cell lysates for overnight. Beads were then washed 
3X with buffer (100 mM NaCl, 50 mM Tris, pH 7.5, 0.1% Triton X-100, 5% 
glycerol). The immunoprecipitates were fractionated by 4-12% Bis-Tris-Plus 
SDS-PAGE gels (Invitrogen) and transferred to PVDF membranes using the iBlot 
Dry Blotting System (Invitrogen). Membranes were blocked for 1 hour with Tris 
Buffered Saline with Tween 20 (TBST) containing 5% nonfat dry milk. Wild-type 
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and mutant GARS proteins were detected using mouse monoclonal V5 antibody 
purchased from Invitrogen. NRP1 was detected by utilizing the same antibody for 
co-immunoprecipitation. After incubated with primary antibodies, membranes 
were washed and incubated with HRP-conjugated anti-mouse or anti-rabbit 
secondary antibodies (Cell Signaling) and followed by detection using ECL 
western blotting substrate (Thermo Scientific) and exposed using the FluorChem 
M imager (ProteinSimple). 
Cloning of Allele-Specific, Mutant GARS-targeted miRNAs: All design rules 
for artificial microRNAs, including: 22 nt mature miRNA length, perfect 
antisense complementarity to the target mRNA (Gars; GARS), <60% GC content 
of the mature duplex, and guide-strand biasing, such that the last 4 nucleotides of 
the antisense 5′ end were A:U rich, and the last 4 nucleotides of the antisense 3′ 
end were G:C rich are previously described in  (33).  All mutant Gars-targeting 
microRNA constructs were designed and engineered in the Harper lab adhering as 
closely as possible to these design rules but with the seed match region focused on 
the differing nucleotides present in the mutant P278KY or ∆ETAQ alleles, with 
intentional mismatches between the mature miRNA guide strand the wild-type 
GARS/Gars. All miRNAs were cloned into a U6T6 expression vector as 
previously described (25).  After in vitro testing was completed, lead candidate 
U6.miRNAs were cloned into a self-complementary proviral AAV plasmid that 
also contained a CMV promoter-driven eGFP reporter gene. scAAV9 viruses 
were generated and titered by the Viral Vector Core at The Research Institute at 
Nationwide Children’s Hospital.  
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Luciferase Assays: The dual luciferase plasmids were created using the 
Psicheck2 vector (Promega), with a Firefly luciferase cassette serving as a 
transfection control, and the various Gars gene target regions cloned downstream 
of the Renilla luciferase stop codon, thereby serving as a 3’ UTR. HEK293 cells 
were co-transfected (Lipofectamine-2000, Invitrogen) with the appropriate dual 
luciferase reporter and an individual U6.miRNA expression plasmid in a 1:5 
molar ratio. GARS silencing was determined by measuring Firefly and Renilla 
activity 24 hours post transfection, using the Dual-Luciferase Reporter Assay 
System (Promega). Triplicate data were averaged and knockdown significance 
was analyzed using two-way ANOVA. Results are presented as the mean ratio of 
Renilla to firefly ± SEM.   
Mice: Mice were housed in pressurized individually ventilated (PIV) racks in the 
research animal facility at The Jackson Laboratory and provided food and water 
ad libitum. All mouse husbandry and experimental procedures were conducted 
according to the NIH Guide for Care and Use of Laboratory Animals and were 
reviewed and approved by The Animal Care and Use Committee of The Jackson 
Laboratory.  Gars (CAST;B6-GarsNmf249/Rwb (referred to as GarsP278KY/+ ) are 
previously described in (1). The official strain designations of the newly 
engineered mouse models are B6;FVB-Gars<em1Rwb>/Rwb (referred to as 
GarshuEx8) and B6;FVB-Gars<em2Rwb>/Rwb (referred to as Gars(∆ETAQ/+)). 
Unless otherwise noted, all experimental cohorts used for direct comparisons 
consisted of littermate animals to match strain and age to the greatest extent 
possible. Both males and females mice were used for each experiment. P0-P1 
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mice were isolated and injected with a gene therapy vector to determine if allele-
specific knockdown of mutant Gars expression prevents the onset of disease 
while both 5-week (early-symptomatic) and 9 week-old symptomatic (late 
symptomatic) mice were used to determine post-disease onset therapeutic effects 
of each gene therapy vector. Each mouse model displays full phenotypic 
penetrance therefore the criteria for each animal to enter an experimental cohort 
only included genotype and age. Randomization was based rolling administration 
with genotype. Each mouse within each cohort was randomly assigned to a 
treatment. Each litter contained mice treated with control or experimental gene 
therapy vectors to eliminate possible litter effects.     
Generation of Gars(∆ETAQ/+) & Gars(+/huEx8) Models With CRISPR/Cas9 
Genome-Editing Technology: Donor Constructs:  For GarshuEx8/+, the mouse 
exon 8 sequence was replaced with a double-stranded donor vector containing the 
human exon 8 sequence. The donor vector was synthesized by recombineering a 
10 kb sequence containing the mouse exon 8 sequence flanked by a 2.8kb long 5’ 
arm of homology and a 7 kb 3’ arm of homology isolated from a C57BL/6J BAC 
library into a retrieval vector containing short arms of homology for this 
fragment. The mouse exon 8 sequence was then removed from the vector and 
replaced with the human exon 8 sequence via restriction digest and subsequent 
ligation with T4 ligase. As for Gars∆ETAQ/+, the donor construct consisted of a ss-
oligonucleotide sequence spanning the first 52 bases of mouse exon 8 with short 
arms of homology (see below for sequence) containing a 12-base deletion (bases 
12-23 of exon 8) referred to as ∆ETAQ.   
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Microinjection: Preparation and microinjection of Crispr/Cas9 reagents was 
performed as described in (34). All components including Cas9 mRNA (100 
ng/µl, either TriLink or synthesized by in vitro transcription), sgRNA, guides 144 
and 1340 (50 ng/µl; guide sequence below), and each donor vector (20 ng/µl 
plasmid DNA or 100 ng/ul ssODN) were injected into the male pronucleus and 
cytoplasm of ~300 zygotes at the pronuclei stage. All zygotes were isolated from 
a superovulated FVB/NJ (JAX stock #001600) females mated with C57BL/6NJ 
(JAX stock #005304) males. After, groups of 15-25 blastocysts were transferred 
into the uterus of pseudopregnant females. 
ssODN donor: 
AGTTTACTTGTAACAGGCTTTGTTTTATTGGAAGCACATTGTCTTACTT
GTAATAGACTGGTTTATTTAATTTTATAGATACTTGAGACCGGGGATTT
TCtTGAATTTCAAACGACTTTTGGAATTCAAC 
sgRNA 144: AAAATTCCCTGTGCAGTTTC 
sgRNA 1340: TCAGAAATGAGATCTCACCT  
Genotyping: Transgenic mice were genotyped based on the presence of either the 
humanized exon 8 or ∆ETAQ constructs. Genomic DNA was prepared from tail 
biopsy lysed with proteinase K incubation (20:1 buffer to enzyme concentration) 
overnight at 55˚ C and then boiled for 15 minutes to inactivate proteinase K. 
Amplification condition was performed in a 20 ul reaction volume consisting of 4 
µl of 5x Phusion GC buffer, 0.4 µl 10 mM dNTPs, 1 µl each of forward and 
reverse primers (sequences listed below) diluted to 10µM, 1 ul of genomic DNA, 
0.6 µl of DMSO, 0.2 µl of Phusion DNA Polymerase (BioLabs, M0530) and 11.8 
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µls of nuclease-free water. PCR reaction was amplified by PCR machine (Biorad) 
with the thermal cycle programmed for 30 seconds at 98˚C as initial denaturation, 
followed by 35 cycles of 10 seconds at 98 C˚ for denaturation, 62 C˚ for 30 
seconds for annealing, 20 seconds for 72˚ C for extension, with a final extension 
at 72˚ C for 5 minutes. PCR products were purified and sequenced by JAX 
sequencing core. 
Primers HuEx8F0_F:CATAACATCACGCGTGGTTCC and 
HuEx8R0_R:CAAGTGTGGCGGTTTCCATC that span the 2.8 kb 5’ arm of 
homology to the 3’ end of Gars exon 8 and subsequent Sanger sequencing with 
HuEx8R0_R was used to identify human single nucleotide polymorphisms in 
exon 8 of Gars within GarshuEx8 founders and subsequent generations. Primers 
delETAQF0_F: GGCCATAAGCATAATTTTACTGTG and 
∆ETAGF0_R:TACAACAGAAACAAACTGTGGTCA with subsequent Sanger 
sequencing with ∆ETAGF0_R to detect the 12 base-pair deletion in bases 13-24 
in Gars(∆ETAQ/+) founders and subsequent generations.  
Reverse Transcription-PCR: Primers Gars2F_ 
CTCCCACCACTGGCAATGAC and Gars2R_ CTCACTCAGCAGCAGCTCC 
were used to amplify a portion of the Gars open reading frame spanning Gars 
exon 8 from first-strand cDNA generated from sciatic nerve RNA isolated from 
Gars(+/huEx8) and Gars(∆ETAQ/huEx8) mice. Humanized exon 8 and ∆ETAQ transcript 
sequences were identified with Sanger sequencing and primer Gars2F.  
Tissue Lysate Preparation: Whole brain samples were isolated from animals 
immediately after they were euthanized by CO2 inhalation. The tissues were 
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frozen in liquid nitrogen and stored at -80 ̊C. Samples were homogenized using a 
mortar and pestle followed by a Dounce homogenizer in 1% NP-40 in phosphate 
buffered saline supplemented with Protease Inhibitor Cocktail Tablets (Roche, 
Basal, Switzerland) then centrifuged at 14,000 g twice for 5 minutes at 4 ̊C. 
Cleared homogenates were then sonicated at 4 ̊C and centrifuged again at 14,000 
g for 5 minutes. Protein concentrations were assessed using a Bradford assay 
(BioRad, Hurcules, CA).  20 µg of protein was then analyzed by immunoblot.  
Western Blot Analysis: Protein lysates were resolved on Mini-PROTEAN 4-
15% Tris-Glycine gels (BioRad, Hurcules, CA) and transferred to an Invitrolon & 
Immobilon-P PVDF membrane for western blot analysis. Membranes were 
blocked with 5% skim milk in TBST (1x Tris-buffered saline, 0.1% Tween-20), 
and incubated overnight with anti- GARS (rabbit, Abcam, 1:1000 dilution) and 
anti-NeuN (mouse monoclonal, Clone A60, Cell Signaling, 1:1000) diluted in 
blocking solution at 4 ̊C. Following three 10 minute washes in TBST, the blots 
were incubated with the appropriate horseradish peroxidase- conjugated 
secondary antibodies (Anti-Mouse IgG (Goat), HRP-Labeled & Anti-Rabbit IgG 
(Goat, HRP-Labeled) Perkin Elmer, Boston MA) diluted in blocking solution. 
After three 10 minute washes in TBST, the blots were developed using Western 
Lightening Plus-ECL, Enhanced Chemiluminescence Substrate (Perkin Elmer, 
Waltham, MA).  
Assessment of Axonal Neuropathy in All Mouse Models: Grip strength was 
evaluated by wire hang test (19) to evaluate gross muscle strength and endurance. 
Nerve conduction studies, motor nerve histology and analysis, neuromuscular 
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junction immunofluorescence and analysis, and body weight evaluation were 
completed as previously described in Chapter 2 Supplementary materials (pg. 
123-125). 
Neonatal Delivery of scAAV9.mi.P278KY & scAAV9.mi.∆ETAQ: Prior to all 
injections of mice at P0-P1, all pups were anesthetized via cryoanesthesia as 
previously described in (35). Once properly anesthetized, all 
intracerebroventricular injections were performed using a Hamilton syringe (cat 
no. 65460_03) with a 32-gauge needle and escalating doses of 
scAAV9.miP278KY as stated in Table S1 or 2.6 x 1011 DRPS/mouse of miETAQ 
(~2-10 uls) diluted in sterile phosphate buffer saline. All gene therapy vectors 
were injected in to the lateral ventricles by position the needle directly lateral to 
the sagittal suture and rostral to the neonatal coronal suture. For intravenous 
injections, all cyroanesthetized mice were injected with 1x1011 DRPS/mouse 
directly into the superficial temporal vein in a caudal orientation with a use of a 
Hamilton syringe (cat no. 7655-01) with a 32-gauge needle.  
Intrathecal Delivery of Gene Therapy Constructs to Post-Onset Mice: With 
the use of a Hamilton syringe (cat no. 7655-01) with a 32 gauge needle, all adult 
post-onset mice were injected with ~1x1011 DRPS/mouse of scAAV9.mi.P278KY 
or scAAV9.mi.∆ETAQ diluted into sterile phosphate buffer saline (~ 10 uls) with 
an intrathecal injection by lumbar puncture. Here, all mice were anesthetized with 
isoflurane and received an injection of the proper vector into the L6 spinous 
process with the use of a Hamilton syringe with a 32-gauge needle. Each vector 
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was slowly injected and the needle left in place for 5-10 seconds prior to 
withdrawal.  
Quantification of Allele-Specific Expression: Whole liver and lumbar dorsal 
root ganglian samples were isolated from animals immediately after they were 
euthanized by cervical dislocation. The tissues were frozen in liquid nitrogen and 
stored at -80 ̊C. Samples were homogenized using a mortar and pestle followed by 
a Dounce homogenizer and RNA was isolated from liver using Trizol Reagent 
(ThermoFishercat no. 15596018) and dorsal root ganglia using either a 
RNeasyMini Kit (Qiagen, cat nos. 74104 and 74106) or mirVanaTM miRNA 
Isolation Kit (ThermFisher Scientific, cat no. AM1560). All RNA samples were 
reversed transcribed using SuperScript™ III First-Strand Synthesis System 
(cat no. 18080051). To quantify allele-specific expression of wildtype and 
mutant GARS, EpigenDx (http://epigendx.com/d/ ) performed pyrosequencing on 
the PSQ96 HS System (Qiagen) following the manufacturer’s instructions, using 
custom assays.  
Statistical Analysis: Statistical tests were performed using GraphPad’s Prism 7 
software. A two-tailed t test, one-way or two-way ANOVA followed Tukey’s 
HSD posthoc comparisons test (as indicated in Figure legend) was used to 
determine significant differences between treatment and/or genotypes for axon 
counts, conduction velocity, grip strength, and body weight. Axon diameters were 
compared using non-parametric Kolmogorov- Smirnov two-sample and Shapiro-
Wilk normality tests. NMJ innervation status between genotypes and categories 
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(fully innervated, partially innervated, and denervated) was evaluated with a two-
way ANOVA followed by Tukey’s HSD posthoc comparisons test.  
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